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Immune mediated injury is a major cause of late kidney graft loss. Donor specific HLA 
antibodies are widely believed to cause chronic rejection because their presence 
correlates strongly with worse graft outcome. However, some renal transplant 
recipients have circulating DSA for many years whilst maintaining stable graft function. 
This dichotomy has led to the hypothesis that the cause of the immune mediated 
damage observed in chronic rejection is likely to be multi-factorial. 
It has previously been demonstrated that donor specific CD4+ T cell activation can be 
observed in patients with chronic antibody mediated rejection using an IFNγ ELISpot 
assay. In some samples, this cellular activation was dependent on the presence of B 
cells, and in others the cellular activation appeared to be regulated by the presence of 
B cells.  
In this thesis, the same patterns of reactivity were observed in renal transplant 
recipients with chronic antibody mediated rejection recruited onto the RituxiCAN C4 
clinical trial. HLA binding B cells were detected flow cytometrically and associations 
between their phenotype and the different patterns of reactivity were analysed. The 
majority of HLA binding B cells were found to be IgM+ and were underrepresented in 
the class switched memory B cell population (CD27+IgM-/CD45RBmem55+IgM-) 
relative to the global B cell population. B cell dependent IFNγ production in response 
to donor specific HLA was associated with a higher ratio of IgM+ memory to IgM+ naïve 
B cells in the HLA binding B cell population.  
CMV gB was used as a model protein to investigate the individual contribution that 
memory (CD27+) and naïve (CD27-) B cells make to antigen specific IFNγ production. 
The results suggest that memory B cells support IFNγ production and naïve B cells 
may be suppressing IFNγ production.  
Collectively the results in this thesis support a role for a cell-mediated component in 
chronic antibody mediated rejection. In order to develop more effective treatments for 
chronic rejection, further investigation into the contribution that T and B cells make to 
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 Transplantation Immunology 
 Human Leukocyte antigen 
Human leukocyte antigen molecules (HLA) are encoded for by the major 
histocompatibility complex (MHC) genes, located on chromosome 6 (consortium, 
1999). Proteins of both endogenous and foreign origin are broken down into peptides 
and loaded onto HLA molecules which are then transported to the cell surface and 
presented to both CD8+ and CD4+ T cells as an HLA:peptide complex by antigen 
presenting cells (APC). Cognate T cells, i.e. T cells that have a receptor specific for 
that particular HLA:peptide complex, will be activated upon binding, provided the other 
necessary signals for activation such as co-stimulation and cytokine binding occur. 
This is one of the fundamental immunological process that underpins adaptive immune 
responses. 
The MHC is the most polymorphic set of genes expressed in humans so there is a high 
variation between individuals. In a conventional disease setting such as infection, this 
has an evolutionary advantage as it creates a population of individuals who have HLA 
molecules that can present a wide range of pathogenic peptides to T cells. It is widely 
believed that the polymorphic nature of the MHC has arisen due to pathogen mediated 
selection (PMS). Several hypotheses have been generated to explain the evolutionary 
mechanisms behind PMS, however designing experiments to test these hypotheses 
empirically has proved challenging (Spurgin and Richardson, 2010). The general 
principles behind these hypotheses are based on an evolutionary interplay between 
host and pathogen where pressure from different pathogens at different points in time 
has led to the selection of HLA molecules that confer resistance to that pathogen. In 
addition, it is thought that being heterozygous for an HLA allele is advantageous, 
because in theory, this would enable the presentation of a greater variety of pathogen 
derived peptides (Spurgin and Richardson, 2010).  In a transplant setting, the 
polymorphic nature of the MHC presents a major challenge to successful 
transplantation as the recipient’s immune system recognises any allelic variants of HLA 
molecules expressed on the donor tissue as foreign and mounts a potent immune 
response termed an alloresponse. The mechanisms by which the immune system 
recognises foreign HLA (allorecognition) are described in section 1.1.2. 
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There are two major types of HLA molecule that are considered important in 
transplantation: class I and class II. HLA class I molecules are expressed on all 
nucleated cells and consist of three alpha subunits and a β2 microglobulin molecule. 
Subtypes of class I molecules considered important in transplantation are HLA-A, HLA-
B and HLA-C molecules. HLA class I molecules present mainly intracellular peptides, 
such as virus-derived peptides, to cognate CD8+ cytotoxic T cells, thus sending a 
signal to the CD8+ T cell that the cell is infected and needs to be killed. HLA class II 
molecules are expressed on antigen presenting cells such as dendritic cells, 
macrophages and B cells, and some other cell types once activated. They consist of 
two alpha subunits and two beta subunits. There are three subtypes of class II 
molecules considered important in transplantation: HLA-DR, HLA-DP and HLA-DQ. 
HLA class II molecules present mostly extracellular peptides, which the cell has taken 
up and processed, to cognate CD4+ helper T cells. The CD4+ T cell is activated to 
produce the T cell survival factor IL-2 and other pathogen-appropriate cytokines in 
order to provide ‘help’ for the CD8+ T cell (Bennett et al., 1998). 
  Pathways of allorecognition 
In transplantation, there are three pathways of allorecognition that have been 
described in the literature; the direct, indirect and semi-direct pathways (Figure 1.1).  
1.1.2.1 The direct pathway 
The direct pathway, which is the dominant pathway early on post-transplant, is unique 
to the alloresponse (Hornick et al., 1998, Braun et al., 1993, Baker et al., 2001, 
Benichou et al., 1999). In the direct pathway, recipient T cells recognise in-tact foreign 
HLA molecules on the surface of the donor’s APCs (Lechler and Batchelor, 1982). 
These APCs, which reside in the graft, are termed passenger leukocytes and once the 
graft has been re-perfused, they migrate to nearby lymph nodes where they come into 
contact with alloreactive T cells. The direct pathway leads to a very vigorous immune 
response due to the high frequency of direct alloreactive T cells which are estimated 
to represent 1:100-1:1000 T cells (Suchin et al., 2001, Lindahl and Wilson, 1977). Such 
high frequencies of direct alloreactive T cells are likely to be a result of the inherent 
capability of a TCR to bind MHC molecules, combined with the fact that some T cells 
are able to recognise and bind more than one peptide (Zerrahn et al., 1997, Felix et 
al., 2007, Scott-Browne et al., 2011). It has been demonstrated that T cells are able to 
cross-react with non-self HLA molecules either by molecular mimicry or by using a 
different binding strategy (Colf et al., 2007). There are two well-established models 
18 
 
used to explain why so many T cells are activated by foreign HLA molecules: the 
multiple binary complex and the high determinant density models of allorecognition. 
The multiple binary complex is a model in which the peptide that is presented in the 
donor MHC molecule plays a role in activating the recipient T cell. The source of this 
antigenic peptide may be a protein of recipient origin, but it is likely that the peptide 
presented in the donor MHC molecule will be different from the peptide presented by 
the recipient MHC molecule, due to the requirement that it has to be able to fit into the 
peptide binding groove of the donor MHC molecule. The recipient T cell in this instance 
is therefore recognising a foreign peptide presented in the context of foreign MHC 
(Afzali et al., 2008, Lakkis and Lechler, 2013). In some cases, allelic variants of HLA 
molecules do not differ greatly in structure and the region that comes into contact with 
the TCR may remain unchanged or only differ by one or two amino acids – this is 
known as molecular mimicry and the result is that a recipient’s TCR is able to bind a 
donor MHC molecule with high affinity (Lombardi et al., 1989). Due to differences in 
the peptide binding groove between the donor and recipient HLA molecules, a large 
number of donor derived peptides being presented in the donor HLA molecule will 
appear novel and foreign to the recipients T cell so a high frequency of T cells will be 
activated. Further to this, it has been shown that a number of alloreactive T cells with 
direct specificity are memory cells and do not require co-stimulation (Flynn and 
Mullbacher, 1996).  
The high determinant density pattern of allorecognition is a second model based on 
the principle that the recipient T cell recognises foreign determinants on the HLA 
molecule itself and activation of the T cell is not dependent on any peptide presented 
by the molecule. The high density of HLA molecules expressed on the donor cell 
results in many receptor- ligand interactions, so any T cell specific for the HLA 
molecule is able to be activated even if it has a TCR with relatively low affinity (Afzali 
et al., 2008). The result of this is that large numbers of T cells are able to react to 
antigen. Experimental evidence to support this model comes from two papers 
published by Elliott and Eisen between 1988 and 1990 where they were able to show 
that an HLA A2 molecule that had been denatured and then reconstituted to its native 
form, was able to activate CD8+ cytotoxic T cells (CTL) independently of peptide (Elliott 
and Eisen, 1990, Smith et al., 1997, Elliott and Eisen, 1988). In addition, Smith et al 
showed that peptide was not required for alloreactive CTL specific for the murine class 
I MHC molecule H-2Kb to kill the cell line T2 (which is defective at antigen processing 
and therefore does not express MHC molecules on its surface) that were transfected 
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with the H-2Kb molecule. These H-2Kb specific CTL also caused rejection of a skin 
graft when injected into a T cell deficient mouse that had been given an H-2Kb 
incompatible graft (Smith et al., 1997).   
1.1.2.2 The indirect pathway of allorecognition 
The indirect pathway of allorecognition is more akin to a conventional immune 
response whereby HLA antigens from the graft are processed and presented by APC 
to alloreactive CD4+ T cells. The indirect pathway has been shown to be the dominant 
pathway of allorecognition long-term post-transplant but can also play a role in driving 
acute graft rejection early on post-transplant (Baker et al., 2001, Brennan et al., 2009, 
Benichou et al., 1999, Liu et al., 1996, Ali et al., 2013). Functional consequences of 
activation of indirect CD4+ T cells include a delayed type hypersensitivity response, 
the production of alloantibody and enhancement of a cytotoxic CD8+ T cell response 
(Vella et al., 1997b, Lovegrove et al., 2001, Conlon et al., 2012, Steele et al., 1996, 
Taylor et al., 2007).  
Animal models have been used to show proof of principle that indirect CD4+ T cells 
are an important component of the alloresponse and can drive rejection independently 
of the direct response. For example, Fangman et al showed in a skin transplant model 
that rats immunised with donor derived class I peptides pre-transplant rejected the skin 
graft quicker than rats who were not immunised (Fangmann et al., 1992). Auchincloss 
et al showed that indirect CD4+ T cells were required for the rejection of skin grafts in 
mice by using class II deficient donors and CD8+ T cell depleted recipients to eliminate 
the effect of the direct pathway (Auchincloss et al., 1993).  Valujskikh et al provided 
evidence for a role of the indirect alloresponse in chronic rejection processes by 
showing that the adoptive transfer of an indirect allospecific CD4+ T cell clone with a 
Th1 phenotype into BALB/c SCID mice who had received a skin-graft caused rejection 
with evidence of mononuclear cell infiltration, necrosis and fibrosis in the graft 
(Valujskikh et al., 1998). More recently, Ali et al demonstrated that the indirect 
response to class II antigens was short-lived but the response to class I alloantigens 
was strong and persistent in a bm12.Kd.IE to C57BL/6 murine transplant model. The 
authors showed that this was due to decreasing availability of donor derived class II 
expressing haematopoietic cells post-transplant, whereas donor parenchyma cells 
provided a constant source of class I alloantigen (Ali et al., 2015).  
In humans, there is evidence to show that indirect allospecific T cells are associated 
with episodes of acute rejection, but may also persist long term post-transplant and 
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contribute to chronic rejection in heart, lung and kidney transplant settings (Suciu-Foca 
et al., 1998a, Vella et al., 1997a, Baker et al., 2001, SivaSai et al., 1999, Liu et al., 
1996). As chronic stimulation can lead to anergy or apoptosis of T cell clones, it has 
been hypothesised that the persistence of the indirect alloresponse may be due to 
epitope spreading (Suciu-Foca et al., 1998b, Ciubotariu et al., 1998). Interestingly, it 
has been shown that renal transplant recipients with chronic rejection have higher 
frequencies of indirect CD4+ T cells specific for non-polymorphic regions of class I 
HLA molecules compared to healthy controls, which highlights the complexity of the 
alloresponse (Smith et al., 2011). 
1.1.2.3 The semi direct pathway of allorecognition 
The semi-direct pathway is the most recently described pathway of allorecognition and 
has provided a potential mechanism for the provision of CD4+ T cell help to a direct 
alloreactive cytotoxic T cell (Ridge et al., 1998, Bennett et al., 1998, Harper et al., 
2015). It has been demonstrated that immune cells are able to exchange many 
different intact cell surface proteins between each other (Davis, 2007). Included in 
these proteins are HLA molecules (Montecalvo et al., 2008, Herrera et al., 2004, Smyth 
et al., 2012). There is evidence to show that an APC can present processed 
allopeptides to an indirect CD4+ T cell whilst presenting an intact version of the same 
HLA molecule to a direct CD8+ T cell (Sivaganesh et al., 2013, Harper et al., 2015, 
Brown et al., 2011) Thus the CD4+ T cell can provide linked help via the APC to the 
CD8+ T cell (Ridge et al., 1998, Bennett et al., 1998, Schoenberger et al., 1998). There 
are therefore major implications of these findings to how the alloresponse is measured, 
as the semi-direct pathway has the potential to contribute to allograft rejection 
















Figure 1.1 Three major pathways of allorecognition 
The direct response involves the recognition of in-tact HLA molecules on donor derived 
APC by recipient T cells. The indirect pathway involves the processing and 
presentation of donor derived HLA antigens to recipient T cells by recipient APCs, and 



















 Types of kidney transplant rejection 
Both humoral and cellular mechanisms are involved in the rejection process, which 
can broadly be defined according to three main clinical presentations relating to the 
timing of rejection after transplantation: hyperacute rejection, acute rejection and 
chronic rejection. 
1.1.3.1  Hyperacute rejection 
Hyperacute rejection is rejection occurring within 24 hours of transplantation. It can 
occur at the time of transplantation, or within minutes of the reperfusion of the graft. 
This is due to the presence of donor specific HLA antibodies (DSA) circulating in the 
recipient’s blood stream before the transplant. These antibodies are present in 
individuals who are pre-sensitised to HLA antigens due to a previous sensitisation 
event such as a previous transplant, pregnancy or a blood transfusion. The DSA bind 
HLA molecules on the endothelium of blood vessels in the graft and activate the 
classical pathway of the complement cascade. This results in a swift destruction of the 
graft (Knechtle et al., 1987, Riella et al., 2014, Kissmeyer-Nielsen et al., 1966, 
Terasaki, 2003, Dorling, 2012). 
1.1.3.2 Acute rejection 
Acute rejection often occurs within weeks to months after the transplant but can 
happen at any point during the life of the transplant. It is characterised by an acute loss 
of graft function and can be caused by either humoral or cellular mechanisms. Acute 
humoral rejection is often accompanied by the detection of circulating DSA, neutrophil 
and macrophage infiltration of the peritubular capillaries and glomeruli, and evidence 
of complement activation in the form of positive C4d staining (Colvin, 2007). Detection 
of both CD4+ and CD8+ T cells and macrophages in the parenchyma or blood vessels 
of the graft is indicative of acute T cell mediated rejection (Sentís et al., 2015, Afzali et 
al., 2007).  
1.1.3.3 Chronic rejection 
In recent years, improvements have been made to graft survival rates within the first 
year post-transplant. This is largely to do with improvements in preservation of the 
donated organ once it has been extracted from the donor, better surgical techniques, 
and more effective immunosuppression regimens. However, little improvements have 
been made in the long term outcomes of graft survival. This was demonstrated in a 
renal transplant setting in a study of USA graft survival by Lamb et al. It is evident in 
this study that there is very little change to the slope of the graft survival curve between 
patients transplanted in 1989 compared to those transplanted 10 years later, and thus 
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the data can be extrapolated to illustrate that 30-40% of renal transplant patients will 
lose their graft within 10 years post-transplantation (Lamb et al., 2011). This study 
highlights the need for improvements to be made in the long-term management of renal 
transplant patients in order to prolong the life of a transplanted kidney. Chronic 
rejection in a renal transplant setting is characterised by a slow progressive decline in 
kidney function, or a ‘creeping creatinine’, with evidence of interstitial fibrosis and 
tubular atrophy upon biopsy (Dudley et al., 2005, Li and Zhuang, 2014). As immune 
mediated injury has been shown to be the major cause of long-term allograft loss in 
renal transplant patients, there is a need to address the effectiveness of current 
immunosuppression regimens and to better understand the underlying mechanisms 




















 B cells 
 B cells develop in the bone marrow 
B cells are lymphocytes that are derived from common lymphoid progenitor cells in the 
bone marrow. Adherent stromal cell niches provide a suitable micro-environment that 
promote B cell survival and development from the pro-B cell stage through to when an 
immature B cell is ready to leave the bone marrow and enter the periphery.  
(Nagasawa, 2006, Herzog et al., 2009). 
Figure 1.2 illustrates the major stages of B cell development from the common 
lymphoid progenitor cell to an immature B cell that is ready to migrate out of the bone 
marrow and into the periphery. The Recombination of the Variable, Diversity and 
Joining (V(D)J) segments of the first allele of the heavy chain locus of the B cell 
receptor (BCR) begins at the pro-B cell stage and is mediated by the recombination 
enzymes RAG-1 and RAG-2. The process of allelic exclusion prevents the expression 
of two BCRs by down-regulating the recombination of the second heavy chain locus. 
A surrogate light chain, which consists of the germline encoded segments VpreB and 
λ5, joins the recombined heavy chain (Igμ) to allow the stable expression of the pre-
BCR on the surface of the pre-B cell. Signalling through the BCR is essential for the 
next stages of B cell development and results in an enrichment of this B cell clone by 
a round of proliferation and progression to the next stage of development, the 
recombination of the VJ segments of the light chain (Reth M, 1987). Signalling through 
the pre-BCR is a tightly regulated process in order to avoid the development of mutated 
B cells that could potentially cause malignant disease (Rickert, 2013).  
Once recombination of the light chain has resulted in the stable expression of a BCR, 
each developing B cell is exposed to autoantigens to judge whether it is suitable for 
entry into the periphery. Ligation of the BCR with an autoantigen deems that particular 
cell to be autoreactive and it will either a) undergo clonal deletion and become an 
apoptotic cell, b) be rendered anergic so it cannot be activated in the periphery, or c) 
commence receptor editing where recombination of the light chain produces a BCR 









Figure 1.2 B cell development in the bone marrow
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 Transitional B cells differentiate into different B cell subsets 
According to dogma, B cells can be broadly divided into T dependent and T 
independent subsets. T dependent B cells require close cell-cell contact with T cells to 
differentiate into high affinity, class switched memory B cells or antibody secreting 
plasma cells. T independent B cells, as the name suggests, do not require such 
interactions with T cells to mount an effective humoral response but are more restricted 
in the type of infection that they are able to clear.  
Recent literature suggests that there may be more overlap between these two subsets 
of B cells than originally thought and a multiple layering of B cell memory has been 
described (Dogan et al., 2009, Good-Jacobson and Tarlinton, 2012). Dissecting the 
complexities of the B cell response is a particularly challenging area of immunology 
because murine and human B cell development do not appear to always follow the 
same paths. Yet the experiments required to investigate this topic in depth are 
impossible to implement in a human, so much of the data reported in murine studies 
must be extrapolated to fit a human setting. Figure 1.3 illustrates a model of human B 
















































Figure 1.3 Peripheral B cell differentiation in humans (from previous page). 
Transitional B cells take one of two differentiation pathways once they reach the T3 stage. T3 cells that are CD27-CD45RBmem55+ differentiate into 
IgM+ memory B cells or human marginal zone B cells – a process that is dependent on signalling through the Notch receptor. T3 B cells that are 




 Transitional B cells 
Successful formation of a non-autoreactive BCR marks the transition from pre-B cell 
to immature B cell and the cell can now migrate out of the bone marrow. At present, it 
is thought that the immature B cell goes through transitional phases T1-T3, which can 
be detected in human peripheral blood as it matures into a naïve B cell. There are 
several markers that have emerged over the last decade that have led to more refined 
subset definitions, however as this is a fast moving area of immunology, discrepancies 
in these definitions are often encountered when the literature is reviewed as a whole. 
Broadly speaking, Transitional B cells can be identified by their positive expression of 
IgD, and high levels of CD24, CD38 and IgM. In addition, they are CD27-, CD5+, and 
CD9+ (Lee et al., 2009). T1 cells express higher levels of CD10 and lower levels of 
CD21 than T2 cells, which are often described as having intermediate levels of CD24 
and CD38 (Sims et al., 2005). T3 and naïve B cells have even lower levels of CD24, 
CD38 and CD10 but they can be distinguished from each other by their differential 
expression of CD5 and the ATP binding cassette transporter-1 (ABCB1): CD5 is 
expressed more brightly on T3 cells than Naïve cells, and Naïve B cells possess a 
greater ability to extrude rhodamine dye using the ABCB1 transporter (Wirths and 
Lanzavecchia, 2005, Lee et al., 2009, Palanichamy et al., 2009). As the transitional 
cell moves along this development continuum, it takes on some of the functional 
characteristics of a naïve cell. Upon engagement with CD40 and the BCR, T3 cells are 
able to differentiate into naïve cells and antibody secreting cells, but remain more 
sensitive to spontaneous apoptosis than naïve B cells under these stimulation 
conditions. T3 cells also display a reduced capacity to proliferate compared to naïve B 
cells (Lee et al., 2009). More recently, it has been shown that T3 cells can be 
subdivided into two populations based on the expression of IgM and a specific isoform 
of CD45RB. The specific antibody clone that recognises this epitope on the CD45RB 
molecule is MEM55, which binds to a glycosylation dependent form of the spliced 
CD45RB exon (Koethe et al., 2011). CD27-IgMhiCD45RBmem55+ B cells are present 
in higher proportions in the blood of children and patients who have undergone 
haematopoietic stem cell transplant indicating that these are a maturing subset of B 
cells (Bemark et al., 2013). Based on this differential expression of CD45RBmem55, it 
has been hypothesised that at the T3 stage, the transitional cells diverge into two 
distinct B cell populations illustrated in Figure 1.3. The CD45RBmem55- subset carry 
on to become naïve follicular B cells and the CD45RBmem55+ subset differentiate into 
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the human equivalent of marginal zone B cells or IgM+ memory B cells (Bemark, 2015, 
Descatoire et al., 2014). 
 The T dependent response 
The majority of surviving transitional B cells become naïve follicular B cells, which 
express their BCR as a low affinity IgM form. The naïve B cell re-circulates through the 
lymphatics and the blood system surveying for antigen. B cells are capable of binding 
antigen in its soluble form but most often, the antigen is picked up by monocytes and 
dendritic cells at the site of infection and delivered to the draining lymph node that is 
rich in naive B cells and naïve T cells (Batista et al., 2001, Batista and Harwood, 2009). 
Within the lymph node, an oligoclonal response is observed, where B cells that are 
specific for the same antigen but their BCR’s are of different affinities are activated 
(O’Connor et al., 2006). The affinity of the interaction between the BCR and the antigen 
at this point influences whether the B cell enters a germinal centre reaction, or 
alternatively by-passes the germinal centre reaction and differentiates into a short lived 
plasma cell. The divergence of the humoral immune response at this point functions to 
a) control the spread of the infection by the secretion of low to moderate affinity 
antibodies by short lived plasma cells and b) provide long lasting immunity by the 
production of high affinity, class switched memory B cells and long lived plasma cells 
(O’Connor et al., 2006, Paus et al., 2006, Good et al., 2009). The fate of the B cell is 
based on the relative affinities of the other B cells in the antigen specific B cell pool at 
the time of antigen encounter: B cells with high affinity receptors are selected to 
differentiate into short lived plasma cells, and those with lower affinities are deemed 
more suitable for a germinal centre reaction, where they can undergo affinity 
maturation and class switch hypermutation (O’Connor et al., 2006). In order for a 
successful germinal centre reaction to occur, the B cell must collaborate closely with 
cognate antigen specific CD4+T cells (Garside et al., 1998).  
1.2.4.1 The germinal centre reaction   
A germinal centre is a structure located in the B cell follicle of the secondary lymph 
node that contains a high concentration of activated, antigen specific B cells that are 
undergoing proliferation, somatic hypermutation and class switch recombination. The 
aim of the germinal centre reaction is to select for those B cell clones that have the 
highest affinity for the target antigen and are therefore the most suitable candidates to 
differentiate into memory B cells and long lived plasma cells. In addition, the germinal 
centre environment provides the B cell with the appropriate signals to class switch into 
an isotype that is most suitable for the immune response required. The germinal centre 
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reaction is highly dynamic and involves the positive selection of the B cell clones that 
are selected for further differentiation as well as a great deal of cell death. The germinal 
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Selection for entry into the germinal centre begins with cognate interactions between 
T and B cells at the T-B cell border. If the expression of the orphan G-protein-coupled 
receptor, Epstein Barr virus induced molecule-2 (EBI2) on the B cell is maintained post 
activation, the B cell will stay in the outer follicle region where it is likely to differentiate 
into a short lived plasma cell. Down-regulation of EBI2 enables the localisation of the 
activated B cell into the inner follicle region where it can partake in the formation of a 
germinal centre (Pereira et al., 2009, Kelly et al., 2011, Gatto et al., 2011).  
The full kinetics of the germinal centre reaction are yet to be elucidated, but studies in 
recent years using photo-imaging have enabled a much more detailed model of the 
germinal centre reaction to be created. The germinal centre structure is organised into 
two distinct zones: the dark zone and the light zone. Germinal centre B cells cycle 
between the two zones during the germinal centre reaction (Victora et al., 2010, Allen 
et al., 2007, Bannard et al., 2013). The dark zone contains mainly proliferating B cells 
and its dark appearance is due to the dense mass of nucleated cells. The light zone 
contains a mixture of cells that includes B cells, CD4+ Follicular helper T cells (Tfh) 
macrophages and follicular dendritic cells (Victora et al., 2010). Historically, B cells 
have been divided into centrocytes and centroblasts according to their location within 
the germinal centre. Centrocytes are found in the light zone and are CXCR4lo, CD83hi 
and CD86hi. Centroblasts are located in the dark zone and are characterised as 
CXCR4hi CD83lo and CD86lo (Allen et al., 2004). In addition to the different leukocyte 
subsets that reside in the germinal centre, a network of reticular stromal cells can also 
be detected. One function of these stromal cells is to secrete different chemokines in 
order to retain the appropriate cell types in the relevant zones in the germinal centre. 
In the dark zone, the stromal cells secrete CXCL12, the ligand for CXCR4 which is 
expressed more highly on centroblasts than centrocytes. In contrast, the stromal cells 
in the Light zone have a differentially higher expression of CXCL13 which is the ligand 
for CXCR5, a chemokine receptor that is expressed highly on Tfh cells (Allen et al., 
2004).  
The B cell is provided with signals from the Tfh cell to undergo class switching and 
somatic hypermutation of its B cell receptor. IL-21 derived from the Tfh is essential for 
the initiation and maintenance of the germinal centre B cells (Zotos et al., 2010, Bryant 
et al., 2007). IL-21 has been shown to maintain the expression of Bcl6 in the germinal 
centre B cells. Bcl6 is a transcription factor that is required for successful somatic 
hypermutation of the variable region and class switching of the Fc portion of the BCR 
(Dent et al., 1997). The expression of Bcl6 also acts to repress/suppress the 
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expression of Blimp-1, the master regulator of Plasma cells, so the germinal centre B 
cells do not prematurely differentiate into plasma cells before they are ready (Tunyaplin 
et al., 2004).  
Once selected, the B cell will either become a long lived plasma cell or a memory B 
cell. The upregulation of BLIMP-1 signals the germinal centre B cell to become a 
plasma cell (Angelin-Duclos et al., 2000). IL-4 regulates IL-21 induced class switching 
in humans and the transcription factor IRF4 is required for both class switch 
recombination and plasma cell differentiation and is important for regulating the 
differentiation of germinal centre B cells into plasma cells (Ochiai et al., 2013, Klein et 
al., 2006, Avery et al., 2008).  
The B cell will process and present the antigen via MHC class II molecules to the CD4+ 
T cell, and an immune synapse will be formed. An important co-stimulatory signal that 
is sent is via ligation of CD40 on the B cell with CD40ligand (CD40L or CD154) on the 
T cell (Garside et al., 1998). CD40-CD40L interactions have been shown to be a 
requirement for a successful germinal centre reaction as patients with Hyper IgM 
syndrome due to mutations in CD40L or CD40 genes are unable to form germinal 
centres (Ferrari et al., 2001, Korthauer et al., 1993, Fuleihan et al., 1993).    Signalling 
through CD40 on the B cell induces proliferation and up-regulation of cytokine 
receptors (Lederman et al., 1992, Elgueta et al., 2009). However, CD40-CD40L 
interactions are complex and bi-directional, and in order for germinal centre formation 
to be initiated and maintained, the T cell must receive signals through CD40L 










 The T independent response: IgM+ memory and Marginal Zone B cells 
1.2.5.1 Phenotype of IgM+ memory B cells 
The existence of a non-class switched IgM+ memory B cell population in humans was 
first demonstrated in two studies by Klein et al where they showed that an IgM+ 
population of B cells with somatically hypermutated V kappa regions could be detected 
in peripheral blood. These cells did not express CD38, CD23 or CD77 and so were 
therefore distinct from naïve and germinal centre B cells. They shared characteristics 
with isotype switched IgM-IgD- populations, such as the ability to quickly differentiate 
into antibody secreting cells upon stimulation in vitro, and the expression of CD27, the 
ligand for the co-stimulatory molecule CD70 expressed on T cells. These studies 
highlighted that within the IgM+CD27+ population, two subsets could be found: 
IgM+IgD- (IgM only) and IgM+IgD+ (Klein et al., 1998, Klein et al., 1997).  
Other studies using a combination of surface phenotype (Kruetzmann et al., 2003) and 
sequencing of their BCR post immunisation with a pneumococcal vaccine (Weller et 
al., 2004) have since confirmed their existence in the peripheral blood and have shown 
that they are directly related to IgM+ memory B cell populations found in the spleen. It 
has therefore been speculated that human IgM+ memory B cells are a re-circulating 
equivalent of murine marginal zone cells in the human (Weller et al., 2004, Maglione 
et al., 2014). Additionally, studies by Berkowska et al and Bagnara et al have shown 
that the IgM only subset has a higher frequency of mutations in their CDR-H3 region 
than the IgM+IgD+ subset and are clonally related to CD27+ class switched B cells. It 
is therefore likely that the IgM only subset represent B cells that have been involved in 
primary germinal centre reactions and are distinct from the IgM+IgD+ memory subset 
(Berkowska et al., 2011, Bagnara et al., 2015). 
1.2.5.2 Function of IgM+ memory B cells 
IgM+ memory B cells are widely considered to be important for the neutralisation of 
polysaccharide-encapsulated bacteria such as Streptococcus pneumoniae, Neisseria 
meningitides or Haemophilus influenzae (Snapper, 2012, Carsetti et al., 2005, 
Cameron et al., 2011). These B cells act shortly after pathogen entry into the body by 
secreting low-affinity, broadly specific IgM antibodies. The immune response is 
therefore less specific than the response from a class-switched memory B cell, but the 
pentamer structure of IgM antibodies and the speed at which this response is mounted 
mean that a variety of microorganisms can be bound by these antibodies to provide 
effective opsonisation for the destruction of the bacteria by neutrophils and 
macrophages (Bjornson and Detmers, 1995). Because of their frontline role in the 
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clearance of bacterial infections, and their lower level of somatic hypermutation 
compared to isotype switched B cells, IgM+ memory B cells have also been termed 
natural effector memory B cells (Capolunghi et al., 2013).  
 Origin of IgM+ memory B cells 
The origin of IgM+ memory B cells is still a matter for debate. It was originally 
hypothesised by Ralf Kuppers and colleagues that IgM+ memory B cells were early 
products of a germinal centre reaction (Klein et al., 1997, Klein et al., 1998). Since the 
publication of these papers, many more studies have been conducted in an attempt to 
elucidate the origins of IgM+ memory B cells and the resultant data provides both 
arguments for and against this original hypothesis. There is a rather compelling body 
of data to suggest that the differentiation pathway of IgM+ memory B cells is distinct 
from class switched memory B cells, where germinal centre formation is not required 
and somatic hypermutation occurs independently of antigen exposure.  
1.2.6.1 IgM+ memory B cells are germinal centre independent but rely on the 
spleen for their development and signalling through TLRs for their 
maintenance 
The observation that neonates, asplenic/splenectomised individuals or a subset of 
individuals with combined variable immunodeficiency disorder (CVID) have reduced 
frequencies of IgM+ memory B cells and often suffer from re-current infections of 
encapsulated bacteria, provides evidence to support the necessary role that these 
cells play in the clearance of bacterial infections, but also that the spleen is required 
for the development and/or maintenance of these cells (Kruetzmann et al., 2003, 
Weller et al., 2004, Carsetti et al., 2005). Interestingly, Cameron et al showed that 
adults who have been splenectomised do not suffer from recurrent infections and that 
a lower IgM+ memory B cell frequency did not correlate with a higher infection rate in 
these patients. This suggests that by adulthood, a healthy individual will have sufficient 
levels of IgM and IgG antibodies to neutralise any infection (Cameron et al., 2011). 
The differentiation of IgM+ memory B cells is thought to be T-independent as 
individuals with hyper IgM syndrome caused by mutations in CD40L or CD40 genes 
(HIGM1 and HIGM3 respectively) are unable to form germinal centres and have 
reduced levels of isotype switched memory B cells and serum IgG levels, but have a 
normal IgM+ memory B cell compartment (Ferrari et al., 2001, Korthauer et al., 1993, 
Fuleihan et al., 1993, Agematsu et al., 1998, Weller et al., 2001). Interestingly, other 
individuals who have hyper IgM syndrome caused by a mutation in AICDA, which 
encodes for AID expression (HIGM2), differ in the fact that they are able to form 
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germinal centres, albeit with abnormal pathology, but have higher levels of the IgM 
only subset of IgM+ memory B cells, presumably because the lack of AID halts their 
differentiation at the isotype switching stage so the product of any germinal centre 
reaction is always IgM+ (Revy et al., 2000, Muramatsu et al., 2000, Weller et al., 2004).  
Asplenic individuals have markedly reduced IgM+ memory B cell frequencies but 
maintain a normal class switched memory B cell compartment. Likewise, those who 
have undergone a splenectomy experience a permanent decrease in their IgM+ 
memory B cell pool with only a transient reduction in their class switched memory B 
cell pool. Thus indicating that the origins of IgM+ memory B cells are different from 
class switched memory B cells (Kruetzmann et al., 2003, Cameron et al., 2011).  
Based on their findings that the IgM+ memory B cell subset in infants under 2 years of 
age have a broad repertoire of antigen receptors, therefore indicating that clonal 
expansion of antigen specific B cells has not occurred, along with evidence of somatic 
hypermutation and AID expression that is only detected in this subset early on in life, 
Weller et al 2008 hypothesised that IgM+ memory B cells may develop in the first two 
years of life and that whilst somatic mutation is occurring, they remain non-functional 
and refractory to both TI and TD antigenic stimulus. This hypothesis could explain why 
infants do not mount immune responses to pneumococcal vaccines under the age of 
2 years (Weller et al., 2008). This study was unable to provide evidence of what was 
inducing the somatic hypermutation in this subset, but subsequent studies have 
hypothesised that bacterial DNA, perhaps from the microbiota that colonises a neonate 
could be responsible. Stimulation with hypomethylated DNA cytosine-phosphate-
guanine (CpG) for 5 days in vitro has been shown to induce a small proportion of cord 
blood transitional B cells to acquire the same phenotype as IgM+ memory cells 
(Capolunghi et al., 2008). These cells up-regulate AID expression and have evidence 
of mutated CDR3 regions (Aranburu et al., 2010). In addition, if these cells are 
incubated for a further 2-4 days, they down-regulate AID expression whilst up-
regulating BLIMP-1 and differentiate into antibody secreting cells of both IgM and IgG 
isotypes (Aranburu et al., 2010, Capolunghi et al., 2008). Moreover, a small proportion 
of the IgM antibodies detected after this stimulus are specific for the S. pneumoniae 
antigen PnPS (Capolunghi et al., 2008). 
These two studies heavily implicate the involvement of TLR ligation, particularly TLR9, 
in the differentiation of IgM+ memory B cells. This is supported by the findings that 
individuals deficient in IRAK-4, MyD88 and TIRAP, which are signalling molecules 
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downstream of TLR9 and many other TLRs, have markedly reduced frequencies of 
IgM+IgD+CD27+ B cells, but normal frequencies of switched B cells and suffer from 
recurrent infections caused by pyogenic bacteria such as S.pneumoniae and S.aureus 
(Weller et al., 2012, Maglione et al., 2014, Picard et al., 2010). As these patients have 
a similar level of mutations in the VH3 of their CDR3 regions as healthy controls, the 
authors thought that signalling through TLRs is more likely to play a role in the 
maintenance and activation of these cells as opposed to their development and 
differentiation. Maglione et al recently showed that patients deficient in IRAK-4 and 
MyD88 differ from healthy controls as they have reduced serum levels of IgM 
antibodies specific for a number of pneumococcal antigens. In addition, circulating 
CD27+ B cells from these patients do not produce IgM antibodies specific for the 
pneumococcal antigen PC in response to stimulation with TLR9 or TLR7 agonists. 
Furthermore, proliferation of circulating IgM+IgD+CD27+ B cells in response to TLR9 
and TLR7 agonists was observed in healthy controls but not in these patients 
(Maglione et al., 2014). The response to TLR7 and TLR9 agonists in patients deficient 
in TIRAP was not included in this study. Interestingly, Weller et al found that the 
frequency of IgM+IgD+CD27+ B cells in patients deficient in UNC-93B was 
comparable to healthy controls (Weller et al., 2012). This suggests that TLR7 and 
TLR9 may not play an essential role in the maintenance of IgM memory B cells as 
UNC-93B is essential for signalling through TLR7 and TLR9 (Casrouge et al., 2006, 
Brinkmann et al., 2007). UNC-93B does not play a role in TLR10 signalling however, 
but TIRAP is downstream of MyD88 in this signalling pathway. Based on this fact and 
the observations that TLR10 is expressed at higher levels on IgM+IgD+CD27+ B cells 
than class switched or naïve B cells, and that TIRAP deficient patients had the most 
marked reduction in their IgM+IgD+CD27+ B cells, the authors proposed that TLR10 
may play an essential role in IgM+ memory B cell maintenance (Hasan et al., 2005, 
Weller et al., 2012). At present this hypothesis cannot be reconciled with the in vitro 
effects observed on this B cell subset in the presence of TLR7 and TLR9 agonists as 
the ligand for TLR10 is still not known (Lee et al., 2014, Oosting et al., 2014).  
1.2.6.2 IgM+ memory B cells are the pre-cursors of class switched memory B 
cells and are a product of germinal centres 
An alternative hypothesis for the origin of IgM+ memory B cells is that they are early 
products of a germinal centre reaction and have left the germinal centre before class 
switching has occurred. This hypothesis is supported by three papers published by 
Ralf Kuppers and colleagues who believe that the IgM only B cell subset 
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(IgM+CD27+IgD-) remains in the germinal centre for longer than the IgM+CD27+IgD+ 
subset, and therefore IgD is down-regulated, but it leaves the germinal centre before 
class switching has occurred. In the first paper they show how a ‘molecular footprint’ 
of germinal centre involvement can be detected in the form of mutations in Bcl6, the 
master transcriptional regulator of germinal centre B cells that is highly expressed in 
germinal centre B cells. By sequencing the CDR3 regions of the IgM+CD27+IgD+ B 
cell subset, they also provided evidence for a clonal relationship between IgM+ 
memory B cells and class switched IgG+ B cells in a small number of clones (Seifert 
and Küppers, 2009). The second paper provided some evidence to suggest that IgM+ 
memory B cells possess a greater homing capacity to the follicle border than naïve or 
IgG class switched subsets and that this may indicate that they may participate in 
secondary germinal centre reactions (Seifert et al., 2015). In the third paper, the group 
used next generation sequencing to show that the IGHV region of IgM only B cells 
(IgM+CD27+IgD-) carries an intermediate number of mutations compared to 
IgM+CD27+IgD+ cells which have the lowest, and IgG+CD27+IgD- which have the 
highest. They found that there was a substantial number of clones amongst the 
different subsets that were related to one another. Interestingly, the larger the number 
of members a clone had, the more likely it was that it would be detected in all three 
subsets. However, they did also show that not all clones had members shared across 
the three different subsets and some were exclusively found only in the 













 B cell functions: beyond antibody production 
During the last decade studies focusing on B cells have established that they are much 
more than just pre-cursors to antibody producing plasma cells. The B cell itself is now 
regarded as having a whole range of functions that contribute to the pathogenesis of 
disease but also to the regulation of an immune response. It has emerged that the 
contribution of B cells in disease pathogenesis is highly complex and an individual’s B 
cells may behave quite differently in two people with the same disease. 
1.2.7.1 B cells as antigen presenting cells 
Dendritic cells are widely viewed as highly efficient antigen presenting cells and are 
often termed “professional APC,” as they are believed to be the APC that prime naïve 
antigen specific CD4+ T cells and induce an adaptive immune response. Only once 
these T cells are primed, can they go on to activate B cells. The influence that these 
activated B cells have on the immune response is not to be dismissed however, as 
they provide a source of antigen specific APC that can efficiently take up protein 
antigen at much lower concentrations than required for DCs, clonally expand and 
present many different epitopes of the antigen to cognate T cells, thus  diversifying the 
original immune response induced by the dendritic cell (Constant, 1999, Constant et 
al., 1995b, Constant et al., 1995a, Mamula and Janeway, 1993, Wilson et al., 2012, 
Rivera et al., 2001). B cells are much more than just pre-cursors to antibody secreting 
cells and several studies using B cell deficient mice have demonstrated that they are 
essential for the formation of diverse and effective primary and secondary immune 
responses.   
Linton et al. showed that B cells were required for optimal priming of a T cell response 
as the expansion of antigen specific CD4+ T cells post immunisation with KLH was 
reduced in µMT mice, which are B cell deficient, compared to wild type. Interestingly, 
they found that when they used multiple boosters in an attempt to overcome the lack 
of B cells and allow DC only priming, this did not have an effect on antigen specific 
CD4+ T cell numbers. They also showed that this reduced expansion of CD4+ effector 
cells had a knock on effect on the development of an optimal memory T cell 
compartment as there were reduced antigen specific memory T cells in µMT mice.  By 
enriching µMT mice with antigen specific B cells, the antigen specific memory T cell 
compartment could be restored (Linton et al., 2000). Some studies using B cell 
deficient mice reported that B cells were not required for priming an effective T cell 
response, so Rivera and colleagues sought to reconcile any differences in the literature 
with regards to the effect that B cell deficiency had on T cell priming. They used µMT 
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mice on different genetic backgrounds to show that T cell priming is consistently 
reduced in the absence of B cells in BALBc, SFL or BALBc/B6 F1 mice, but results 
were more variable when C57BL/6 (B6) were used. By using bone marrow chimeras 
where the immune system had been able to develop in the presence of B cells, but 
was then subsequently depleted of them, they showed that the reduced priming of the 
T cell response was not due to impaired development of the immune system (Rivera 
et al., 2001).  
B cells may also play a role in skewing the type of T cell response depending on the 
antigen. For example, Wilson et al described that B cells specific for aggrecan, an 
antigen important in the induction of proteoglycan-induced arthritis in mice, were as 
efficient as DCs, and more efficient than macrophages, at stimulating antigen specific 
CD4+ T cell IFNγ production and differentiation of Th1 cells (Wilson et al., 2012). 
However, Linton et al found that in OT-II transgenic mice, B cells were required for the 
production of Th2 cytokines IL-4 and IL-13 and that in their absence the immune 
response was skewed towards a Th1 phenotype upon antigen challenge with OVA 
peptide (Linton et al., 2003).   
Several studies in mice have demonstrated that the initiation of autoimmune disease 
is dependent on the presence of B cells (Molnarfi et al., 2013, Noorchashm et al., 1997, 
Shlomchik et al., 1994). For example, Falcone et al. demonstrated that in NOD mice, 
B cells were required for an optimal T cell response to Type I Diabetes antigen GAD65 
(Falcone et al., 1998). To complement this finding, Serreze et al showed that B cell 
deficient NOD.Igμnull mice did not develop diabetic disease. Moreover, reconstitution of 
these mice with immunoglobulin did not render them susceptible to disease. 
Interestingly, they found that although other APC could propagate T cell responses to 
GAD, they were less adequate than B cells at inducing these responses in the first 
place (Serreze et al., 1998). A series of papers published by Shlomchik and colleagues 
demonstrated that B cells were required for the pathogenesis of murine lupus. In a 
spontaneous model of murine lupus (MLR lpr/lpr), mice who lacked B cells had greater 
frequencies of CD8+ and CD4+ naïve T cells and therefore reduced frequencies of 
activated and memory T cells than their B- intact counterparts (Chan and J. Shlomchik, 
1998). When this model was genetically modified to have an intact fas gene (MR/+) 
and therefore more representative of a human, the absence of B cells abrogated the 
development of lupus nephritis (Chan et al., 1999b).  By creating a transgenic Ig MLR 
lpr/lpr mouse model so immunoglobulin could not be secreted, Chan et al 
demonstrated that B cells exerted their pathogenic effect in an antibody independent 
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manner, most likely mediated by antigen presentation to the T cells, or secretion of 
pro-inflammatory cytokines (Chan et al., 1999a).  
In support of a role for B cells as essential antigen presenting cells, Lund et al. used 
bone marrow chimeras to specifically knock out MHC Class II expression on B cells in 
a mouse model of Pneumocystis carinii. They showed that formation of effective T cell 
effector and memory responses as well as clearance of the pathogen was dependent 
on the presence of B cells that had intact MHC class II expression (Lund et al., 2006, 
Opata et al., 2015). This study was supported by data from Crawford et al who reported 
that both primary and secondary responses to a peptide from Moloney murine 
leukaemia virus were reduced in the MHC class II bone marrow chimeras (Crawford 
et al., 2006) and Molnarfi et al who more recently demonstrated that B cell MHC class 
II expression is required for the induction of disease in a rhMOG immunised model of 
EAE (Molnarfi et al., 2013). 
Finally, there is evidence for B cells as antigen presenting cells in murine models of 
transplantation. The most convincing study was published by Zeng et al. They used a 
combination of µMT and AID/µS knockout mice (the latter cannot secrete antibodies) 
to show that B cells in the absence of antibodies are sufficient to mediate chronic 
allograft vasculopathy in a heterotopic cardiac transplant model. Moreover, they 
showed that CD4+ and CD8+ T cell cytokine responses and graft infiltration were both 
reduced in the absence of B cells. The effects observed in the µMT mice were thought 
to be partially mediated by B cell antigen presentation to T cells and partially by 
disruption of the lymphoid architecture (Zeng et al., 2014). Noorchasm et al showed 
that mice deficient in MHC class II expressing B cells reject a vascularised heart 
transplant at a slower rate than wild type mice and had delayed production of antigen 
specific antibody. This model did however rapidly reject a skin transplant (Noorchashm 
et al., 2006). A similar result was observed in a skin transplant using a B cell deficient 
µMT mouse model, however the authors of this study reported that B cells promoted 
the differentiation of effector CD8+ and CD4+ T cells into memory T cells (Ng et al., 
2010). Recently, Tse et al showed that infiltrating B cells could be detected in tertiary 
lymphoid structures within a murine renal graft with chronic allograft damage (CAD). 
These B cells secreted CCL1, CCL5 and CXCL10, which are known chemoattractants 
of neutrophils, macrophages and T cells, and pro-inflammatory cytokines IL-16, IL-18 
and TNFα. When B cells were depleted using an anti-CD20 antibody, the extent of the 
CAD was reduced along with a reduction in tertiary lymphoid structures (Tse et al., 
2015). There is therefore potentially a role for B cells in promoting the alloresponse 
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long-term and contributing to chronic rejection. As skin is the most immunogenic tissue 
to transplant, it is possible that any effect of the B cells as APCs is largely 
overshadowed by resident dendritic cells, but the results from the other studies suggest 
that B cells may play a more significant role in the rejection of other organs such as 
























 B cells as regulatory cells 
The capacity for a B cell to provide a regulatory role in an immune response is currently 
of great interest to many immunologists. Unearthing the mechanism of action and 
phenotype of so-called Breg cells could potentially lead to novel and effective therapies 
that could be used in the control of allograft rejection and a number of autoimmune 
diseases.  
1.2.8.1 Evidence for regulatory B cells in mice 
Studies have been published in a number of mouse models that suggest an essential 
role for B cells in the effective regulation of the immune response. Tedder and 
colleagues have identified a subset of murine IL-10 producing B cells that have been 
termed B10 cells. B10 cells are found in the spleen and are predominantly 
CD1dhighCD5+ (Yanaba et al., 2009, Yanaba et al., 2008). In vitro, this subset of cells 
can be induced to produce IL-10 after stimulation with TLR4 agonist LPS, in 
combination with mitogens PMA and ionomycin. In vivo, they have been shown to 
increase in numbers and prolong survival in a NZB/W mouse lupus model (Watanabe 
et al., 2010). Interestingly, the importance of B10 cells to the regulation of the immune 
response in this model was emphasised when it was found that reduced regulatory T 
cell numbers could be restored in CD19-/- NZB/W mice upon adoptive transfer of 
CD1dhighCD5+ cells from CD19+/+ mice.  
B cell deficient mice (µMT) develop more severe disease than wild type mice when 
injected with MOG antigen known to induce an experimental model of multiple 
sclerosis (experimental autoimmune encephalitis (EAE)). IL-10 production by B cells, 
and subsequently its protective effect in this model, was shown to be dependent on 
stimulation of antigen specific B cells in combination with CD40 ligation (Fillatreau et 
al., 2002). Interestingly, the protective effect of IL-10+ B cells was only seen after a 
number of days when disease symptoms in the wild type mice were alleviated 
compared to the µMT mice. This suggests that the B cells with regulatory function in 
this model need to undergo a maturation process before they can exert their inhibitory 
effects. This line of thinking is supported by the fact that when the same mice were 
knocked out for CD40, only an IgM response was mounted which did not result in the 
production of IL-10, suggesting that in this model, the B cells may require germinal 
centre reactions and class switching in order to develop regulatory capacity (Fillatreau 
et al., 2002).IL-10 producing B cells have been shown to positively impact regulatory 
T cell numbers in a mouse model of collagen induced arthritis. The specific depletion 
of IL10+ B cells from mice resulted in exacerbated arthritis disease and a significant 
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decrease in numbers of FoxP3+ T cells, coupled with an increase of Th1 and Th17 
cells. In this model, the marginal zone transitional 2 B cells were deemed the 
necessary cell population required to restore the Treg/Th1/Th17 cell balance and not 
B10 cells (Carter et al., 2012). 
1.2.8.2 Evidence for regulatory B cells in humans 
In humans, B cells have the potential to secrete IL-10 and have been shown to have 
the ability to expand regulatory T cells, suppress T cell proliferation, inhibit the 
differentiation of naïve T cells into pro-inflammatory Th1 cells and suppress pro-
inflammatory cytokine secretion by monocytes (Blair et al., 2010, Chesneau et al., 
2015, Iwata et al., 2011, van de Veen et al., 2013, Chen et al., 2009).  
1.2.8.3 Phenotype of regulatory B cells 
As the study of regulatory B cells (Bregs) in humans is still in its infancy, work is 
ongoing to establish whether there is a common origin for all Bregs and if a unique 
phenotype can be assigned to this population. The potential to produce IL-10 is one of 
the most common features used to define a Breg.  In humans, phenotypes using cell 
surface markers of circulating B cells are variable and include that of transitional B 
cells, CD38hiCD24hi (Blair et al., 2010, Flores-Borja et al., 2013, Das et al., 2012a), 
memory B cells CD24hiCD27+ (Iwata et al., 2011), activated B cells; large CD25+ B 
cells and CD25+CD71+CD73- (Tretter et al., 2008, van de Veen et al., 2013) and 
CD24hiCD27int plasmablasts (Matsumoto et al., 2014). Additional markers that have 
also been used to describe a Breg include CD1d, CD5, CD10 and TIM-1 (Ma et al., 
2014, Blair et al., 2010). These varied results suggest that regulatory properties are 
not exclusive to one subset of B cells, a hypothesis that is supported by the findings of 
Cherukuri et al which showed that all B cell subsets (transitional, naïve and memory) 
were able to produce IL-10, but it was the balance between anti-inflammatory IL-10 
and pro-inflammatory TNF-a produced by each B cell subset that equipped them with 
the ability to suppress a Th1 response (Cherukuri et al., 2014).  
1.2.8.4 Regulatory B cells suppress the inflammatory T cell response 
Maximum inhibition of the production of Th1 cytokines TNFα and IFNγ by CD4+CD25-
T cells has been shown to be directly mediated by IL-10 derived from CD40L+CpG 
stimulated transitional B cells, in combination with the ligation of co-stimulatory 
molecules CD80 and CD86, indicating that regulatory B cells exert their functions by 
both soluble factors and direct cell-cell contact (Blair et al., 2010). In addition, this 
subset of B cells has been shown to inhibit the differentiation of naive T cells into either 
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IFNγ+T-bet+ (Th1) or RORC2+ (Th17) cells in  either Th1 or Th17 cell polarising 
conditions, but the authors did not investigate whether this was IL-10 dependent 
(Flores-Borja et al., 2013).  
1.2.8.5 Regulatory B cells support the Regulatory T cell response 
Flores-Borja et al demonstrated that CD24hiCD38hi B cells were able to convert 
CD4+CD25- T cells into CD4+CD25+CD127- regulatory T cells that were able to 
suppress the proliferation of autologous CD4+CD25-CD127+ T cells. This process was 
partially dependent on IL-10 secretion by the B cells (Flores-Borja et al., 2013).   
1.2.8.6 Regulatory B cells Inhibit T cell proliferation 
A study by Chesneau et al suggests that one of the mechanisms that B cells use to 
regulate a T cell response is by inducing apoptosis in the T effector cell. By co-culturing 
CD40L+CpG activated B cells with activated CD4+CD25- T cells, they showed that the 
inhibition of T cell proliferation was dependent on B cell derived Granzyme B 
production and cell-cell contact. In addition, they found that a higher proportion of 
CD4+CD25- T cells expressed Annexin 5 upon co-culture with activated B cells 
(Chesneau et al., 2015). Apoptosis was also shown to be the mechanism by which 
large CD25+ B cells inhibited CD4+ T cell proliferation in a study by Tretter et al where 
the B cells were polyclonally stimulated with anti IgM/IgG or Cowan I antigen of S. 
aureus (SAC) prior to co-culture with the CD4+ T cells (Tretter et al., 2008).  
Bouaziz et al showed that B cells activated with CpG and anti-Ig were able to inhibit 
proliferation of CD4+CD25- T cells in a partially IL-10 dependent manner (Bouaziz et 
al., 2010). They did not investigate T cell apoptosis in these experiments but the 
findings of Chesneau et al may reconcile why IL-10 did not completely inhibit T cell 
proliferation.   
1.2.8.7 Regulatory B cells in disease 
Regulatory B cells have been studied in a variety of disease settings. Reduced Breg 
frequencies are associated with increased disease activity in patients with rheumatoid 
arthritis (Ma et al., 2014) and the ability of B cells to produce IL-10 upon polyclonal 
stimulation is reduced in both RA and SLE (Blair et al., 2010, Flores-Borja et al., 2013). 
In addition, B cell infiltrates have been detected in solid epithelial tumours and are 
hypothesised to suppress anti-tumour immunity by inhibiting T cell proliferation in a 
granzyme B dependent manner (Lindner et al., 2013). It has also been hypothesised 
that regulatory B cells contribute to the control of chronic viral infection through IL-10 
production. Serum IL-10 levels and increased frequencies of regulatory B cells 
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correlate with periods of decreased viral load and disease flares in patients infected 
with Hepatitis B (Das et al., 2012a).  
At present, studies on regulatory B cells suggest that more than one subset of B cells 
can exhibit a regulatory function if exposed to the correct combination of stimuli. In 
addition, the mechanism of regulation, and the regulatory or suppressive effect of these 
B cells differs according to experimental design and disease setting. Most studies that 
investigate regulatory B cells in humans involve polyclonal methods of B cell 
stimulation such as LPS, CpG and CD40L, so the importance of BCR ligation and 
antigen specificity to the differentiation or activation of regulatory B cells remains 
unclear.  Whether the differentiation and activation of regulatory B cells is dependent 
on specific antigenic stimulation or just the right inflammatory environment requires 
further investigation.  
1.2.8.8 Regulatory B cells in transplantation and transplant tolerance 
A patient is defined as operationally tolerant to their transplant if they have stable graft 
function in the absence of immunosuppression for at least one year (Brouard et al., 
2012). These patients are a rare phenomenon in a renal transplant setting, but when 
such patients are identified, they become a valuable resource for studying potential 
mechanisms by which the immune system becomes tolerant to a transplant (Brouard 
et al., 2012). 
Interest around the contribution that B cells make to allograft tolerance has gained 
momentum since it was reported that tolerance could only be induced in a mouse 
model of cardiac transplantation when B cells were present, and that direct interaction 
between T and B cells via costimulatory molecules CD40 and CD80/86 was essential 
for this process (Deng et al., 2007). Since then, there have been several studies 
published that point towards B cell involvement in the induction or maintenance of 
operational tolerance in a kidney transplant setting. Several studies have proposed a 
B cell signature of tolerance as tolerant patients were found to have a differential gene 
expression from patients who had stable graft function and were on 
immunosuppression. Many of the differentially expressed genes were associated with 
B cell differentiation, proliferation, immunoglobulin receptor editing and apoptosis 
(Newell et al., 2010, Sagoo et al., 2010, Chesneau et al., 2015, Pallier et al., 2010). 
There is however discordance between these studies with regards to what B cell 
related genes are differentially expressed, a fact which makes it difficult to know where 
to focus future studies in terms of functionally assessing the immune-mediated 
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mechanisms behind these gene expression profiles. Nevertheless, attempts have 
been made to correlate in vitro findings in these patients with clinical outcomes and 
their respective gene expression profiles. One of the most consistent findings that has 
been reported across the studies is that tolerant patients have both higher numbers 
and frequencies of B cells in their peripheral blood compared to the stable patients on 
immunosuppression (Sagoo et al., 2010, Newell et al., 2010, Louis et al., 2006, Pallier 
et al., 2010). It has also been reported that tolerant patients have a higher frequency 
of transitional B cells than stable patients and thus potentially have a higher frequency 
of regulatory B cells, as for now, these B cell subsets have an indistinguishable 
phenotype (Pallier et al., 2010, Chesneau et al., 2015, Newell et al., 2010). 
Interestingly, one study has reported that tolerant patients produce more IL-10 after 
polyclonal stimulation than stable patients (Newell et al., 2010) and other studies have 
reported that there was no difference in the B cell IL-10 profile of the two groups 
(Chesneau et al., 2015, Pallier et al., 2010, Silva et al., 2012, Sagoo et al., 2012). In 
addition to these IL-10 related findings, tolerant patients have also been found to 
express more granzyme B than stable patients (Chesneau et al., 2015), have a skewed 
phenotype towards increased TGF-β production (Sagoo et al., 2012, Sagoo et al., 
2010), express a lower ratio of activating to inhibitory FC receptors (FcgRIIa:FcgRIIb) 
and have a higher proportion of memory B cells that express co-stimulatory molecules 
CD80/86 and CD40 (Pallier et al., 2010). It is important to stress that in many of the 
parameters measured in the studies mentioned above, the tolerant patients were 
remarkably similar to the healthy controls. This finding was confirmed in a study by 
Silva et al where they concluded that tolerance was indicated by an intact immune 
system, particularly with regards to its regulatory capacity (Silva et al., 2012).  
In support of a regulatory role for B cells in controlling the alloimmune response, lower 
frequencies of transitional B cells have been reported in patients who are rejecting their 
grafts (Cherukuri et al., 2014, Nouel et al., 2014, Shabir et al., 2015). In addition, 
Cherukuri and colleagues found that the transitional B cells of those patients that were 
rejecting their grafts expressed a lower ratio of IL-10:TNFα and that this lower ratio of 







 The role of B cells in human disease: lessons learned from Rituximab 
Determining the role that B cells play in human disease requires extrapolation from 
data reported on patients with the primary immunodeficiency disease x-linked 
aggamglobulinaemia and the use of the B cell depleting agent Rituximab. Rituximab is 
a chimeric human/mouse IgG1 anti-human CD20 monoclonal antibody that was first 
approved in 1997 by the Food and Drug Administration (FDA) for use in the treatment 
of the B cell malignancy Non-Hodgkins lymphoma (Plosker and Figgitt, 2003, Harrison 
et al., 2014). CD20 is exclusively expressed on the surface of B cells from the immature 
bone marrow stage, right up until differentiation into a plasma cell. Rituximab is 
therefore effective at targeting B cells but not plasma cells. It’s mechanism of action 
remains unclear but it is hypothesised that it could be killing both malignant and healthy 
B cell populations through 2 different mechanisms. Firstly, by antibody mediated 
cytotoxicity (ADCC), where Rituximab forms a complex between the B cell via the 
CD20 specific fab region, and an NK cell or monocyte via CD16, the FCγRIIIA receptor. 
This interaction would lead to activation of the NK cell and subsequent killing of the B 
cell. The second proposed mechanism is by complement dependent cytotoxicity 
(CDC) where the Fc portion of Rituximab binds the classical complement pathway c1q 
and initiates the cascade of events that leads to the membrane attack complex being 
formed on the B cell. 
1.2.9.1 Rituximab in autoimmune disease 
Autoimmune disease is caused by the breakdown of tolerance mechanisms which 
normally prevent the immune system from recognising self-antigens as foreign. B cells 
are thought to play a role in the pathogenesis of several autoimmune diseases 
including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple 
sclerosis (MS), pemphigus vulgaris and ANCA-associated vasculitis. In many of these 
diseases, class switched antibodies against self-antigens, such as rheumatoid factor 
in RA, anti-dsDNA antibodies in SLE or anti-neutrophil cytoplasmic antibodies in ANCA 
associated vasculitis, are detected in the blood stream or at the sites of inflammation 
(Jones, 2014, De and Barnes, 2014, Hoffmann and Meinl, 2014, Bugatti et al., 2014). 
The presence of these antibodies is an indication that B cells have been activated and 
are engaged in interactions with cognate T cells. These B cells are therefore potentially 
contributing to disease pathogenesis not only through antibody-mediated 
mechanisms, but also through antigen presentation and cytokine secretion as 
discussed above. This hypothesis has led to the use of Rituximab in the treatment of 
several autoimmune diseases with varying levels of success. In RA and SLE, 
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Rituximab use has been reported to be effective at reducing disease activity in patients 
refractory to traditional lines of treatment (Lu et al., 2009, Edwards et al., 2004, 
Edwards and Cambridge, 2001, Leandro et al., 2006, Roccatello et al., 2011, Moore 
et al., 2004) and has been successfully used in combination with mycophenolate 
mofetil (MMF) and methylprednisolone, but in the absence of oral steroids, to reduce 
symptoms of lupus nephritis (Condon et al., 2013). A meta-analysis of studies of 
pemphigus patients concluded that those treated with Rituximab achieve complete 
remission quicker than those receiving conventional therapy only (Wang et al., 2015), 
and in multiple sclerosis patients, Rituximab has proved successful in improving 
disease symptoms in patients with relapsing remitting MS, but less so in those with 
primary progressive MS (Castillo-Trivino et al., 2013). Dissecting out the role that the 
B cells are playing as antigen presenting cells and cytokine secretors in these diseases 
is difficult, as a reduction in autoantibodies is often observed in patients that have 
improved clinically after receiving Rituximab (Lu et al., 2009, Edwards and Cambridge, 
2001, Cambridge et al., 2006). However, Leandro et al reported that relapse in their 
RA patients was associated with higher frequencies of memory B cells re-populating 
the B cell compartment post Rituximab treatment (Leandro et al., 2006, Edwards and 
Cambridge, 2001). Thus, results from studies using Rituximab in humans, combined 
with data from the animal studies using µMT mice described above, can be 
extrapolated to hypothesise that depleting B cells affects autoimmune disease 
pathogenesis in multiple ways, and is not exclusively due to reducing the deleterious 
effects of autoantibodies. 
Rituximab has also informed us of the role that B cells may play in regulating 
autoimmunity, as in some cases, treatment with Rituximab has led to the exacerbation 
of existing disease or the onset of new inflammatory diseases (Dass et al., 2007, 
Mielke et al., 2008, Fassi et al., 2008, Goetz et al., 2007).  
Although licensed for use for treating Non–Hodgkins lymphoma, the use of Rituximab 
for autoimmune disease remains largely off-label due to varying reports of efficacy 
from clinical trials that have used the drug (Beckwith and Lightstone, 2014). 
1.2.9.2 Rituximab and chronic antibody mediated rejection 
Off-label use of Rituximab in a transplant setting is becoming more common and its 
effectiveness at controlling both acute and chronic allograft rejection is being studied 
in several clinical trials. Table 1.1 provides a summary of studies and clinical trials that 








RTX 2x 375mg/m2/wk 
IVIg 1g/kg/wk  
Graft survival rates no different to control patients. Treatment associated with higher frequency of 
adverse events. 
(Bachelet et al., 2015) 
CAMR. Adults RTX 1x 375mg/m2 
IVIg 0.4g/kg for four days 
 
Stabilisation of graft function was associated with RTX treatment. Higher graft survival rates at 3 
year follow up were associated with RTX treatment and low proteinuria.  




Banff ’05 criteria 
IVIg 4x 1g/kg/wk  
RTX 1x 375mg/m2 
 
Improvement or stabilisation of glomerular filtration rate at 6 months post intervention in 70% 
patients studied. 100% patients without TG responded, compared to only 45% who had TG. A 
greater degree of TG was associated with non-responsiveness. Class I and II DSA became 
undetectable in 7/20 patients 12 months post intervention. 
(Billing et al., 2012) 
CAMR. Adults RTX 1x 375mg/m2 (day 1) 
IVIg 0.4g/kg/day (days 2-5) 
Improvement of graft function seen in 4/4 patients for first 6 months post treatment. Reduction of 
DSA observed in 2/4 patients.  




RTX 2-4x 375mg/m2/wk 
 
Stabilisation of kidney function and reduction in albuminuria observed in 7/14 (50%) of patients 
given Rituximab when patients monitored for 30 month period post Rituximab administration.  
(Rostaing et al., 2009) 
CAMR. 
Paediatrics.  
IVIg 4x 1g/kg/wk  
RTX 1x 375mg/m2 
 
Improvement or stabilisation of glomerular filtration rate in 4/6 patients studied. Non-
responsiveness to therapy associated with a greater degree of TG at intervention. 
(Billing et al., 2008) 
CAMR. Adults RTX 2x1g: day 0 and day 14.  N/A RituxiCAN C4 trial 
Clinicaltrials.gov.uk no: 
NCT00476164. Trial still 
ongoing.  




 Rationale for this thesis 
 Chronic antibody mediated rejection: are antibodies really the cause?  
The presence of circulating anti-donor antibody pre-transplant is a well-established 
contraindication to transplantation as it can result in hyperacute rejection. Many studies 
have reported that kidney transplant patients can generate de novo donor specific HLA 
antibodies (DSA) within months to years post-transplant, but the importance of these 
antibodies in terms of mediating rejection remains poorly understood (Wiebe et al., 
2012). Despite this lack of mechanistic insight, the term ‘chronic antibody mediated 
rejection’ (CAMR) is routinely used as a diagnosis, due to the well-established 
correlation between the presence of circulating DSA post-transplant and worse long 
term graft survival (Lachmann et al., 2009, Campos et al., 2006, Worthington et al., 
2003, Pelletier et al., 2002, Lee et al., 2002). In support of the hypothesis that 
antibodies are the cause of the pathology observed in chronic rejection, several studies 
have found that C4d deposition in the endothelium of renal grafts also correlates with 
graft deterioration (Böhmig et al., 2002, Feucht et al., 1993, Lederer et al., 2001, 
Gaston et al., 2010, Mauiyyedi et al., 2001). When an antibody binds graft endothelium, 
it activates the classical complement cascade. C4d is a stable by-product of the 
classical complement cascade as it covalently binds to the graft endothelium and 
hence can be detected long after the antibody first binds and is no longer detectable 
itself. C4d deposition has therefore become a surrogate marker for antibody mediated 
complement activation that is routinely used in the diagnosis of antibody mediated 
rejection (Mauiyyedi et al., 2001). From these associations between poor graft 
outcome, DSA and C4d deposition, a model to describe the pathogenesis of CAMR 
was devised by Robert Colvin and colleagues and is frequently referenced by 
transplant clinicians and scientists throughout the world (Wiebe et al., 2012, Colvin and 
Smith, 2005, Smith et al., 2008, Colvin, 2007, Djamali et al., 2014). The model is 
illustrated in Figure 1.5. 
Despite these strong associations, it has become apparent that there are some 
anomalies that require addressing before a definitive mechanistic cause of antibody 
mediated rejection can really be concluded. Primarily, these are: 1) The observation 
that some individuals maintain good graft function for many years after the 
development of donor specific antibody (Bartel et al., 2008, Hayde et al., 2014, Banasik 
et al., 2013, Campos et al., 2006, Lee et al., 2002).  2) Some individuals meet the 
histological or clinical criteria for CAMR but do not have evidence of circulating DSA 
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or C4d deposition (Akalin et al., 2007, Worthington et al., 2003, Campos et al., 2006, 
Wiebe et al., 2012, Haas et al., 2014, Sis et al., 2009, Rostaing et al., 2009). 3) The 
length of time between development of DSA and graft dysfunction can be many years. 
This highlights the question, why do the antibodies in a chronic setting mediate 
rejection at a much slower rate than in hyperacute or acute AMR? 4) To date, there is 
no published evidence in humans to demonstrate directly that antibodies are causing 
the damage observed in CAMR.  
In addition, there is evidence to suggest that low concentrations of antibody may play 



























Figure 1.5 The four stages of CAMR 
The first three stages of CAMR are sub-clinical, where graft function is yet to 
deteriorate. The onset of this slow progression to graft deterioration begins with 
formation and subsequent detection of DSA in the circulation (I). These antibodies then 
bind the donor HLA molecules on the graft endothelium and activate the classical 
complement pathway, which is detected by positive C4d staining on the endothelium 
(II). Once enough complement activation has occurred to cause substantial damage 
to the architecture of the endothelium, this can be detected on biopsy in the form of 
interstitial fibrosis and tubular atrophy (III). Eventually, this damage becomes extensive 
enough to cause a decline in graft function which can be detected clinically by rising 
creatinine levels, decreasing glomerular filtration rates (eGFR) and proteinuria (IV).  








 Evidence for a cellular component in chronic antibody mediated 
rejection.  
Given the data presented in section 1.2, it is important to keep an open mind when 
investigating the cause of chronic rejection and long term graft failure. The presence 
of class switched DSA in the circulation provides evidence that cellular activation of 
the immune system has occurred and that there has been cognate interactions 
between T and B cells. It is possible that DSA are merely a biomarker of this cellular 
activity and potentially non-pathogenic. An observational study carried out in the 
supervisors lab has provided evidence to suggest that in some individuals, there may 
be a cellular component involved in driving chronic rejection (Shiu et al., 2015). In this 
study, an indirect IFNγ ELISpot assay was used to investigate the contribution that B 
cells and regulatory T cells make to CD4+ T cell IFNγ production in response to donor 
membrane proteins. The data revealed that cellular responses to donor membrane 
proteins in kidney transplant patients with CAMR are both complex and 
heterogeneous. In a subset of samples, in vitro depletion of CD19+ cells revealed B 
cell dependent IFNγ production.  When B cell activation was inhibited by adding 
Btk/Syk inhibitors to the cultures of these samples, IFNγ production was diminished. 
In addition, IFNγ production was also diminished in these samples when the antigen 
processing and presentation pathway was targeted by adding leupeptin/pepstatin 
A/E64-d or an anti-class II antibody to the cultures. Together, these experiments 
provide evidence to suggest that B cells may be processing and presenting donor 
antigens to pro-inflammatory CD4+T cells. Conversely, a potential regulatory role for 
B cells was revealed in some samples, as IFNγ production in response to donor 
membrane proteins increased post CD19+ cells depletion (Shiu et al., 2015).  
The results from this study also provided evidence to suggest that chronic rejection is 
not necessarily simply due to a dysregulated alloimmune response as IFNγ production 
in response to donor membrane proteins was only revealed in some samples when 
CD25+ cells were depleted from the cultures. To add to the complexity, B cell 
dependent IFNγ production was only revealed in some samples upon depletion of both 
CD25+ and CD19+ cells, suggesting that in these samples, CD4+ T cell IFNγ 
production was mediated by B cell antigen presentation but was suppressed in the 
presence of CD25+ cells (Shiu et al., 2015).  
Finally, the patterns of reactivity in response to donor membrane proteins changed 
over time suggesting that the cellular alloimmune response in these patients is highly 
dynamic (personal communication with K Y Shiu and A Dorling). The results from this 






Figure 1.6 A working model for the contribution of B cells to cellular mediated rejection 
via the indirect pathway of allorecognition.  
(a) When HLA antigens are shed from the graft they bind B cells that possess antigen 
specific B cell receptors on their surface. (b) The antigen-BCR complex is internalised 
and the antigen is processed and presented as peptides to helper CD4+ T cells. These 
T cells may or may not have been previously primed by other antigen presenting cells 
(c). (d) The CD4+ T cells are activated to produce pro-inflammatory cytokines such as 
IFNγ which in turn activates effector CD8+ T cells and macrophages which home to 
the graft and cause damage (e). (f) The interaction between the B cell and the CD4+ 
T cell is reciprocal. The CD4+ T cell provides signals for the B cell to differentiate into 





























Based on the results described in Shiu et al, and the working model described in Figure 
1.6, the major aims of this thesis were: 
1. To replicate the different patterns of reactivity found in the IFNγ ELISpot 
reported by Shiu et al. in a different cohort of renal transplant patients with 
chronic antibody mediated rejection who have been enrolled in the RituxiCAN 
C4 clinical trial. 
 




3. To investigate the phenotype of B cells as they re-populate the periphery in a 
subset of patients enrolled in the RituxiCAN C4 trial who received Rituximab 
treatment. 
 
4. To detect and phenotype HLA specific B cells in the circulation of patients 
enrolled in the RituxiCAN C4 trial. 
 
 
5. To correlate the phenotype of HLA specific B cells with the pattern of reactivity 













Based on the literature reviewed above, the following hypotheses were made: 
1. The patterns of reactivity in the IFNγ ELISpot reported in Shiu et al will be 
broadly replicated in the patients enrolled in the RituxiCAN C4 trial. 
 
2. The phenotype of HLA specific B cells will be predominantly a class switched 
memory phenotype. 
 
3. The phenotype of the HLA specific B cells will correlate with the pattern of 
reactivity in the IFNγ ELISpot:  
a) Individuals who produce IFNγ in response to HLA proteins in a B 
dependent manner, will have an HLA specific B cell phenotype that is 
skewed towards a memory phenotype. 
b) Individuals who have a B regulated pattern of reactivity in response 
to HLA proteins will have an HLA specific B cells that are skewed 















2 Materials and Methods 
 
 RituxiCAN C4 trial: Patient recruitment and study 
overview 
All patient blood samples used in this thesis were taken from patients enrolled onto the 
RituxiCAN C4 trial. Ethical approval for this study was obtained from the Hammersmith 
and Queen Charlotte’s ethics committee, the research ethics approval (REC) number 
for the study is 06/Q0406/119. The clinicaltrials.gov identification number for the trial 
is NCT00476164. Figure 2.1 provides an overview of the study protocol.  Patients 
enrolled onto the trial must have been given a diagnosis of CAMR with positive C4d 
staining and an estimated glomerular filtration rate (eGFR) of ≥20 mls/min and have 
evidence of graft dysfunction, with either a creeping creatinine (Dudley et al., 2005) 
and/or significant proteinuria (defined as a urine protein:creatinine ratio of >50). A 
baseline blood sample was taken upon enrolment and processed as described in 
section 2.2. From a patient’s perspective, the trial was split up into three phases. Phase 
I ‘run-in’ lasted 3-5 months, and all patients received optimised doses of Tacrolimus 
and Mycophenolate Mofetil (MMF). There were three potential outcomes at the end of 
phase I: a) Graft function stabilised (or proteinuria settled), and the patient transitioned 
into phase III, where they were then followed for three years and peripheral blood 
mononuclear cell (PBMC) samples were taken every 3 months (Fig. 2.1 (a)); b) Graft 
function did not stabilise, or proteinuria did not settle, and the patient was consented 
to be randomised into phase II, where they either received Rituximab in addition to 
optimised Tacrolimus and MMF or continued with just optimised Tacrolimus and MMF 
(Fig. 2.1 (b)); c) graft function deteriorated such that eGFR fell to <20mls/min or the 
graft function was lost altogether during phase I and the patient was withdrawn from 
the trial or transitioned straight to phase III. Those patients who received Rituximab 
were given a 1g dose of Rituximab on day 0 followed by a further 1g dose on day 14, 
with the first dose given within a month of randomisation. The primary endpoint of the 
trial was reached 3-5 months post randomisation and another PBMC sample was 
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 Blood Sample acquisition and processing 
Approximately 60ml of blood was collected in EDTA K2 vacutainers and approximately 
20ml of blood was collected in red top vacutainers (BD Bioscience, Oxford, UK) at 
every time-point in the trial. Blood samples from Guy’s Hospital, London and The 
Hammersmith Hospital, London, were processed on the same day as blood draw. All 
other samples were shipped overnight at ambient temperature and processed the next 
morning. External sites that had patients enrolled on the trial were at St. James’s 
University Hospital, Leeds; University Hospital of Wales, Cardiff; Queen Elizabeth 
Hospital Birmingham; and Glasgow Royal Infirmary, Glasgow.  When available, up to 
60ml of blood was collected in EDTA K2 vacutainers from live donors to be used for 
making membrane proteins as detailed in section 2.3.1. 
Blood from healthy volunteers was obtained in the form of concentrated leukocytes 
provided by the blood transfusion service as a by-product of the blood donation 
process. These samples will be referred to as Leukocyte cones throughout this thesis. 
The Leukocyte cones were delivered the day after the blood was drawn and processed 
immediately. 
 Serum collection 
Blood samples were left to clot in the red top vacutainers for two hours and then 
centrifuged at 500g for 10 minutes. The Serum was aspirated and aliquoted in 2ml 
volumes and stored at -80°C. 
 PBMC isolation 
Blood was diluted 1:2 with Dulbecco’s Phosphate Buffered Saline (PBS) (Sigma- 
Aldrich, Dorset, UK) and layered onto 15ml of Lymphoprep™ (Alere, Cheshire, UK) in 
50ml tubes. The blood was then centrifuged at 800g for 30 minutes at 20°C. The layer 
of peripheral blood mononuclear cells (PBMC) was removed with a Pasteur pipette 
and diluted at least 1:3 with PBS. Diluted PBMC were centrifuged at 500g for 10 
minutes, the supernatant was poured off and PBMC were pooled and re-suspended in 
50ml RPMI medium (SIGMA-ALDRICH). PBMC were then centrifuged at 300g for 7 
minutes, and re-suspended in 15ml RPMI ready for counting. To count, the PBMC 
were inverted to mix and a 10µl aliquot was removed and mixed with 10µl Trypan blue 
solution (SIGMA-ALDRICH). 10µl PBMC-Trypan blue solution was loaded onto a 
haemocytometer and PBMC in three large squares on the haemocytometer grid were 
counted. A live mononuclear cell was defined as bright and round. Red blood cells 
were identified as smaller, very round cells and were not included in the PBMC count. 
Cells that were blue in colour were deemed non-viable and excluded from the count. 
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 Freezing of PBMC 
Once counted, 1 x106 cells were removed for RNA isolation; the cells were centrifuged 
for 5 minutes at 13000rpm and re-suspended in 800µl TRIzol® solution (Life 
Technologies, Paisley, UK) for two minutes before being frozen at -80° C. The 
remaining PBMC were centrifuged at 500g for 5 minutes and re-suspended at a 
concentration of 40x106 cells/ml in human AB serum (Life Technologies). An equal 
volume of human AB serum+20% DMSO was then added dropwise to make the final 
concentration 20x106 cells/ml and the PBMC were aliquoted in 1ml volumes into 
cryovials and placed into a Mr Frosty™ (Thermo Scientific, UK) for controlled freezing 
in the -80° C freezer. PBMC were transferred to Liquid Nitrogen (LN2) storage the day 
after. 
 Thawing of PBMC 
All assays in this thesis were carried out using frozen PBMC. All PBMC were thawed 
using the following method: PBMC were removed from Liquid nitrogen storage and 
500µl of warm AIMV media (Life Technologies) plus 10% Human AB serum (from here 
on in abbreviated to AIMV10) plus 1% Bovine pancreas DNase (Merck Chemicals Ltd, 
Nottingham, UK) was added to the cryovial before thawing at 37°C in a water bath. 
The cryovial was removed from the water bath just before the aliquot had completely 
thawed and transferred into 10ml AIMV10 plus 1% DNase media. Cells were spun at 
500g for 5 minutes and re-suspended in 10ml AIMV10 plus 1% DNase. Cells were 
then rested for 20 minutes at 37° C, 5% C02. 
After the resting period, the cells were passed through a 70µm strainer (BD Bioscience) 
to remove any clumps and then counted using a haemocytometer as described in 
section 2.2.2. Cells were centrifuged at 500g for 5 minutes and re-suspended in the 








 Detection of IFNγ production in response to donor 
membrane proteins 
 Donor membrane protein preparation 
If a live donor was available, their PBMC was used as a source of donor HLA proteins. 
Donor PBMCs were thawed in the same way as described in section 2.2.4. Cells were 
then re-suspended in 50ml cold PBS and washed twice at 500g for 5 minutes. Cells 
were re-suspended in 1ml of lysis buffer (detailed in Table 2.1) and transferred into a 
1.5ml tube. Cells were spun at 13000rpm, 4°C, for 2 minutes and re-suspended in 1ml 
of lysis buffer. The cells were then subjected to 3x freeze thaw cycles in order to lyse 
the cells. This involved immersing the cells in LN2 for 5 minutes, then thawing them in 
a water bath set to 37°C whilst intermittently shaking and vortexing them to help break 
up the cells. After the third freeze thaw cycle, the cells were spun at 2000g, 4°C for 2 
minutes. The supernatant containing the membrane proteins was transferred into a 
fresh 1.5ml tube and spun at 3000g, 4°C for 2 minutes. The supernatant was aspirated 
and transferred into a 10.4ml sterile autoclaved ultracentrifuge bottle (Beckman 
Coulter, High Wycombe, UK) and topped up with lysis buffer so the bottle was full. The 
membrane proteins were placed in a cold fixed bucket T1270 rotor and spun in an 
ultracentrifuge (Thermo Scientific) at 33100rpm for 1 hour. The supernatant was 
carefully aspirated to leave a small pellet of membrane protein which was dissolved in 
solubilising solution and frozen in 5µl aliquots at -80°C for long term storage. The 
concentration of the membrane protein was determined using the BCA assay 
described in section 2.3.2 
Table 2.1 Recipe for lysis buffer required for preparing donor membrane proteins 
Reagent Concentration Volume Manufacturer 
ddH2O NA 17.65ml NA 
Tris (pH 7.5) 0.5M 2.00ml SIGMA ALDRICH 
EDTA (pH 7.5) 0.3M 20µl SIGMA ALDRICH 
Soybean trypsin 
inhibitor 
1mg/ml 10µl SIGMA ALDRICH 
PMSF 0.1M 2µl SIGMA FLUKA 
Protease inhibitor 
cocktail 
NA – mixture of 
different inhibitors 
2.5µl SIGMA ALDRICH 
Nonidet P 40* NA 2.5µl SIGMA FLUKA 





 BCA assay 
The concentration of donor membrane proteins was determined using a bichinchoninic 
acid (BCA) assay kit (Thermo Scientific). Standards were made up using Bovine serum 
albumin (BSA) provided in the kit. The dilutions used to make the standard curve are 
detailed in table 2.2. 
Table 2.2 Dilution volumes for standards in BCA assay 
Vial Volume of  PBS 
diluent (µl) 
Volume BSA (µl) Final BSA concentration 
(µg/ml) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of vial B 750 
E 325 325 of vial C 500 
F 325 325 of vial E 250 
G 325 325 of vial F 125 
H 400 100 of Vial G 25 
I 400 0 0 
 
Working reagent was made by mixing 50 parts of BCA reagent  A with 1 part of BCA 
reagent B. 100µl of working reagent was mixed with duplicate wells of a flat bottom 96 
well plate containing 10µl of either the standards, PBS + solubilising solution control, 
or the donor membrane protein solution. The plate was wrapped in aluminium foil to 
prevent evaporation and incubated at 37°C for 30 minutes. 
The plate was left to cool to room temperature then read at 562nm to measure the 
optical density of each well. The mean of each duplicate was calculated and a standard 
curve was used to calculate the concentration of donor membrane proteins. The value 
calculated in the PBS only wells was subtracted as background from the wells 
containing the donor membrane protein. 
  Analysis of HLA antibodies 
As part of their routine patient monitoring, circulating HLA specific antibodies in the 
patient’s serum were detected using a Luminex® assay carried out by the clinical 
laboratories at each of the sites where patients were recruited onto the RituxiCAN trial. 
The Luminex® assay uses a matrix of polystyrene beads that are impregnated with 
different concentrations of fluorescent dye to create a gradient of fluorescence intensity 
along which each bead can be recognized when acquired. Each different bead is 
coated with a different HLA antigen. The patient’s serum is incubated with the HLA 
antigen coated beads and antibodies that are specific for that HLA antigen will bind the 
65 
 
bead. A detection anti-IgG antibody conjugated to a different fluorochrome from the 
polystyrene beads is then added to enable detection of serum antibodies that have 
bound the beads.  
Where available, the raw data read outs of mean fluorescence intensity (MFI) from this 
assay were obtained from the clinical laboratories and analysed to enable a full 
analysis of all of the HLA specific antibodies that were present in the patient’s serum. 
Each antibody that gave a positive result was categorized into MFI of 100+, 200+, 
300+, 400+, 500+ and 1000+. This method enabled the detection of HLA antibodies 
that may be relevant for choosing a surrogate donor as described in section 2.3.4. 
Where the raw data was not available, final analysis conducted by the clinical 
laboratory was obtained. This included both donor specific and non-donor specific HLA 
antibodies. However, MFIs of below 500-1000 were not reported in these analyses. 
 Choosing a surrogate donor 
In circumstances where the transplanted kidney was from a deceased donor, 
membrane proteins were sourced from a bank of surrogate donors that had known 
HLA genotypes. 
When choosing a suitable surrogate donor the HLA type of the recipient, the donor, 
and any previous donors needed to be considered, along with the HLA antibody profile 
that each patient had. The following rules were applied when choosing the surrogate 
donor: 
1. The surrogate donor must possess HLA alleles that the donor has and that the 
recipient has a circulating antibody against. 
2. Any HLA alleles that the surrogate donor has, but the real donor does not have, 
must match those of the recipient where possible. 
3. A surrogate donor must not be used if it has an HLA allele that is the same as 
a previous transplant and not shared with the current donor. 
4. A surrogate donor must not be used if it has an HLA allele that is not the same 
as the donor’s but the recipient has circulating antibodies against it. 
 Indirect IFNγ ELISPOT assay 
2.3.5.1 Depleting leukocyte subsets from PBMC 
PBMC were thawed as described in 2.2.4 counted and re-suspended at 4x106 cells/ml. 
As this was an indirect IFNγ ELISpot to assess the antigen presentation capabilities of 
B cells, magnetically labelled beads were used to deplete all PBMC of CD8+ cells, to 
eliminate any potential for the direct alloimmune response to cause IFNγ production. 
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Cells were then depleted of either B cells with CD19+ beads, Treg cells with CD25+ 
cells or both B cells and Tregs combined.  All beads used were Dynabeads® and 
washed prior to use in PBS + 2mM EDTA+ 0.1% FCS (Dynabead® buffer) according 
to the manufacturer’s instructions. 100µl of beads was applied for every 1ml of cell 
suspension and the cell-bead mixture was incubated on a roller at 4°C for 30 minutes.  
The 15ml tube containing the cell-bead suspension was then placed in a magnet (Life 
Technologies) so any positive cells that had bound to the labelled magnetic beads 
were removed from suspension and the depleted cells were aliquoted into a fresh 15ml 
tube. 150µl of cell suspension was removed for staining for flow cytometry to check 
the efficiency of the depletions. PBMC suspensions were counted post depletion to 
use in the analysis of the ELISpot as described in section 2.3.5.6. 
Figure 2.2 shows example plots of before and after each depletion. The average 
efficiency of depletion for each condition was 92% for CD8+ cells, 92% for CD19+ cells 




Figure 2.2 Representative dot plots to illustrate depletion of different lymphocyte 
subsets using the Dynabead® system.  
68 
 
2.3.5.2 Donor membrane proteins 
The appropriate membrane proteins were used at two different concentrations in the 
assay and diluted in AIMV10 media to either 1µg/ml or 0.2µg/ml so the final 
concentration in the assay was 0.5µg/ml and 0.1µg/ml respectively. 
2.3.5.3 Viral cocktail and CD3/CD28 beads as positive controls 
A viral cocktail was used as a positive control for antigen processing and presenting in 
the assay. The cocktail comprised three protein antigens that the majority of individuals 
in the general population are likely to have been exposed to: Varicella Zoster Virus 
glycoprotein E (VZV gE, Prospec, Rehovot, Israel) and Cytomegalovirus pp65 and 
glycoprotein B (CMV pp65 and CMV gB, Abcam, Cambridge, UK). VZV gE and CMV 
gB were used at a concentration of 0.03µg/ml and CMV pp65 was used at 0.003µg/ml. 
All viral proteins were combined and diluted in AIMV10. 
CD3/CD28 human T activator beads (Life Technologies) were used as a polyclonal 
stimulus as a way of checking T cell viability and the ability to produce IFNγ. The beads 
were used according to the manufacturer’s instructions with 10µl of bead solution being 
added to each well. 
2.3.5.4 Preparing the ELISpot plate 
The same batch of IFNγ ELISpot kit (MABTECH, Nacka Strand, Sweden) was used 
for every patient sample. 96 well plates with a PVDF membrane were pre-coated with 
anti-IFNγ capture antibody by the manufacturer. The plates were washed twice with 
200µl of sterile PBS and then blocked with 100µl AIMV10 medium at room temperature 
for two hours to prevent any non-specific binding. Blocking solution was then removed 
and 100µl of the donor membrane proteins and viral cocktail were added to the plate. 
Wells containing only AIMV10 were also set up as an un-stimulated control to measure 
any non-specific IFNγ that was produced by the cells.  Wells were always set up in 
triplicates for each condition apart from the CD3/CD28 beads where only one well was 
used for each sample of PBMC. In all wells that did not have membrane proteins, the 
solubilising solution that the membrane proteins were dissolved in was added at an 
equivalent concentration to account for any toxic effects that this carrier solution may 
have on the PBMC. Wells with only AIMV10, 0.2µg/ml membrane proteins or viral 
cocktail without any PBMC were also set up as negative controls. 
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Once the antigens had been added to the plate, 100µl of well mixed PBMC from each 
of the depletion conditions was dispensed directly into the centre of each well. The 
ELISpot plate was then wrapped in foil to prevent evaporation and incubated for 24 
hours at 37°C, 5% CO2. 
2.3.5.5 Adding the detection antibody 
PBMC were removed from the ELISpot plate with a flick and 200µl of ddH2O was added 
to each well for 2 minutes to lyse any residual cells. This step was repeated and then 
each well was washed 5 times with 200µl PBS and tapped dry. An anti-IFNγ detection 
antibody conjugated to alkaline phosphatase (ALP) was diluted to 1:200 in PBS with 
0.5% FCS and 100µl was added to each well. The plate was then wrapped in foil and 
incubated at room temperature for 1.5-2 hours. 
Each well was then washed 5 times in PBS, tapped dry and 100µl of 0.45µm filtered 
substrate solution 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium 
(BCIP/NBT) was added to each well. The plate was washed well with tap water to stop 
the reaction once defined spots had appeared in the wells (approximately 30 seconds). 
Plates were then dried overnight. 
2.3.5.6 Analysing the ELISpot plates 
Spots on the ELISpot plates were counted using an automated counting system (AID 
ELISpot reader system, Strassberg, Germany). As a quality control measure, each well 
was checked to make sure the spot count was accurate. The mean spot count for each 
triplicate condition was calculated and the mean spot count in the un-stimulated wells 
was subtracted from this. The frequency of CD4+ cells in each depletion condition was 
calculated using the flow cytometry staining data in conjunction with the PBMC count 
post depletion to calculate the number of IFNγ spots per million CD4+ T cells. A sample 
was deemed reactive to the donor membrane proteins or viral cocktail if it produced ≥ 
25 IFNγ+ spots per million CD4+ lymphocytes after the subtraction of background.        
Throughout the thesis, the pattern of reactivity when either CD8+&CD19+ cells, 
CD8+&CD25+ cells or CD8+, CD19+ & CD25+ cells were depleted was defined using 
the same criteria used in Shiu et al. and are as follows: 
B dependence (Bdep): If the number of IFNγ spots per million CD4+ T cells was 
reduced by ≥20%, or did not reach above ≥25 spots per million CD4+ lymphocytes 
when CD19+ cells were depleted, the sample was deemed B dependent.  
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B regulation (Breg): If the number of IFNγ spots reached above the ≥25 spots per 
million CD4+ lymphocytes cut off, or increased by ≥20% when CD19+ cells were 
depleted, the sample was deemed B regulated. 
Treg (Treg): If the number of IFNγ spots reached above the ≥25 spots per million CD4+ 
lymphocytes cut off, or increased by ≥20% when CD25+ cells were depleted, the 
sample was deemed T regulated. 
Bnon: Any change in the number of IFNγ spots per million CD4+ T cells observed post 
CD19+ cell depletion was not large enough to meet the criteria above.  
 Blocking IL-10 in the IFNγ ELISPOT assay 
The ELISpot was carried out as described in section 2.3.5 using PBMC from leukocyte 
cones with CMV gB as the stimulating antigen. Anti- IL-10 or the appropriate isotype 
control were added to the wells at a concentration of 10µg/ml to measure the effect 


















 Flow cytometry 
 General flow cytometry method 
Flow cytometry is used heavily throughout this thesis for both surface and intracellular 
staining. A general protocol was followed for all flow cytometry with appropriate 
modifications being made to suit the assay where necessary. All antibodies were 
titrated to determine the optimum volume per test to use. In many instances, the 
optimum concentration of antibody to be used had been established by previous 
members of the supervisor’s laboratory before this thesis began. Table 2.5 
summarises details of all of the antibodies used in this thesis. Antibodies were made 
up into cocktails on the day of staining. The FACS staining buffer used was PBS+30% 
human AB serum or PBS+30% FCS if IgM was included in the staining cocktail. 
Cells were transferred to a 96 deep well plate and washed in 300µl FACS staining 
buffer at 500g for 5 minutes, 4 °C. All subsequent wash steps were carried out using 
these parameters. The cells were then re-suspended in 50µl of antibody stain cocktail 
and incubated for 30 minutes at 4°C in the dark. Cells were washed twice in 400µl cold 
PBS to remove any unbound antibody, and re-suspended in 200µl of cold Live Dead 
solution (Life Technologies) and incubated for 30 minutes at 4 °C in the dark. Excess 
Live dead dye was removed by washing the cells twice in 400µl of cold PBS+ 2% FCS 
(FACS wash buffer). PBMC were then re-suspended in 200µl of a 1% PFA solution 
(Alfa Aesar, Karlsruhe, Germany) and incubated for 10 minutes at 4°C in the dark. The 
cells were then washed once in 400µl of FACS wash buffer and re-suspended in 300µl 
of FACS wash buffer before being transferred into 5ml polystyrene tubes and stored 
at 4°C in the dark ready for acquisition. PBMC were always acquired on the flow 











Table 2.3 List of flow cytometry antibodies used throughout thesis 





HIB19 47-0199 eBioscience Hatfield, UK 1 
Anti-human IgG 
V450 
G18-145 561299 BD Biosciences Oxford, UK 5 
Anti-human IgM 
APC 




O323 46-0279 eBioscience Hatfield, UK 2 
Streptavidin PE NA 12-4317 eBioscience Hatfield, UK 0.2 
Streptavidin 
BV421 
NA 405226 Biolegend London, UK 0.4 
Anti-Human 
CD4 FITC 




OKT-4 17-0048 eBioscience Hatfield, UK 1 
Mouse IgG2a, k 
PE 




NA MG2A28 Life 
Technologies 
Paisley, UK 0.5 
Anti-human 
CD38 Qdot®605 
HIT2 Q10053 Life 
Technologies 
Paisley, UK 0.4 
Anti-human 
CD10 APC 
HI10a 332777 BD Biosciences Oxford, UK 2 
Mouse IgG1 k, 
isotype control 
PE-Cy7 
P3.6.2.8.1 25-4714 eBioscience Hatfield, UK 0.25 
Mouse IgG1 k 
isotype control 
FITC 
P3.6.2.8.1 11-4714 eBioscience Hatfield, UK 0.25 
Anti-Human 
CD25 PE 
BC96 12-0259 eBioscience Hatfield, UK 2 
Anti-human 
CD39 PE-Cy7 
eBioA1 25-0399 eBioscience Hatfield, UK 0.25 
Mouse IgG1 k 
Isotype Control 
PE 





UCHT2 25-0059 eBioscience Hatfield, UK 0.25 
Anti-human CD8 
Qdot®605 
3B5 Q10009 Life 
Technologies 
Paisley, UK 0.2 
Anti-Human 





Paisley, UK 0.5 
Anti-human 
CD38 PE-Cy7 












London, UK 1 
Anti-human 
CD45RB 
(MEM55)  FITC 






MEM-55 310204 Biolegend London, UK 2 
Anti-Human IL-
10 PE-Cy7 








NA L34957 Life 
Technologies 


















eBioscience Hatfield, UK 1.25 
Anti-human 
HLA DR FITC 
L243 11-9952-42 
 





Bio-Techne Abingdon, UK 10 
Anti-human 
TACI PE 
165604 FAB1741P Bio-Techne Abingdon, UK 10 
Anti-Human 
CD10 PE Cy7 




 Intracellular cytokine staining 
Cell cultures were set up to replicate the conditions of the ELISpot but carried out in 
round bottomed 96 well plate without a membrane. CMV gB at a concentration of 
0.3µg/ml was used as the stimulating agent. 1µl of Brefeldin A (eBioscience, Hatfield, 
London), was added to the cultures for the last 5 hours of incubation to facilitate the 
accumulation of cytokines within the cell. Triplicate wells of each condition were pooled 
and washed twice in FACS wash buffer and surface staining was carried out as 
described in 2.4.1.  
Cells were then fixed in 100µI of IC fixation buffer (eBioscience) for 20 minutes at room 
temperature in the dark. Cells were washed once in 400µl of permeabilisation buffer 
(eBioscience) and then incubated for 20 minutes at room temperature in the dark in 
100 µl of permeabilisation buffer that contained the anti-IL-10 and anti-IFNγ antibodies 
or the appropriate isotype controls. Cells were washed once in 400µl of 
permeabilisation buffer and then again in 400µl of FACS wash buffer. Cells were then 
immediately acquired on the flow cytometer. 
 Acquisition on flow cytometer 
OneComp eBeads (eBioscience) were used to make single stain controls for 
compensation before each new acquisition.  Anti-CD25 PE and CD14 Pacific Blue 
were used as a substitute for streptavidin PE and streptavidin BV421. 1 drop of 
OneComp ebeads was incubated with 1µl of the appropriate antibody and incubated 
at 4°C for 20 minutes in 5ml polystyrene tubes. Unbound antibody was washed off in 
2ml FACS buffer at 500g for 5 minutes and re-suspended in 300µl FACS buffer ready 
for acquisition. Acquisition was carried out on a Fortessa LSR II flow cytometer (Becton 
Dickinson) using DIVA software (Becton Dickinson). Application settings were used to 
help account for the changes in laser power over time. Data was analysed using Flowjo 








 Detection of antigen binding B cells 
The basic principle of this method is based on antigen specific B cells binding a 
biotinylated antigen which can then be visualised on the flow cytometer using 
streptavidin conjugated to a fluorochrome. The addition of a B cell phenotyping panel 
allows the phenotype of the antigen binding B cells to be determined. This method was 
initially developed using a CMV gB antigen which was biotinylated in-house. The 
method was then applied to a patient setting where ready-made biotinylated Pure™ 
HLA proteins were used.  
  Biotinylating the CMV gB protein 
0.18mg of pure HCMV glycoprotein B (CMV gB) protein (abcam, Cambridge, UK) at 
1.0mg/ml in 0.5% Tris HCL buffer was exchanged into PBS buffer using a Zeba™Spin 
desalting column (Thermo Scientific). The Zeba™Spin column was placed in a 15ml 
tube and washed four times by loading 200µl of PBS and centrifuging at 500g for 2 
minutes. 180µl of CMV gB protein was loaded onto the column followed by a 40µl PBS 
stacker. The column was placed in a fresh 15ml tube and centrifuged at 500g for 2 
minutes. The CMV gB protein was removed from the bottom of the 15ml tube and 
placed in a 1.5ml Eppendorf tube ready for biotinylation using an EZ-Link®Sulfo-NHS-
biotin biotinylation kit (Thermo Scientific). 
The biotinylation of the CMV gB was carried out according to manufacturer’s 
instructions. A 20 molar excess of biotin was used in order to ensure that every viral 
protein was biotinylated. Briefly: 1mg of biotin was reconstituted in 224µl of ultrapure 
water and a 12.2µl aliquot was mixed with the CMV gB and incubated for 30 minutes 
at room temperature. Excess biotin was removed by inserting the mixture into a 0.1-
0.5ml Slide-A-Lyzer® dialysis cassette (Thermo Scientific) and immersing it in 500ml 
sterile PBS for 2 hours at room temperature, followed by a replenishment of the PBS 
and an overnight incubation at 4°C. The CMV gB protein was then removed from the 
dialysis cassette using a 1ml syringe, aliquoted into 5µl volumes and stored at -20°C. 
 Determining the efficiency of the biotinylation process 
In order to check that all of the CMV gB protein had been biotinylated, the biotinylated 
protein was run through an SDS PAGE gel with or without prior incubation with 0.1unit 
of streptavidin (SIGMA-ALDRICH) for 30 minutes at room temperature. The 
biotinylated CMV gB was mixed 1:1 with 1x Laemli sample buffer (BIO-RAD, Hemel 
Hempstead, UK) and a 30µl volume was immediately loaded into a ready-made 10% 
SDS PAGE gel (BIORAD). 5µl of a 10kb – 250kb protein ladder (Promega, 
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Southampton, UK) was also added to one of the lanes. The gel was run at 100 volts 
for approximately 100 minutes using the running buffer detailed in Table 2.4. 
Once the gel had finished running, it was removed from its cask and fixed for 30 
minutes in 100ml of the fixing solution detailed in Table 2.5. 3ml of Coomassie blue 
stock solution was then added to the fixing solution and the gel was stained for 25-40 
minutes (see Table 2.6). The staining solution was then removed and the gel was 
incubated for 2.5 hours in de-stain solution which is detailed in Table 2.7. Figure 2.3 
shows that 100% of the CMV gB was biotinylated as the CMV gB-biotin-streptavidin 
complex can be seen as a large molecule at the very top of the gel in lane 4, with no 
protein detected at the 25kDa mark where both the CMV gB and CMV gB biotin can 


























Figure 2.3 Determining the biotinylation efficiency 
The biotinylated CMV gB was incubated with streptavidin for 30 minutes at room 
temperature and then run on an SDS PAGE and stained with coomassie blue. Lane 1: 
Protein ladder (10-225kDa). Lane 2: CMV gB, Lane 3: CMV gB+biotin, Lane 4: CMV 
gB+biotin +streptavidin. The bands at ~ 25kDa represent the CMV gB virus. In lane 4, 
a protein band is visible at the very top of the gel where the streptavidin has formed a 
large complex with the biotinylated CMV gB. The lack of a band present at ~25kDa 
suggests that there are no CMV gB molecules present in the solution that have not 
been biotinylated. The BCA assay was used as described in section 2.3.2 to determine 















1 2 3 4 
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 Table 2.4 Recipe for 10x SDS PAGE running buffer 
Reagent Quantity to dissolve in 1L ultrapure water(g) 
Tris 25mM (Sigma-Aldrich) 30.28 
Glycine 192 mM (Sigma-Aldrich) 144g 
SDS 0.1% (Sigma-Aldrich) 10g 
 
 
Table 2.5 Recipe for fixing solution for Coomassie blue staining 
Reagent Volume (ml) 
Methanol (Thermo Scientific) 50 
Acetic acid (SIGMA ALDRICH) 10 
Deionised H20 40 
 
 
Table 2.6 Recipe for Coomassie blue stock solution 
Reagent Quantity 




Acetic acid 30ml 
 
 
Table 2.7 Recipe for de-staining solution for Coomassie blue staining 
Reagent Volume (ml) 
Methanol 45 
Acetic acid  10 










 Phenotyping antigen binding B cells by flow cytometry 
The biotinylated antigen was diluted to the optimal concentration in AIMV media with 
10% FCS and kept on ice. Each different antigen that was used was titrated prior to 
use in order to determine the optimal concentration that would lead to effective binding 
of antigen specific B cells with minimal background binding. This is detailed in the 
relevant sections of chapter 4. 
Whilst working on ice at all times to prevent the internalisation of the viral or HLA 
proteins by the B cells, 1-5x106 PBMC were re-suspended in 200µl of cold biotinylated 
antigen solution and incubated for 30 minutes on ice in a 96 well round bottom plate. 
Unbound protein was then washed off by adding 300µl of cold PBS and centrifuging 
at 500g for 5 minutes, re-suspending the cells and washing them again. The PBMC 
were then stained with a B cell phenotyping panel using the method described in 
section 2.4.1, with an amendment to the protocol that all incubations were carried out 
















 Determining if the antigen binding is specific. 
 Cold inhibition assay 
PBMC were incubated with 0.35µg/ml biotinylated CMV gB as described in section 
2.5.3. To competitively inhibit the binding of this protein to the BCR, non-biotinylated 
CMV gB was titrated into each sample from 0.0µg/ml to 14.0µg/ml. VZV gE was titrated 
into separate samples at the same concentrations to use as a negative control which 
should not affect antigen specific binding of the gB to the BCR. Subsequent steps of 
flow cytometry staining were carried out as described in section 2.4.1. 
 Blocking the BCR 
PBMC were incubated with 0.35µg/ml biotinylated CMV gB as described in section 
2.5.3. To block binding of the biotinylated CMV gB to the BCR, anti-human IgM/IgG 
Fab (H+L) (Jackson ImmunoResearch Laboratories inc, Westgrove, PA, USA) was 
titrated into each sample from 0.0µg/ml-6.4µg/ml. Subsequent steps of flow cytometry 
staining were as described in section 2.4.1. 
 Blocking the FcγRIIB receptor 
PBMC were incubated with 0.35µg/ml biotinylated CMV gB as described in section 
2.5.3. To check that the biotinylated CMV gB was not non-specifically binding to 
FCγRIIB (CD32) expressed on B cells, PBMC were incubated with anti-human CD32 
(eBioscience) at a concentration of 10µg/ml for 30 minutes at 4°C and washed twice 
in AIMV 10% FCS prior to incubating with the biotinylated CMV gB. PBMC that had 
not been incubated with anti-human CD32 were used as a negative control. 
Subsequent steps of flow cytometry staining were carried out as described in section 
2.4.1. 
 Single cell sorting for downstream sequencing and cloning of CMV gB 
binding B cells 
PBMC from 3 leukocyte cones were incubated with CMV gB and stained as per the 
protocol detailed in section 2.5.3 and 2.4.1. PBMC were then passed through a FACS 
Aria III sorter, where single CMV gB binding, IgMhi B cells were collected in each well 
of a 96 well plate that contained SLYRT buffer (contains lysis buffer and reagents 
required for reverse transcription). The gating strategy and examples of the cells pre 
and post sort are shown in Figure 2.4. As the distinguishing feature of the CMV gB 
binding B cells was that they were IgMhi, it was decided that the cells that would be 
sorted would be CMV gB+ and IgMhi as shown in Figure 2.4. Index gating was set up 
on the sorter so the exact phenotype of each CMV gB binding B cell could be related 
back to its antibody production once the BCR sequence had been sequenced and 
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cloned. The 96 well plates were handed over to Verena Hehle who performed several 
rounds of PCR in order to amplify the genes from the single cells so they could be sent 
off for BCR sequencing. Once known, the BCR sequence was then integrated into a 
pVitro vector and transformed into E.coli. The plasmid DNA from the E.coli culture was 
then extracted using a Miniprep kit and transfected into 293T cells. Cell culture 
supernatants containing immunoglobulin were measured for their ability to bind the 






















 Isolation of B cells and B cell subsets 
 Isolating B cells from PBMC 
B cells were isolated from whole PBMC using a negative isolation magnetic bead kit 
(Miltenyi,Bergisch Gladbach, Germany) so the B cells were left as untouched as 
possible. According to the manufacturer’s instructions: the PBMC were washed at 
500g for 5 minutes in PBS+0.5% FCS and 2mM EDTA (MACS buffer), re-suspended 
in 40µl MACS buffer per 1x107 PBMC plus 10µl of biotin-antibody cocktail per 1x107  
PBMC and incubated for 5 minutes at 4°C. 30µl MACS buffer per 1x107 PBMC plus 
20µl anti-biotin microbeads per 1x107 PBMC was then added for a further incubation 
of 10 minutes at 4°C. The MACS column was washed three times and then the labelled 
cell suspension was passed through the column. The negative fraction containing the 
isolated B Cells was collected in a sterile tube, counted, and re-suspended in RPMI 
10% FCS. B cells were stained to check their purity using flow cytometry (see figure 
2.5). The average purity of the isolated B cells was 91.1%.  
 Isolating CMV gB B cells from isolated B cells 
To isolate the CMV binding B cells from the CMV non-binding B cells, the isolated B 
cells were incubated with 200µl of cold CMV gB at a concentration of 0.35µg/ml, 
washed twice in cold MACS buffer at 500g for 5 minutes and then incubated with 0.1µl 
of streptavdin PE in 50µl MACS buffer for 30 minutes at 4°C. Excess streptavidin was 
washed off by washing twice in cold MACS buffer at 500g for 5 minutes. Cells were re-
suspended in 80µl MACs buffer per 1x107 total cells plus 20µl of Anti-PE microbeads 
per 1x107 total cells and incubated for 15 minutes in the refrigerator. Cells were washed 
in 2ml MACS buffer, re-suspended in 500µl of MACS buffer and then passed through 
the pre-washed MACS column. The resulting CMV+ and CMV- fractions of cells were 
counted and re-suspended in AIMV10. Both fractions were stained to check their purity 
using flow cytometry (see dot plots in Figure 2.6).   
 Isolating CD27+ and CD27- B cells from isolated B cells 
B cells were isolated as described in section 2.7.1, re-suspended in 80µl of MACS 
buffer per 1x107 total cells. 20µl per 107 total cells of CD27 labelled magnetic beads 
(Miltenyi Biotec) were mixed with the cells, and incubated in the refrigerator for15 
minutes. Cells were then washed in 2ml MACS buffer at 300g for 10 minutes and re-
suspended in 500µl of MACS buffer. 500µl of MACS buffer was passed through an MS 
column (Miltenyi Biotec) followed by the magnetically labelled cells. The CD27- cells 
were collected in the flow through and the CD27+ cells were removed from the column 
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using the plunger provided with the column. Both CD27- and CD27+ B cell fractions 
were counted as described in section 2.2.2 and a small aliquot was removed for flow 
cytometry staining to check the purity of the cells. The average purity from these 
experiments was 75.7% for the CD27+ population and 94.15 % for the CD27- B cell 






























Figure 2.7 Example dot plots of CD27+/CD27- separation 
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 Statistical analysis 
All statistical analysis was performed using Graphpad Prism® software version 5. 
Paired samples were compared using a Wilcoxon matched pairs signed rank test with 
two tailed P values. Unpaired samples were compared using a Mann Whitney U test 
with two tailed P values. A Kruskal-Wallis test with Dunn’s multiple comparison was 






















3 Results part 1 
 
 Introduction 
The major aim of this chapter was to establish that the patterns of reactivity to donor 
membrane proteins observed in the observational study reported in Shiu et al. could 
be reproduced in another cohort of patients whom fitted the diagnostic criteria for 
CAMR in a kidney transplant setting. This chapter addresses aims 1-3 in section 1.4. 
Patients enrolled on the RituxiCAN C4 trial were chosen to be tested in the IFNγ 
ELISpot based on the criteria that they would be finished the trial within the timescale 
that this thesis required completion, as this would enable the correlation of the patterns 
of reactivity in the indirect IFNγ ELISpot with the clinical outcomes in these individuals. 
The IFNγ ELISpot will be carried out on PBMC samples on the remaining patients at a 
later date and added to the data presented in this thesis for publication. 
The enrolment, end of phase I and end of phase II samples from patients that were 
consented into phase II of the trial were tested in the indirect IFNγ ELISpot. For those 
that were not randomised and went straight to phase III, the enrolment and end of year 
1 samples were tested. Where samples from later time points were available, these 
were also tested in the IFNγ ELISpot at approximately yearly intervals. A full set of 
PBMC samples were not acquired for all patients, as some patients were withdrawn 
from the study due to either graft failure or the patient withdrawing consent. In such 
circumstances, the ELISpot was carried out on all available PBMC samples up until 
they stopped being collected. If a sample was not collected at the exact time point, for 









 Results  
 IFNγ production can be detected in response to donor membrane 
proteins 
PBMC from each time point tested were depleted of either CD8+ cells, CD8+&CD19+ 
cells, CD8+&CD25+ or CD8+, CD19+&CD25+ cells (triple depletion) and then 
stimulated in the IFNγ ELISpot with donor membrane proteins as described in section 
2.3.5. As one of the aims of this study was to broadly replicate the findings of Shiu et 
al. the proportions of reactive and non-reactive samples in all samples tested was 
analysed. Of the 104 samples thawed, from 33 patients, 97 were found to be viable. 
The number of IFNγ+ spots per million CD4+ lymphocytes produced by each CD8+ 
depleted PBMC sample when stimulated with either live donor membrane proteins or 
surrogate donor membrane proteins is  shown in Figure 3.1. 18/97 (19%) samples 
were deemed reactive as their spot count was ≥25 IFNγ+ spots per million CD4+ 

























Figure 3.1 Response to donor membrane proteins of all samples tested in the indirect 
IFNγ ELISpot.  
Spot counts shown are a mean of triplicate wells with background subtracted and 
multiplied up to give spot counts per million CD4+ lymphocytes. A total of 97 samples 
were tested: 18/97 were reactive, 79/97 were non-reactive.  A reactive response was 
defined as ≥25 IFNγ+ spots per million CD4+ lymphocytes. Black bars on graph 





















































 IFNγ production in response to donor membrane proteins is dependent 
on B cells 
The criteria stated in section 2.3.5.6 of the material and methods was used to define 
whether each sample was ‘reactive B dependent’ or ‘reactive B regulated’ after in vitro 
depletion of CD19+ cells. Of the 18 samples that were deemed reactive, enough 
PBMC were available from 17 of them to deplete CD19+ cells. Figure 3.2 (a) shows 
the IFNy production pre and post CD19+ depletion in samples that were deemed 
‘reactive B dependent’: IFNγ production was reduced by more than 20% post B cell 
depletion in all 17 of these samples. 
In the 79 samples that were non-reactive, CD19+ cell depletion revealed that 6/79 
samples could be classed as ‘reactive B regulated’. IFNy production pre and post B 
cell depletion by these 6 samples is shown in Figure 3.2 (b).  
 
 
Figure 3.2 Impact of CD19+ depletion on IFNγ production 
(a) Sufficient PBMC were available to deplete CD19+ cells from 17/18 reactive 
samples: IFNγ decreased post CD19+ cell depletion in all 17 samples. (b) Sufficient 
PBMC were available to deplete CD19+ cells from 76/79 non-reactive samples: IFNγ 
increased to ≥25 IFNγ+ spots per million CD4+ lymphocytes post CD19+ cell depletion 
































































































 Depleting CD25+ cells reveals IFNγ production in response to donor 
membrane proteins in a subset of samples. 
Sufficient PBMC were available to deplete CD25+ cells from 80 of the 97 samples 
tested. CD25+ cell depletion lead to an increase in IFNγ production in 9/80 samples 
which were classed as ‘reactive T regulated’ based on the criteria stated in section 
2.3.5.6 of the materials and methods section. IFNγ production pre and post CD25+ 




Figure 3.3 Impact of CD25+ cell depletion on IFNγ production 
Sufficient PBMC were available to deplete CD25+ cells from 80 of the 97 samples 
tested. IFNγ production increased to ≥25 IFNγ+ spots per million CD4+ lymphocytes 
post CD25+ cell depletion in 9/80 samples shown here. 7/9 samples were non-reactive 


















































 Depleting CD19+ and CD25+ cells increases the frequency of samples 
that can be defined as reactive towards donor membrane proteins. 
When the patterns of reactivity described above are considered together, the analysis 
reveals that 31/97 (32%) of the samples have the capacity to produce IFNγ in response 
to the donor membrane proteins. Figure 3.4 illustrates that samples can be sub-divided 
with regards to their reactivity whether it is revealed post CD19+ cell depletion (Breg) 
or post CD25+ cell depletion (Treg). These subgroups will be referred to in subsequent 
analysis throughout this thesis. Also included in this graph is the data from the triple 
depletion condition that was possible to test in 69/97 samples. This condition revealed 
reactivity in one sample that was previously non-reactive in all other depletion 
conditions. The two samples that were reactive Treg before CD25+ depletion are 
included In the CD8 dep column and one sample that was both Breg and Treg is 
included in the CD8 & CD19 dep column.  6/9 reactive Treg samples are therefore 
included in the CD8 & CD25 dep column. 
A breakdown of the number of samples tested in the IFNγ ELISpot for each patient 
along with details of the time point is shown in Table 3.1. The data in this table 
illustrates how the pattern of reactivity in response to donor membrane preps changes 
over time. 18/33 patients had evidence of reactivity towards donor membrane proteins 
at 1 or more time points.  It also highlights that in vitro depletion of CD19+ cells in 
individuals who have received Rituximab can still have an impact on  IFNγ production. 
Included in this table is a summary of the DSA detected in the serum of each patient. 
If a patient has had a DSA detected at any time point post transplantation it has been 
recorded in this table. DSA were not necessarily detected at every time point that the 
serum was tested in the Luminex® assay in each patient. The time points at which the 
serum was tested was at the discretion of the clinical laboratory at each site and often 
does not match the time point tested in the IFNγ ELISpot. This therefore has not made 
it possible to directly correlate the presence of DSA with the pattern of reactivity in the 
IFNγ ELISpot. However, it can be highlighted that 29/33 patients tested had evidence 
of DSA post-transplant. 16/33 patients had evidence of both DSA and reactivity in the 
IFNγ ELISpot and 13/33 patients had evidence of DSA but no evidence of reactivity in 
the IFNγ ELISpot. 2/33 patients had no evidence of DSA but did have evidence of 
reactivity in the IFNγ ELISpot. The remaining 2/33 had no evidence of DSA or reactivity 










Figure 3.4 IFNγ response to donor membrane proteins 
Depletion of CD19+ and CD25+ subsets (or a combination of the two) reveals reactivity 
in samples that were non-reactive when just CD8+ cells were depleted. One sample 
had an increase of IFNγ to ≥25 IFNγ+ spots per million CD4+ lymphocytes post CD19+ 
cell depletion and CD25+ cell depletion and has been included in the CD8&CD25 dep 
column on this graph. Black bars on graph represent the median. Dep is an 









































































































Patient ID Class I DSA Class II DSA
In phase II? Timepoint ELISpot tested
Response to donor 
membrane proteins
Response to        
viral cocktail
W001 A1 DQ5 No Baseline Reactive Reactive
W002 No Baseline Reactive, Bdep Non-reactive
9 mnths (Phase III) N/A - cells not viable
W003 A30, B63 No Baseline Non-reactive Reactive, B/Treg
6 mnths (Phase III) Non-reactive Reactive, B/Treg
9 mnths (Phase III) Non-reactive Non-reactive
21 mnths (Phase III) Non-reactive Reactive, Treg
30 mnths (Phase III) Non-reactive Reactive, Bdep
W004 B44 DR53 No Baseline N/A - cells not viable
3 mnths (End phase I) N/A - cells not viable
12 mnths (Phase III ) Reactive, Bdep Reactive, Bdep
W005 No Baseline Non-reactive Reactive, Breg
W006 A1 DR17 Yes no Ritux Baseline Reactive, Bdep Non-reactive
12 mnths (End phase I) Reactive, Bdep Reactive, Bdep, Treg
15mnths (End phase II) Reactive, Breg Reactive, Bdep
42 mnths (Phase III) Non-reactive Non-reactive
W008 Yes no Ritux Baseline Reactive, Treg Reactive, Treg
3 mnths (End phase I) Non-reactive Non-reactive
6 mnths (End phase II) Reactive B/Treg Reactive, Bdep
12 mnths (Phase III) Non-reactive Reactive, Breg
W009 B44 DQ8, DR4, DR53, DR51 No  Pre-recruitment Non-reactive Non-reactive
Baseline Non-reactive Non-reactive
10 mnths (Phase III) Non-reactive Reactive, Breg
28 mnths (Phase III) Reactive, Bdep Reactive, Breg
W010 Cw7 DR53 Yes Ritux Baseline Reactive, Bdep Reactive, Bdep
5 mnths (End phase I) Reactive, Breg Reactive, Breg
10 mnths (End phase II) Reactive, Bdep Reactive, Breg
W011 A2 No Baseline Non-reactive Non-reactive
12 mnths (Phase III) Non-reactive Non-reactive
W012 (DQ7, DQ8, DQ9) No Baseline Non-reactive Non-reactive
12 mnths (Phase III) Non-reactive Non-reactive
W013 DR53, DQ7 (DQ6) No Baseline Non-reactive Reactive, Treg
12mnths (Phase III) Non-reactive Reactive, Bdep
W014 DQ6, DQ7 No Baseline Non-reactive Reactive, Breg
3 mnths (end phase I) Non-reactive Reactive, Treg
16mnths (Phase III) Non-reactive Reactive, Treg
29 mnths (Phase III) Non-reactive Reactive, Bdep, Treg
W016 No Baseline Non-reactive Reactive, Bdep
3mnths (End phase I) Non-reactive Reactive, Treg
6mnths (Phase III) Non-reactive Non-reactive
W017 A24, B60, B7 No Baseline Non-reactive Non-reactive
3mnths (End phase I) Reactive, Bdep Reactive, Bdep
15mnths (Phase III) Reactive, Breg Reactive, Breg
25mnths (Phase III) Reactive, Bdep Reactive, Treg
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Table 3.1b Summary of all samples from Guy’s Hospital tested in the IFNγ ELISpot 
 
 
Patient ID Class I DSA Class II DSA
In phase II? Timepoint ELISpot tested
Response to donor 
membrane proteins
Response to        
viral cocktail
G001 B8 DQ2 No Baseline Non-reactive Reactive, Bdep
4 mnths (End phase I) Non-reactive Non-reactive
13 mnths (Phase III) Reactive, Treg Reactive, Breg, Treg
G002 A1 Yes  no Ritux Baseline Reactive, Bdep Reactive, Bdep
3mnths (End phase I) Non-reactive Reactive, B/Treg
6mnths (End phase II) Non-reactive Reactive, Bdep
14mnths (Phase III) Reactive, Bdep Non-reactive
G003 B8 Yes Ritux Baseline Reactive, Breg Non-reactive
5mnths (End phase I) Reactive, Breg,Treg Reactive, Breg
10 mnths (End phase II) Non-reactive Non-reactive
24mnths (Phase III) Non-reactive Non-reactive
37mnths (Phase III) Non-reactive Non-reactive
G004 DR51, DQ7 No Baseline Non-reactive Non-reactive
4 mnths (Withdrawal) Non-reactive Reactive, Breg, Treg
G006 DR7, DR53, DQ2 No Baseline Non-reactive Non-reactive
5mnths (End phase I) Reactive, Bdep, Treg Reactive, Treg
8mnths (Phase III) Non-reactive Non-reactive
11mnths (Phase III) Non-reactive Non-reactive
G007 A2 DR12 Yes  no Ritux Baseline Non-reactive Non-reactive
4mnths (End phase I) Non-reactive Non-reactive
7mnths (End Phase II) Non-reactive Non-reactive
G008 A11 DQ2 No Baseline Non-reactive Non-reactive
4mnths (End Phase I) Non-reactive Reactive, Breg
10mnths (Phase III) Non-reactive Non-reactive
G009 DR13, DR52 Yes Ritux Baseline Non-reactive Reactive, Treg
5mnths (ritux 1mnth 
later) Non-reactive Reactive, Bdep, Treg
G010 A1 DR1, DP1, DP17 Yes Ritux Baseline Non-reactive Reactive, Bnon
5mnths (End phase I) Non-reactive Non-reactive
10mnths (End phase II) Non-reactive Non-reactive
G012 A23, A2 DR53, DQ2, DR7, DR53 Yes Ritux Baseline Reactive, Treg Reactive, Treg
4mnths (End phase I) Non-reactive Non-reactive
9mnths later (End phase II) Non-reactive Non-reactive
15mnths (Phase III) Non-reactive Non-reactive
G013 Cw6 Yes  no Ritux Baseline Reactive, Treg Non-reactive
4 mnths (End phase I) Non-reactive Reactive, Bdep
7mnths (End Phase II) Reactive, Bdep Non-reactive
13mnths (Phase III) Non-reactive Non-reactive
G014 A1, A2 DQ5 No Baseline Non-reactive Non-reactive
4mnths later (End phase I) Non-reactive Non-reactive
14mnths (Phase III) Non-reactive Non-reactive
G015 DR52, DR14 No Baseline Non-reactive Reactive, Bdep
3mnths (End phase I) Non-reactive Non-reactive
13mnths (Phase III) Non-reactive Reactive, Breg
G017 A23 Yes Ritux Baseline Reactive, Treg Reactive, Treg
13mnths (End phase I) Reactive, Bdep Reactive, Bdep
19mnths (End Phase II) Non-reactive Non-reactive
G023 DQ7, DQ8, DQ9, DR53 Yes no Ritux Baseline Reactive, Bdep Non-reactive
4mnths (End phase I) Reactive Treg Reactive, Treg
11mnths (End phase II) Non-reactive Non-reactive
G025 DQ2, DQ7,DR53 Yes Ritux Baseline Reactive, Bdep Non-reactive
4mnths (End phase I) Non-reactive Reactive, Bdep
7mnths (End Phase II) Reactive, Bdep Non-reactive
G027 B8 DQ2, DQ6, DR51, DR3, DR16 Yes no Ritux Baseline Non-reactive Non-reactive
5mnths (End phase I) N/A cells not viable
11mnths (End phase II) Non-reactive Non-reactive
G029 DR4, DR53 Yes Ritux Baseline Non-reactive Non-reactive
3mnths (End phase I) N/A cells not viable Non-viable
6mnths (End phase II) Reactive, Breg Non-reactive
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 Similar patterns of reactivity observed in the response to donor 
membrane proteins are also observed in the response to a viral cocktail 
Every sample tested in Figure 3.1 was also tested for their response to a cocktail of 
viral antigens that the majority of individuals should have been exposed to and are 
known to induce both a humoral and a T cell response: CMV pp65, CMV gB and VZV 
gE (Manikkavasagan et al., 2010, Vyse et al., 2009, Sylwester et al., 2005, Pötzsch et 
al., 2011, Gonczol and Plotkin, 2001, Arvin, 2008). This served as a control to assess 
the antigen processing and presenting ability of those individuals who did not produce 
IFNγ in response to donor membrane proteins. As with the donor membrane protein 
stimulated samples, different patterns of reactivity were seen in response to the viral 
cocktail. Samples were assigned a pattern of reactivity according to the criteria stated 
in section 2.3.5.6 of the materials and methods. Figure 3.5 shows the number of 
reactive samples revealed with each depletion condition and those that did not respond 
to the viral cocktail in any depletion condition. When just CD8+ cells were depleted, 
IFNγ was produced in response to the viral cocktail in 30/97 samples. IFNγ production 
was reduced upon in vitro depletion of CD19+ cells in 18/30 of these samples. 6/30 of 
these samples showed evidence of B regulation and 9/30 showed evidence of T 
regulation. In 2 of these samples, evidence of both B regulation and T regulation was 
observed and are detailed in Table 3.1. 
7/97 samples only showed evidence of reactivity when CD19+ cells were depleted and 
8/97 non-reactive samples responded to the viral cocktail when CD25+ cells were 
depleted. 3/97 samples responded to the viral cocktail only in the triple depleted 
condition when both CD19+ and CD25+ cells were depleted. Therefore in total, 48/97 
(49%) samples showed evidence of reactivity to the viral cocktail.  
Importantly, 22/79 of the samples that were non-reactive to the donor membrane 
proteins when just CD8+ T cells were depleted, responded to the viral cocktail. This 
suggests that there is not a global defect in the antigen processing and presenting 
capability of the patients that these samples were derived from. Additionally, only 8/18 
of the samples that produced IFNγ in response to donor membrane proteins when only 
the CD8+ cells were depleted also responded to the viral cocktail, thus supporting the 
hypothesis that an antigen specific response is being observed in the patients with 
regards to their reactivity to donor membrane proteins. 
39/97 samples were globally hypo-responsive and did not produce IFNγ in response 
to either donor or viral antigens in any of the depletion conditions. It is worth noting that 
due to limited PBMC availability for some samples, CD19 depletion was possible in 
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35/39 samples, CD25 depletion possible in 29/39 and triple depletion possible in 24/39 
samples so it is possible that in some samples reactivity would have been revealed if 
all of the depletion conditions had been possible.     
Finally, the pattern of reactivity observed in response to donor membrane proteins was 
not always mirrored in the response to the viral cocktail suggesting that B cells may 


























Figure 3.5 IFNγ production in response to a viral protein cocktail 
Samples were incubated with a viral cocktail at the same time as the donor membrane 
proteins. A reactive response was defined as ≥25 IFNγ+ spots per million CD4+ 
lymphocytes and is marked by the dotted line. Each depletion condition is shown along 
the X-axis. Samples were grouped according to the depletion condition where a 
response was observed. If a sample was both B regulated and T regulated, it has been 




























































































 B cell phenotype does not correlate with pattern of reactivity in the 
indirect IFNγ ELISpot 
Because all of the reactive samples that were depleted of CD19+ cells showed B cell 
dependent IFNγ production, it was hypothesised that the B cell phenotype in these 
samples may differ from those that were non-reactive. The phenotype of the B cells at 
enrolment were therefore correlated with the pattern of reactivity in the IFNγ ELISpot 
at enrolment. There were no reactive Breg samples at enrolment so in this analysis 
the non-reactive group contains all samples that were non-reactive when only CD8+ T 
cells were depleted. Analyses of later time points has not been included because a) 
some patients received Rituximab and therefore were depleted of B cells and b) the 
majority of the samples from those that were not given Rituximab were non-reactive. 
Patient W004 could not be used in any analysis that involved just enrolment samples 
as their enrolment PBMC sample was non-viable upon thawing. Figure 3.6 shows the 
initial gating strategy that was used prior to any panel specific analysis: doublets were 
gated out using FSC-W versus FSC-A, followed by non-live cells. Lymphocytes were 
defined as CD14-. An example of the gating strategy used for the B cell phenotyping 
panel is shown in Figure 3.7.  Both a patient enrolled on the RituxiCAN C4 trial and a 
Leukocyte cone are shown (Fig 3.7 (a) and 3.7 (b) respectively). Isotype control 
antibodies were used to guide the gating for the CD1d+, CD5+ and CD10+ populations 
as illustrated in Fig 3.7 (a).  
Figures 3.8 and 3.9 show a comparison between the phenotype of the B cells of each 
enrolment sample and whether the samples were reactive or non-reactive when just 
CD8+ cells were depleted. Figure 3.8 shows that no differences in the frequency of 
CD19+ cells (Fig 3.8 (a)) or naïve, intermediate and transitional B cells (Fig 3.8 (b), (c) 
& (d)) were found between reactive and non-reactive samples (P >0.05). Additionally, 
no difference was found in the frequency of CD27+ or CD27- B cells, or the ratio of 
these two subsets between the reactive and non-reactive samples (Fig 3.9 (a), (b) & 
(c), P>0.05).  
The phenotype of regulatory B cells has been reported to include the expression CD10, 
CD5 and CD1d (Blair et al., 2010, Ma et al., 2014), so the frequency of naïve, 
intermediate and transitional B cells that expressed these markers was analysed. No 












Figure 3.6 General gating strategy for phenotyping T and B cells.  
The initial gating strategy to define the live lymphocytes was used for both the T and 
B cell phenotyping panels. Doublets were gated out (a), followed by the dead cells (b). 





Figure 3.7 Gating strategy for B cell phenotyping 
(a) B cells were defined as CD19+ lymphocytes and then divided into CD27+ (memory) 
and CD27- (non-memory) subsets. Within the CD27- population, the B cells were 
further divided into naïve (CD38loCD24lo), intermediate (CD38intCD24int) and 
transitional subsets (CD38hiCD24hi). CD1d, CD5 and CD10 expression was gated on 
using the isotype control as a guide and then applied to each CD27- cell subset. (a) 
Shows representative plots from a CAMR patient and (b) shows representative plots 













Figure 3.8 Correlation of B cell frequencies and phenotypes with reactivity in the IFNγ 
ELISpot at enrolment 
The frequency of CD19+ cells and CD19+ subsets (Naïve (a), Intermediate (b) and 
Transitional (c)) were compared in enrolment samples grouped according to reactivity 
to donor membrane proteins when just CD8+ cells were depleted. CD19+ cells are 
expressed as frequency of lymphocytes. Naïve, Intermediate and Transitional subsets 
are expressed as frequency of CD19+ lymphocytes. Black line represents the median. 































































































































Figure 3.9 Correlation of CD27+ and CD27- B cell subset frequencies with reactivity in 
the IFNγ ELISpot at enrolment 
The frequency of CD27+ (a)  and CD27- (b)  B cells was compared in enrolment 
samples grouped according to reactivity to donor membrane proteins when just CD8+ 
cells were depleted. The ratio of CD27:CD27- B cells was compared between the two 
groups (c). CD27+ and CD27- subsets are expressed as frequency of CD19+ 
lymphocytes. Black line represents the median. Samples were compared using a 































































































Figure 3.10 Correlation of CD5+, CD1d+ and CD10+ cell frequencies with reactivity in the 
IFNγ ELISpot at enrolment 
Enrolment samples were grouped according to reactivity to donor membrane proteins 
when just CD8+ cells were depleted. Black line represents the median. Reactive and 
non-reactive samples were compared for CD5, CD1d and CD10 expression on each 
B cell subset (Naïve, Intermediate and transitional) using a Mann Whitney U test. 














































 T cell phenotype does not correlate with patterns of reactivity in the 
indirect IFNγ ELISpot. 
At the same time as the B cell phenotyping and IFNγ ELISpot, PBMC were also stained 
with a T cell panel principally to characterise surface marker expression associated 
with regulatory T cells. CD4+ T cells were separated into CD25hi, CD25+ and CD25- 
subsets. The co-expression of CD25 and CD39 on CD4+ T cells was also analysed 
and CD25hiCD39+ cells were gated on, as this is a Treg subset that has recently been 
reported in the literature (Grant et al., 2014, Deaglio et al., 2007, Dwyer et al., 2010, 
Salcido-Ochoa et al., 2010). Example FACS plots of a RituxiCAN C4 patient and a 
leukocyte cone are shown in Figure 3.11 (a) and (b) respectively. 
The T cell phenotype was correlated with the pattern of reactivity observed in the IFNγ 
ELISpot when CD25+ cells were depleted. Samples from all time points were used in 
this analysis and grouped as follows: a) non-reactive, which includes samples that 
were ‘reactive B regulated’, b) ‘reactive, Treg’ which are samples that responded to 
donor membrane proteins only when CD25+ cells were depleted c) reactive, which are 
samples that responded to donor membrane proteins when only CD8+ cells were 
depleted and includes 1 sample that also had evidence of T cell regulation. No 
differences were observed in the frequency of T cell subsets and the pattern of 
reactivity in the IFNγ ELISpot (Fig 3.12, P>0.05). In addition, no differences were 
observed when the reactive sample that was T regulated was included in the ‘reactive 

















Figure 3.11 Gating strategy for T cell phenotyping 
 CD4+ T cells were gated on, followed by either CD25hi to define Tregs, or a quadrant 
gate was used to divide the CD4+ T cells into four populations based on their CD25 
and CD39 expression. Within the quadrant gate, a specific population of Tregs were 
gated on based on their high expression of CD25 and positive expression of CD39 
(CD25hiCD39+ Tregs). (a) is an example of a CAMR patient, (b) is an example of a 









Figure 3.12 Comparison of frequency of T cell subsets between samples grouped 
according to their pattern of reactivity in IFNγ production upon CD25+ depletion.  
The frequency of four different T cell subsets was compared between all samples 
grouped according to IFNγ production in response to donor membrane proteins pre 
and post CD25+ cell depletion: 1. Non-reactive, which includes samples that were 
‘reactive B regulated’, 2. ‘Reactive, Treg’ which are samples that responded to donor 
membrane proteins only when CD25+ cells were depleted; 3. Reactive, which are 
samples that responded to donor membrane proteins when only CD8+ cells were 
depleted and includes 1 sample that also had evidence of T cell regulation. (a) CD25hi 
T cells, (b) CD25+ T cells, (c) CD25+CD39+ T cells (d) CD25hiCD39+ T cells. All 
subsets expressed as frequency of CD4+ lymphocytes.  Black lines on graph represent 
the median. Groups compared using a Kruskal-Wallis test with a Dunn’s multiple 














































































































































































































 Patients who produced IFNγ in response to donor membrane proteins at 
enrolment did not pass phase I. 
Data from the observational study reported in Shiu et al has produced some interesting 
correlations with clinical outcome. Although somewhat complex, these correlations 
suggest that the pattern of reactivity in the ELISpot can be used to predict the clinical 
outcome (manuscript in preparation). Following on from these findings, similar 
correlations were made with the clinical outcomes of the patients enrolled on the 
RituxiCAN trial. An in depth clinical analysis is being prepared for publication, but for 
the purpose of this thesis, it was decided that the clinical outcome at the end of phase 
I would be correlated with the in vitro measured parameters, as at this point in the trial 
all patients had been subjected to the same treatment protocol. Figure 3.13 shows the 
clinical course reported as estimated glomerular filtration rate (eGFR) for each of the 
patients included in Figure 3.1. There were three potential outcomes at the end of 
phase I: a) the patient’s creatinine stabilised and they transitioned to phase III where 
they continued on optimised therapy and a PBMC sample was taken every 3 months, 
b) the patient’s creatinine did not stabilise and they were consented and randomised 
into phase II where they continued on optimal therapy with or without the addition of 
Rituximab or c) the patient was ineligible for phase 2 on account of the eGFR falling to 


















Figure 3.13 Estimated glomerular filtration rates over time of patients enrolled on the 
RituxiCAN C4 trial. 
Patients were divided into three groups based on their outcome at the end of phase I.  
Passed phase I:  the patient’s creatinine stabilised and they transitioned to phase III 
where they continued on optimised therapy and a PBMC sample was taken every 3 
months (n=10). Failed phase I: the patient’s creatinine did not stabilise and they were 
eligible for randomisation (requiring second consent) into phase II where they 
continued on optimal therapy with or without the addition of Rituximab (n=18). Graft 
failure or eGFR<20mls/min: the patient did not reach the end of phase I due to graft 
failure, or at the end of phase I the eGFR had fallen below 20mls/min, making them 
ineligible for the randomisation phase (n=4). Data for figure obtained from A. Dorling 
and modified for this thesis to only include patients that have been tested in the IFNγ 
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The pie charts in Figure 3.14 illustrate the proportions of patients who responded to 
donor membrane proteins in the IFNγ ELISpot at enrolment and their corresponding 
pattern of reactivity with regards to CD19+ and CD25+ cell depletion. 
9/10 (90%) patients who passed phase I were non-reactive to donor membrane 
proteins and remained non-reactive after subsequent CD19+ or CD25+ depletions. 
Sufficient PBMC were not available from two of these non-reactive patients to do 
subsequent CD25+ cell depletions. 1/10 of these samples (10%) was reactive.  
50% of patients that failed phase I showed evidence of reactivity to donor membrane 
proteins when they were enrolled onto the trial: 5/18 patients (28%) were reactive with 
a B dependent IFNγ response. 4/18 (22%) patients were non-reactive when only CD8+ 
cells were depleted, but 1/4 (5%) had a B regulated IFNγ response and 3/4 (17%) had 
a T regulated IFNγ response. The remaining 9/18 patients (50%) were non-reactive 
and did not change upon depletion of CD19+ or CD25+ cells, however sufficient PBMC 
were not available from one of these non-reactive patients to do subsequent CD19+ 
and CD25+ cell depletions.  
3/4 (75%) of the patients who experienced graft failure before the end of phase I did 
not respond to donor membrane proteins. 1/4 patients whose graft failed before the 
end of phase I responded to donor proteins. It is unknown whether this response was 
B dependent as there was insufficient PBMC available from this sample to do the 
CD19+ cell depletion in the ELISpot. 




















Figure 3.14 Correlating ELISpot reactivity at enrolment with clinical outcome 
Patients were grouped according to those who passed phase I (n=10), failed phase I 




































 B cell phenotype at enrolment does not correlate with clinical outcome at 
the end of phase I 
The B cell phenotype of the enrolment samples was analysed according to the three 
groups described in Figure 3.14. This analysis includes two patients that did not pass 
phase I and had B cell phenotyping carried out on their samples but no ELISpot due 
to the lack of an appropriate surrogate donor. There was no difference observed 
between the overall frequency of CD19+ cells, the frequency of naïve, intermediate 
and transitional B cell subsets or the proportions of CD27+ and CD27- populations 
between the three groups (Fig 3.15 and 3.16). In addition, there was no difference 
observed between the frequency of CD1d+, CD5+ or CD10+ cells within the naïve, 




















Figure 3.15 Comparison of the frequency of B cell subsets at enrolment with clinical 
outcome at the end of phase I 
Patients were grouped according to those who failed phase I (n=20), passed phase I 
(n=10) or had their graft fail/had an eGFR <20mls/min during phase I (n=4). Black lines 
on graph represent the median. Groups compared using a Kruskal-Wallis test with a 






















































































































































































































Figure 3.16 Comparison of CD27+ and CD27- B cell frequencies at enrolment with clinical 
outcome at the end of phase I 
Patients were grouped according to those who failed phase I (n=20), passed phase I 
(n=10) or had their graft fail/ had an eGFR <20mls/min during phase I (n=4). Black 
lines on graph represent the median. Groups compared using a Kruskal-Wallis test 






































































































































































Figure 3.17 Comparison of the frequency of CD5+ cells, CD1d+ cells and CD10+ cells 
within the naive, intermediate and transitional B cell subsets at enrolment with clinical 
outcome at end of phase I 
Patients were grouped according to those who failed phase I (n=20), passed phase I 
(n=10) or had their graft fail/ had an eGFR <20mls/min during phase I (n=4). Frequency 
of CD5 (a), CD1d (b) or CD10 (c) expressed on each B cell subset (Naïve, Intermediate 
or Transitional) was compared between the three groups of patients. Black lines on 
graph represent the median. Groups compared using a Kruskal-Wallis test with a 












































 Patients who did not pass phase I have a lower frequency of CD4+CD25+ 
T cells than those who passed phase I 
As in section 3.2.9, the T cell phenotype of the enrolment sample from each patient 
was correlated with the clinical outcome at the end of phase I. No differences were 
found between the two groups with regards to the frequency of CD4+ lymphocytes or 
the regulatory T cell subsets when defined as either CD4+CD25hi, 
CD4+CD25+CD39+ or CD4+CD25hiCD39+ (Fig 3.18(a), (b) (d) & (e)). However, 
patients who did not pass phase I were found to have a lower frequency of effector 























Figure 3.18 Comparison of frequency of CD4+ T cells and CD4+ T cell subsets at 
enrolment with clinical outcome at end of phase I 
Patients were grouped according to those who failed phase I (n=18), passed phase I 
(n=10) or had their graft fail/ had an eGFR <20mls/min during phase I (n=4). The 
frequency of T cell subsets was compared between the three groups. (a) CD4+ T cells 
(b) CD25hi T cells, (c) CD25+ T cells, (d) CD25+CD39+ T cells (e) CD25hiCD39+ T 
cells. CD4+ T cells expressed as frequency of lymphocytes, all other subsets 
expressed as frequency of CD4+ lymphocytes. Black lines on graph represent the 
median. Groups compared using a Kruskal-Wallis test with a Dunn’s multiple 
comparison test. Patients who did not pass phase I were found to have a lower 
frequency of effector CD4+CD25+ T cells than those who did pass phase I  (P= 
































































































































































































































































 Correlating B cell phenotype in patients enrolled on the RituxiCAN C4 trial 
with Leukocyte cones 
The B cell phenotype of the enrolment samples was compared to the phenotype of 12 
leukocyte cones to assess whether there were any gross differences between renal 
transplant patients with healthy volunteers. The leukocyte cones had been frozen in 
Liquid nitrogen for 3 years before being stained for flow cytometry in order to replicate, 
as close as possible, the conditions that the RituxiCAN C4 trial samples had been 
stored under as this may have had an effect on some B cell populations or the 
expression of certain cell surface markers. Figure 3.19 shows that the frequency of 
CD19+ cells in the enrolment samples is significantly lower than in the leukocyte cones 
(P=0.0004).   
When the frequency of different B cell populations were compared between the 
leukocyte cones and the enrolment samples, the analysis revealed that the leukocyte 
cones have a higher frequency of transitional and intermediate B cell subsets 
compared to the enrolment samples (Fig. 3.20 (a) and (b), P=0.0105 and P=0.0079  
respectively). No significant differences were found between the two groups with 
regards to the frequency of naïve cells or memory cells (CD27+) (Fig. 3.20 (c) and (d)).  
The frequency of CD5+ cells was highest in the transitional population and lowest in 
the naïve population in both the enrolment samples and the leukocyte cones. However 
within each population, there was a significantly lower representation of CD5+ cells in 
the enrolment samples compared to the leukocyte cones (Fig 3.21 (a), P <0.0001 for 
all three populations). In both the enrolment samples and the leukocyte cones, the 
frequency of CD1d+ cells was very similar on naïve and intermediate cells but slightly 
lower on the transitional cell population. However, the frequency of CD1d expressing 
cells within each population was higher in the enrolment samples than the leukocyte 
cones (Fig 3.21(b), P<0.0001 for naïve and intermediate, P=0.0407 for Transitional). 
Finally, a lower frequency of CD10+ cells in the transitional and intermediate 
populations was observed in the patients compared to the leukocyte cones (Fig 3.21 












Figure 3.19 Comparison of CD19+ lymphocyte frequency between leukocyte cones and 
enrolment samples from patients enrolled on the RituxiCAN C4 trial 
The patients have a lower frequency of CD19+ lymphocytes than Leukocyte cones, 
P=0.0004. Black lines on graph represent the median frequency, P value obtained 












































Figure 3.20 Comparison of B cell subset frequencies between leukocyte cones and 
enrolment samples from patients enrolled on the RituxiCAN C4 trial 
(a) and (b): transitional and intermediate B cells were found at lower frequencies in 
RituxiCAN C4 patients compared to leukocyte cones (P=0.0105 and P=0.0079 
respectively). P>0.05 for Naïve and CD27+ subsets ((c) and (d)). Black lines represent 








































































































Figure 3.21 Comparison of CD5+, CD1d+ and CD10+ cell frequencies within the naive, 
intermediate and transitional subsets between leukocyte cones and enrolment samples 
from patients enrolled on the RituxiCAN C4 trial  
(a) A lower frequency of CD5+ cells on all subsets (Naïve, Intermediate and Transitional) was 
measured in the enrolment samples compared to the leukocyte cones (P= < 0.0001 for all three 
subsets). (b) A higher frequency of CD1d+ cells was measured in the enrolment samples 
compared to the leukocyte cones (P<0.0001 for naïve and intermediate, P=0.0407 for 
transitional). (c)  A lower frequency of CD10+ cells was measured in the intermediate and 
transitional cells in the enrolment samples compared to the leukocyte cones (P=0.0032 and 















































 B cell phenotypes post Rituximab 
A delayed re-population of B cells post Rituximab treatment has previously been 
reported in cohorts of renal transplant patients with CAMR (Rostaing et al., 2009, 
Billing et al., 2012). One of the aims of this thesis was therefore to address how long 
this process would take in renal transplant recipients with CAMR enrolled onto the 
RituxiCAN C4 trial, and investigate whether there is preferential repopulation of a 
certain subset of B cells into the circulation before others. The absolute B cell numbers 
per µl of blood over time for each patient who was randomised into phase II are shown 
in Table 3.1. Data was collated from information collected from the clinical laboratories 
where blood samples were sent for routine monitoring. All available data has been 
included in this table. The patients have been grouped according to whether they 
received Rituximab or not. In the Rituximab treated group, there was a sharp decrease 
in B cell numbers between months 3 and 6 where the mean number of B cells/µl of 
blood reduced from 118 to 3. In contrast, the mean number of B cells per µl of blood 
in the non-Rituximab treated group increased from 76-93. The mean number of B cells 
in the Rituximab group remained low over the subsequent 36 months and were far 
from returning back to the numbers observed before Rituximab treatment.  
B cells were stained by flow cytometry before and at several time points post 
Rituximab. In the majority of patients, very few events were detected in the CD19+ 
gate. Four patients who received Rituximab had enough B cells return to their 
peripheral blood to be able to do some basic phenotyping analysis. The B cell subsets 
were only phenotyped based on their CD27+ and CD27- expression as the small 
number of events was prohibitive to analysing the B cell subsets any further. In 3/4 
patients, B002, G012 and G003, the B cells that were detectable in the circulation 12-
19 months post enrolment were predominantly CD27+ (Fig 3.22 (b)). At later time 
points, this frequency declined and an increase in CD27- B cells was observed. By 33-
39 months post enrolment, the frequency of CD27+ and CD27- B cells was more 
reflective of that measured at enrolment (Fig 3.22 (a) and (b)). The repopulation of the 
remaining patient (G017) at time point 1 was in contrast to the other patients as they 
had an equal distribution of CD27+ and CD27- B cells. However, a similar pattern was 
observed in all four patients between time points 1-3 where an overall decrease in 








Table 3.2 B cell numbers over time in patients randomised in phase II 
 
Patients are grouped according to whether they received Rituximab or not. Numbers 
represent number of B cells per µl of blood. All available information is shown. 
 
Patient ID
Rituximab 0 3 6 9 12 15 18 21 24 27 30 33 36
W010 90 23 0 4 5 6 9
G003 203 89 13 19 2 17 10 2 4 1 5 10 2
G009 154 170 2
G010 16 19 0
G012 269 173 4 6 1 6 5 9 10 9 6
G017 56 186 4 1 1 2 1 4 2
G025 224 164 1 1 2 5 1 2
Mean 145 118 3 6 3 7 5 4 5 5 5 10 2
No Rituximab
W006 630 517 758 287 143 142 288 321 275
W008 47 48 67 61 65 114 104 84 114 90 62
G002 49 148 100
G007 36 17 19 34 11 20 21 16
G011 21 40 16
G013 133 160 189 230 172 165 196 179 241 204 190 186 217
G023 43 60 30
G027 87 60 100 69 60 30
Mean 59 76 93 87 85 68 110 101 163 111 190 138 140






Figure 3.22 Frequency of CD19+ lymphocytes and CD27+ and CD27- B cell subsets pre 
and post Rituximab in four patients randomised in phase II 
Rituximab was administered between time point 0 and 1. Time point 0 = enrolment, 
Time point 1 = 12-19 months post enrolment, Time point 2 = 24-29 months post 
enrolment,Time point 3 = 33-39 months post enrolment.  
 
 







































































































 Key points in chapter 3 
 
1. The B dependent, B regulated and T regulated patterns of IFNγ production in 
response to donor membrane proteins that were reported in Shiu et al. were 
reproduced in PBMC samples from the RituxiCAN C4 trial. 
 
2. The patterns of reactivity in the IFNγ ELISpot did not correlate with the 
phenotype of B cell or Treg cell subsets.  
 
3. IFNγ production at enrolment onto the RituxiCAN C4 trial correlated with clinical 
outcome at the end of phase I: The majority of patients who produced IFNγ in 
response to donor membrane proteins at enrolment had eGFRs that continued 
to decline post optimisation of oral immunosuppression. 
 
4. PBMC from patients enrolled onto the RituxiCAN C4 clinical trial have 
significantly lower frequencies of circulating CD19+ cells and Intermediate and 
Transitional B cells than Leukocyte cones.   
 
5. Rituximab mediated B cell depletion from the peripheral blood is highly effective 
in renal transplant recipients with CAMR. B cell numbers remained low up to 
36 months post Rituximab administration. Upon B cell repletion, CD27+ 
memory B cells were the predominant B cell subset that could be detected in 














The indirect pathway of allorecognition has been known for over two decades and is 
regarded as the most important pathway for long-term outcomes in solid organ 
transplantation. Despite this, there is no reliable way of correlating indirect alloreactivity 
with clinical outcome and a routine clinical test that can be used to monitor indirect 
alloreactivity in transplant recipients is yet to be established.  
In this chapter, a previously published IFNγ ELISpot assay used to measure indirect 
alloreactivity in renal transplant recipients with chronic rejection, was applied to a new 
cohort of patients with CAMR to establish whether this assay merits further 
development for use as a tool to study the relationship between the indirect pathway 
of allorecognition and the progression of CAMR (Shiu et al., 2015).  
The group of patients studied were recruited onto the RituxiCAN C4 trial and were 
therefore a more uniform group of patients than used in the observational study 
published in Shiu et al. Alongside the initial aim of measuring the magnitude of the 
indirect alloreactive response to donor derived membrane proteins, was the aim of 
investigating the contribution that B cells make to this response as well as establishing 
if there was a role for Treg cells in regulating the indirect alloresponse. To this end, the 
contribution of B cells was measured in vitro by magnetic bead based depletion of 
CD19+ cells in the IFNγ ELISpot and in vivo by using Rituximab as a B cell depleting 
agent. The contribution of Treg cells was measured using in vitro depletion of CD25+ 
cells in the IFNγ ELISpot. In order to eliminate interference from the semi-direct or 
direct pathways in the IFNγ ELISpot, CD8+ T cells were in vitro depleted in every 
experiment. To complement the results from the IFNγ ELISpot, global phenotyping of 
the T and B cells in these patients was carried out. The analysis of the results focuses 
on the in vitro findings because at the time of writing this thesis, the RituxiCAN C4 
clinical trial had not been completed, so in depth analyses of clinical outcomes have 
not been included. There was however the opportunity to study the effect that 
Rituximab treatment had on the depletion and subsequent reconstitution of the B cell 
population in this cohort of patients and to do some basic analyses with regards to the 
ELISpot pattern of reactivity at enrolment and how this related to the clinical outcome 




 The patterns of reactivity to donor membrane proteins detected in the 
RituxiCAN C4 cohort broadly replicates those reported in Shiu et al and 
highlight the complex and dynamic nature of the alloresponse 
Shiu et al. reported that CD4+ IFNγ production in response to donor membrane 
proteins was both complex and dynamic in renal transplant recipients with chronic 
rejection (the Biopsy for cause-CAMR, or BFC-CAMR group). The data reported in this 
chapter broadly supports these findings as the same patterns of reactivity have been 
observed in the RituxiCAN C4 cohort. In Shiu et al. 36% of CD8+ depleted samples in 
the BFC-CAMR group produced IFNγ in response to donor membrane proteins 
compared to 19% of the RiuxiCAN C4 samples. When CD19+ cells were depleted from 
the samples that were hyporesponsive to donor membrane proteins when just CD8+ 
cells were depleted, IFNγ production was revealed in 18% of the BFC-CAMR samples 
compared to 8% in the RituxiCAN C4 samples. Similarly, when CD25+ cells were 
depleted from the hyporesponsive samples, IFNγ production was revealed in 34% of 
the BFC-CAMR samples and 9% of the RituxiCAN C4 samples (Shiu et al., 2015). The 
frequency of samples that display each pattern of reactivity is not the same in the two 
cohorts of patients, but there are limitations to the conclusions that can be made by 
making such gross comparisons, as the two groups were recruited using different 
criteria and the number of samples tested is not the same for each patient. The 
RituxiCAN C4 samples are from patients recruited onto a clinical trial and so therefore 
are more tightly defined and controlled than the BFC-CAMR group who were part of 
an observational study. Moreover, the RituxiCAN C4 patients all received the same 
treatment intervention of Tacrolimus and MMF in the first phase of the study and a 
subset of patients received Rituximab thereafter.  
An appropriate way of using the data from both cohorts is to highlight that active cellular 
processes against donor antigens can be detected in the peripheral blood of renal 
transplant recipients with CAMR and that B cells are likely to be playing a role in 
facilitating this immune activation through processing and presenting donor antigen to 
indirect alloreactive CD4+ T cells. In the RituxiCAN C4 cohort, IFNγ production was 
dependent on the presence of B cells in 100% of the samples that responded to the 
donor membrane proteins when only CD8+ cells were depleted. Similarly, 76% of the 
reactive BFC-CAMR samples showed evidence of B cell dependent IFNγ production. 
The fact that the CD19+ depletion had such a dramatic effect on IFNγ production 
suggests that they were the dominant APCs in the culture. This is not surprising as 
others have previously shown that B cells are more efficient at processing and 
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presenting low concentrations of antigen than other APCs (Constant, 1999, Constant 
et al., 1995b, Constant et al., 1995a).  
The data from both studies also highlights that there is a substantial proportion of 
samples that do not produce IFNγ in response to donor membrane proteins but that in 
some of these samples there is evidence of a regulated immune response towards 
donor antigens. Interestingly, some samples produce IFNγ when B cells are depleted 
suggesting that in these individuals, B cells are playing a regulatory role and that other 
APCs are active in these samples. Similarly, some samples produce IFNγ only when 
CD25+ cells are depleted from the PBMC mixture revealing that in these samples there 
are active anti-donor processes occurring but they are being kept in check by 
regulatory T cells. This evidence of immune regulation is not entirely unexpected as in 
a conventional immune response setting such as infection, the immune system is 
highly effective at clearing the pathogen whilst maintaining regulation so adverse 
pathology does not occur. Considering this point, it is perhaps more surprising that 
evidence of regulation could not be detected in more samples. This may be due to a 
technical limitation of this assay in that some effector cells may also have been 
depleted using the CD25+ Dynabeads, or it might be due to a fundamental lack of 
regulation in these patients which may have contributed to their progression to CAMR. 
The latter is hard to reconcile with the data as a whole because the majority of samples 
remain hyporesponsive to donor membrane proteins even when CD19+ or CD25+ 
cells are depleted. An IFNγ response to a cocktail of common viral proteins could be 
detected in some of these donor hyporesponsive samples and all samples produced 
IFNγ when polyclonally stimulated with anti-CD3/CD28 beads, so it is unlikely that the 
lack of response to donor membrane proteins is due to an intrinsic inability to respond 
to antigen or produce IFNγ. It is possible that the donor-specific CD4+ T cells were 
either in the graft or a draining lymph node at the time of blood draw as opposed to the 
peripheral blood. It is also possible that there was a response to donor antigen in these 
samples but the cytokine output was not IFNγ. The fact that the patients were all 
receiving potent immunosuppressive drugs may also impact the ability to detect a 
donor specific IFNγ response in vitro. 
 Evidence of donor specific reactivity at enrolment was mainly detected in 
patients who did not stabilise their graft function during phase I 
The data in this study highlights that the response to donor membrane proteins is 
complex, but it also shows that the response is highly dynamic: each patient can 
display a different pattern of reactivity at each different time point. This constant 
changing in the dynamics of the alloresponse makes it difficult to determine which 
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subset of leukocytes to target in order to slow down the progression to graft loss. The 
data from the RituxiCAN C4 cohort does however suggest that evidence of donor 
specific reactivity- whether that be B cell dependent, B regulated or T regulated – is an 
indication that graft function will continue to decline and that these patients are 
refractory to optimised immunosuppression of TAC and MMF. 10/11 (91%) of the 
patients that showed evidence of donor specific reactivity at enrolment failed to 
stabilise their graft after optimal treatment was administered (end of phase I).  
It must be noted that patients who did not pass phase I were divided into two different 
groups based on their graft function at the end of phase I. Patients whose kidney 
function failed to stabilise were eligible to be re-consented into phase II and those who 
had graft failure or an eGFR<20 mls/min during or at the end of phase I were withdrawn 
from the trial. It is perhaps surprising that only a small percentage of patients who 
produced IFNγ in response to donor derived proteins were found in the latter group, 
as it would follow that donor reactivity would lead to a poorer clinical outcome in all 
patients who did not pass phase I. It is possible however, that this group of patients 
were recruited onto the trial with an eGFR that was already lower than can benefit from 
intervention and that their poor renal function at enrolment was the major cause of the 
subsequent decline to graft failure, as opposed to any immunological mechanism 
(A.Dorling, personal communication).  
 Rituximab treatment leads to prolonged depletion of B cells from 
peripheral blood 
Rituximab administration led to a prolonged reduction in B cell counts in the patients 
that were randomised to receive Rituximab in the RituxiCAN C4 trial. Such a prolonged 
reduction of B cells is not commonly seen in individuals who receive Rituximab for the 
treatment of Non-Hodgkin’s Lymphoma, RA, SLE or Type I Diabetes, where B cells 
have been reported to re-populate the circulation by 12 months post Rituximab 
administration (Anolik et al., 2007b, Leandro et al., 2006, Palanichamy et al., 2009, 
Roll et al., 2006, Palanichamy et al., 2012, Pescovitz et al., 2009). It is possible that 
prolonged depletion of B cells post Rituximab is a feature of CAMR as previous studies 
that have included Rituximab as a treatment drug for CAMR or CAMR associated 
biopsy features have reported that B cells do not return to the circulation. Rostaing et 
al. reported that circulating B cells had not returned by 30 months post Rituximab 
administration (Rostaing et al., 2009)  and Billing et al. reported that in 3/6 patients 
they treated with Rituximab, B cells remained completely depleted at their 12 month 
follow up, 1/6 had partial reconstitution and 2/6 had reconstituted their B cells (Billing 
et al., 2008).  
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Interestingly, the B cells that have been detected in the circulation of the RituxiCAN C4 
patients are of a CD27+ memory phenotype which is in contrast to the phenotype of 
the B cells that re-populate the circulation in individuals treated with Rituximab for 
autoimmune diseases or Non-Hodgkin’s Lymphoma, where re-population of the B cell 
compartment is in line with B cell ontogeny (Anolik et al., 2007b, Palanichamy et al., 
2009, Roll et al., 2006). The first population to be detected in the peripheral blood post 
Rituximab therapy in these patients is of a transitional phenotype and a delayed 
reconstitution of the memory B cell population is often observed (Sidner et al., 2004, 
Roll et al., 2006, Anolik et al., 2007a). It is possible that the memory B cells detected 
in the peripheral blood of the RituxiCAN C4 patients post Rituximab originate from a 
pool of memory B cells that were never depleted by the Rituximab treatment 
(Kamburova et al., 2013). Alternatively, either CAMR itself, or the combination of 
Tacrolimus, MMF and Rituximab, may have a detrimental effect on B cell homeostasis 
post Rituximab treatment. The fact that the RituxiCAN C4 patients are being treated 
with immunosuppressant drugs Tacrolimus and MMF, in addition to the Rituximab, 
makes it difficult to directly compare B cell reconstitution in CAMR patients with those 
receiving treatment for Non-Hodgkins Lymphoma and autoimmune diseases. Whilst 
immunosuppressant drugs are used to treat some autoimmune diseases, Tacrolimus 
and MMF were not used in combination with Rituximab in the papers cited above. 
Similar results were found in a cohort of renal transplant recipients who received a 
single dose of Rituximab at the time of transplant; B cell numbers remained low for two 
years after Rituximab treatment. These patients did not have CAMR, but were also 
treated with Tacrolimus and MMF which suggests that it is the combination of these 
two immunosuppressant drugs that is preventing the reconstitution of B cells post 
Rituximab treatment (Kamburova et al., 2014).   
Whether the administration of Rituximab in the RituxiCAN C4 CAMR patients has a 
favourable clinical outcome is yet to be determined as the RituxiCAN C4 trial is 
ongoing. 
 CD4+ T cell phenotype does not correlate with pattern of reactivity in the 
IFNγ ELISpot in RituxiCAN C4 patients 
No correlations were found between the phenotype of T cell subsets and the ELISpot 
patterns of reactivity in the RituxiCAN C4 cohort of patients. This finding is not in 
agreement with the observational study by Shiu et al. where they reported that donor 
reactive samples (ie. those that produced IFNγ in response to donor membrane 
proteins when just CD8+ cells were depleted) had significantly higher frequencies of 
CD4+CD25+ T cells than those who were non-donor reactive, suggesting that these 
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samples had a higher frequency of activated effector T cells. Shiu et al. also reported 
that samples with a T regulated donor reactive response had significantly higher 
frequencies of CD4+CD25hi T cells. It is important to note however, that this data is 
based on samples from all of the cohorts studied in Shiu et al and not just the BFC-
CAMR group. Interestingly, in the RituxiCAN C4 cohort a higher frequency of 
CD4+CD25+ T cells at enrolment was associated with a better clinical outcome at the 
end of phase I of the trial. This result is the opposite of what was predicted as it was 
expected that better clinical outcome would be associated with higher frequencies of 
CD4+CD25hi Treg cells. It does not appear that the positive clinical outcome in these 
patients is related to a reduction in the CD4+CD25+ subset or an increase in 
CD4+CD25hi cells between enrolment and the end of phase I as no obvious changes 
in the phenotype in either of these subsets were apparent in these samples. 
 Global phenotype of B cells at enrolment does not correlate with pattern 
of reactivity in IFNγ ELISpot or clinical outcome 
No gross differences could be found in overall B cell phenotype at enrolment that 
distinguished the patients from one another in terms of their pattern of reactivity in the 
IFNγ ELISpot or their clinical outcome. This mirrors what was found in the 
observational study by Shiu et al. However, it was found that CAMR patients have 
lower frequencies of B cells than Leukocyte cones. Leukocyte cones are a source of 
PBMC derived from individuals who are blood donors and so in theory should be 
suitable to be used as healthy controls. Within the B cell population it was also found 
that CAMR patients have lower frequencies of transitional and intermediate 
populations than Leukocyte cones. Both of these findings are consistent with Shiu et 
al and others (Silva et al., 2012, Nova-Lamperti et al., 2016, Shiu et al., 2015, Nouel 
et al., 2014). Interestingly, it was found that CAMR patients have a higher proportion 
of CD1d expressing B cells than the Leukocyte cones. The reason for this remains 
unclear. 
Correlating global phenotypes with an antigen specific response is a rather crude way 
of studying the immune system. The phenotype of individual allospecific B cells may 
not reflect that of the overall B cell population and may indeed correlate with the B cell 
dependent or B regulated patterns of reactivity. In the following chapter of this thesis, 
an assay to flow cytometrically detect antigen binding B cells was developed to help 
address this point. 
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 Technical limitations of the IFNγ ELISpot and potential improvements 
Whilst being one of the most sensitive immunological techniques available for 
detecting antigen specific responses, the ELISpot assay does have some limitations 
which could explain some of the variability that is seen in patient responses. For 
example, the fact that the response to donor membrane proteins was highly dynamic 
over time could be due to ever changing in vivo dynamics of the alloresponse or it 
could merely be a reflection of the alloreactive T and B cell clones that happened to 
be present in the vial of cells that was thawed on the day of the experiment. If a different 
composition of cells was added to the wells in the ELISpot, a different result may have 
been detected. This variability in results, as well as the high levels of background 
observed may be, in part, due to the fact that cryopreserved PBMCs were used for all 
of the experiments. Whilst this has the advantage that all patient samples can be tested 
on the same day with the same reagents, therefore reducing the impact of batch effects 
and other laboratory variables such as temperature and operator, it does lead to a 
freeze-thaw process which could potentially damage some of the antigen specific T 
and B cells and also lead to high number of non-antigen specific IFNγ spots being 
produced. Conducting these experiments using fresh blood would help preserve the 
antigen specific T and B cells and make it easier to resolve the antigen specific IFNγ 
producing T cells from the background.    
 Technical limitations of membrane proteins and potential alternatives 
ELISpots have been used in many studies to determine the contribution that the 
indirect pathway of allorecognition makes to transplant rejection. Peptides containing 
known sequences of epitopes can be easily manufactured to study T cell responses, 
however, finding a readily available and economic source of HLA proteins to study the 
contribution that B cells make to the T cell alloresponse is more difficult. Many studies, 
including this one, have used cell membrane fragments as their source of HLA proteins 
(Baker et al., 2001, Benichou et al., 1999, Nadazdin et al., 2011, Nadazdin et al., 2010, 
Shiu et al., 2015, Breman et al., 2014). This has the advantage of being able to study 
the alloresponse to all alloantigens (including minor histocompatibility antigens) but the 
disadvantage of not knowing the exact composition or concentration of alloantigens 
that the cells are being exposed to. This limits the knowledge that can be gained from 
these antigens in terms of investigating whether the T cell or B cell population is 
skewed towards certain HLA epitopes or even HLA subtypes, eg. Class I or class II. In 
addition, if a membrane protein preparation has a particularly low yield of HLA 
molecules, a donor specific response could be missed due to insufficient antigen being 
used in the assay. Using surrogate donor membrane proteins enables patients who 
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had a cadaveric transplant to be studied in the ELISpot assay, however this also 
means that they are being stimulated with antigens that are not completely 
representative of the actual donor. In order to minimise any non-donor specific 
responses observed when using surrogate donors, patients were carefully matched 
with appropriate surrogate donors using their HLA antibody profiles and previous 
transplant history. Finally, the method used to manufacture the membrane proteins 
used in this thesis is laborious and highly dependent on the quality of the starting 
material. In addition, the solubilising solution required to dissolve these membrane 
fragments is toxic to cells and can have a detrimental effect in the ELISpot assay if too 
much is used. Breman et al demonstrated that HLA monomers could be used as an 
alternative to cell fragments to activate an HLA A2 specific T cell clone and the use of 
Pure™ HLA proteins will be described as an alternative source of intact HLA molecules 
in the next chapter of this thesis (Breman et al., 2014).  
 Limitations to the interpretation of the data 
There are several limitations to the interpretation of the data in this chapter that must 
be noted. Firstly, it has been assumed that in the reactive B dependent samples, the 
B cells are processing and presenting the donor or viral antigens to CD4+ T cells. Shiu 
et al. has previously shown that when B cell activation was inhibited by adding Btk/Syk 
inhibitors to the cultures of the B dependent samples in the observational study, IFNγ 
production was diminished. In addition, IFNγ production was also diminished in these 
samples when the antigen processing and presentation pathway was targeted by 
adding leupeptin/pepstatin A/E64-d or an anti-class II antibody to the cultures. These 
experiments have not been repeated on the RituxiCAN C4 patient samples but it has 
been assumed that similar results would be seen if they were. It has also been 
assumed that the CD4+ T cells are the source of IFNγ when the number of IFNγ+ spots 
reached above the cut off of ≥ 25 IFNγ+ spots per million CD4+ T cells. This 
assumption is based on the rationale that if an antigen is added to a PBMC culture 
without any non-antigen specific stimulus, the cells that are activated to produce IFNγ 
should, in theory, be those that are specific to the antigen. By depleting CD4+ cells 
from ELISpots, it has been shown indirectly in other studies that using protein or 
peptide antigens elicits a CD4+ T cell response (Schmittel et al., 2001, Smith et al., 
2001, McConkey et al., 2003, Arif et al., 2004) Since 92% of the CD8+ T cells were 
depleted from the cultures, it is unlikely that CD8+ T cells are producing the antigen 
specific IFNγ in the ELISpot system used here. Whilst depleting CD4+ T cells from the 
ELISpot may not definitively show that the CD4+ T cells are the source of the IFNγ it 
may be a worthwhile experiment to strengthen the evidence for making this 
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assumption. It is possible that the reduction in IFNγ observed when B cells are 
depleted is because the B cells themselves are the source of the IFNγ. Whilst B cells 
are not known as major IFNγ producing cells (unlike CD8+ and CD4+ T cells) this 
cannot be ruled out as a possibility as it has been shown in both mice and humans that 
B cells have the ability to produce IFNγ under certain stimulation conditions 
(Ganapamo et al., 2001, Lund, 2008, Gagro et al., 2006, Fillatreau, 2015). Recently, 
Olalekan et al demonstrated that development of proteoglycan induced arthritis in a 
mouse required the presence of IFNγ producing B cells, probably because they were 
able to inhibit in vivo differentiation of Tregs (Olalekan et al., 2015). 
In samples where IFNγ production increased when either CD19+ cells or CD25+ cells 
were depleted it has been assumed that these cells were playing a regulatory role by 
suppressing IFNγ production. This is only indirect evidence of suppression of an 
antigen specific response, no attempt has been made in this chapter to perform 
suppression assays to directly demonstrate that the CD25hi or CD19+ populations that 
were depleted from the ELISpot assay are capable of suppressing CD4+ T cell IFNγ 
production in the presence of either donor membrane or viral proteins.  
Finally, the contribution of the direct and semi-direct pathways have not been assessed 















4 Results part 2 
 Introduction 
The results in chapter one established that both B-dependent and B-regulated 
responses to donor membrane proteins in the IFNγ ELISpot could be observed in two 
independent cohorts of renal transplant recipients with chronic rejection: those from 
the observational study published by Shiu et al, and those enrolled onto the RituxiCAN 
C4 clinical trial and reported here. Analysis of the global phenotype of the B cells in 
both cohorts did not reveal any gross differences between the samples when grouped 
according to their pattern of reactivity in the IFNγ ELISpot. It was therefore 
hypothesised that differences between the samples may be detected in the antigen 
specific B cell compartment. Thus, the next step towards addressing the aims of this 
thesis was to investigate whether the phenotype of antigen specific B cells differed 
between samples that had a B dependent IFNγ response and those that had a B 
regulated IFNγ response. This chapter addresses aims 4 and 5.  
 Detection of antigen specific B cells by flow cytometry  
Detecting antigen specific antibodies in an individual’s serum using an ELISA is 
common practice for monitoring the response to a vaccine, such as Hepatitis B, and 
for the diagnosis and routine monitoring of many diseases such as rheumatoid factor 
in rheumatoid arthritis and HLA antibodies in transplantation. If a more specific and 
sensitive analysis of an antigen specific B cell compartment is required then an 
ELISpot is often used to enumerate the number of antibody producing cells that are 
specific to the antigen of interest (Cao et al., 2010, Crotty et al., 2004, Nanan et al., 
2001). Although these techniques provide useful information, they only inform the 
investigator of the specificity and isotype of the antibodies that the B cell population of 
interest produces. They do not provide any insights into the phenotype of the B cells 
that were the precursors to those antibody producing cells.  
As we are now able to divide B cells into functional subsets using a combination of cell 
surface markers such as CD38, CD24, CD10, CD27 and immunoglobulin isotype, it 
would be useful to be able to ascertain the phenotype of the B cells that are specific to 
the antigen of interest. This could prove useful in guiding the appropriate B cell targeted 
treatment for each individual depending on their antigen specific B cell phenotype. For 
example, depleting the HLA specific B cells that are antigen presenting cells in a 
patient with CAMR may lead to a reduced rate of rejection. Conversely, if an individual 
has an antigen specific B cell population that is of a regulatory phenotype, then 
depleting this population may increase the rate of rejection.   
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However, developing a reliable assay for flow cytometrically detecting and phenotyping 
antigen specific B cells comes with its own challenges. It is not surprising that the 
antibody is chosen to be detected over the antigen specific B cell, as serum antibodies 
are much more abundant in peripheral blood than antigen specific B cells, and the 
binding of an antigen in an ELISA to a specific antibody is a much ‘cleaner’ detection 
method than detecting an antigen specific B cell, where successful detection requires 
the specific binding of an antigen to the BCR, with minimal background binding of the 
antigen to either non-antigen specific BCRs or other receptors on the surface of that B 
cell. Other factors that need consideration are the requirement for the bound antigen-
receptor complex to remain on the surface of the B cell for effective detection, and the 
potential for B cell-antigen complexes to form with two or more B cells binding to 
different epitopes on the same antigen (Moody and Haynes, 2008). The choice and 
preparation of the antigen is therefore very important to get right. For example, if the 
detection of an epitope specific B cell is desired, using a whole virus as the source of 
antigen would not be appropriate, as this would contain many epitopes that potentially 
several B cell clones could bind. A viral protein containing the epitope of interest would 
not completely eliminate this problem, but it is likely to yield much cleaner results. 
Correct preparation of the cells is also important in reducing the number of cells that 
will bind non-specifically to the antigen via Fc receptor bound antigen specific 
immunoglobulin (Irsch et al., 1995, Bell and Gray, 2003). Thorough washing of the 
cells prior to incubating with the antigen will reduce the number of antigen specific 
antibodies that bind to Fc receptors on B cells and other cell types (Hoven et al., 1989).   
The first attempt to detect antigen binding B cells was by Julius et al in 1972 where 
antigen specific B cells from a mouse were FACS sorted using either fluorescent 
antigen to coat the B cells or the use of a fluorescent antigen specific antibody that 
would bind to antigen coated B cells (Julius et al., 1972). Many of the challenges in 
identifying an antigen specific B cell population in 1972 remain today and this has 
hampered progress in improving the assays employed to identify and phenotype a very 
specific antigen B cell population. As a result, the techniques used to flow 
cytometrically identify an antigen specific B cell population today are remarkably similar 
to those used  40 years ago, with most studies choosing to use either a fluorescently 
labelled or biotin labelled antigen to form a complex with the antigen specific BCR 
(Hoven et al., 1989, Nossal et al., 1978, Taylor et al., 2012, Doucett et al., 2005, Irsch 
et al., 1995, Pape et al., 2011, Pötzsch et al., 2011, Doria-Rose et al., 2009, Khaskhely 
et al., 2012, Leyendeckers et al., 1999)  The majority of these studies have been 
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carried out in a murine setting, and those that have managed to identify an antigen 
specific B cell population in humans do not phenotype these cells in depth.   
As similar patterns of reactivity to the cocktail of viral antigens were observed in the 
patients studied in Chapter 3, it was hypothesised that similar results would be 
obtained if this assay was performed using PBMC isolated from leukocyte cones. Viral 
proteins could be used as a model antigen to develop an assay which would enable 
the flow cytometric detection and phenotyping of viral protein specific B cells, in 
conjunction with determining the pattern of reactivity to the same viral protein in the 
IFNγ ELISpot. This approach had the advantage that the assay could be optimised 
before applying it to a patient setting and thereby reducing the use of valuable patient 
samples for this purpose. In addition, the results may be of interest to the transplant 
field in general, as the viral proteins used in this chapter are derived from viruses that 


















 Developing a method to detect and phenotype CMV gB binding B cells 
4.2.1.1 Leukocyte cones produce IFNγ when stimulated with CMV gB protein 
Initially, the IFNγ ELISPOT assay was modified so the response to each individual viral 
protein that was used in the viral cocktail could be assessed. CMV gB, VZV gE and 
CMV pp65 were used individually, but at the same concentration used in the viral 
cocktail, to stimulate PBMC from 8 leukocyte cones. The response to each individual 
viral protein is shown in Figure 4.1. CMV gB induced IFNγ production in 4/8 individuals, 
with 3/4 of these individuals only producing IFNγ above the cut off of ≥25 IFNγ+ spots 
per million CD4+ lymphocytes when B cells had been depleted (Fig.4.1(a), (c) and (e)). 
In contrast, IFNγ production in response to CMV gB was B dependent in the remaining 
individual (Fig. 4.1(b)). CMV pp65 induced IFNγ above the cut off in 1/8 individuals 
tested, and this was only when B cells had been depleted (Fig.4.1 (e)). VZV gE induced 
IFNγ in 3/8 individuals tested, with 2/3 showing a B dependent response (Fig. 4.1(b) 
and (d)) and 1/3 individuals only producing IFNγ above the cut off when B cells were 
depleted (Fig.4.1(h)). These results clearly demonstrate that each individual responds 
differently to these three protein antigens in the IFNγ ELISpot assay. CMV gB was 
chosen as the model protein that would be used to develop the assay to detect antigen 
specific B cells as it elicited IFNγ production with both B dependent and B regulated 









Figure 4.1 Patterns of reactivity in response to three viral proteins in the IFNγ ELISpot 
(a-h) PBMC from 8 leukocyte cones were stimulated for 24 hours with either 0.03µg/ml 
CMV gB, 0.003 µg/ml CMV pp65 or 0.03 µg/ml CMV gE in a CD8+ (pink) or 
CD8+/CD19+ depleted (blue) ELISpot to investigate whether one of these protein 
antigens elicits a stronger IFNγ response than the others. A reactive response was 
defined as being ≥25 IFNγ+ spots per million CD4+ lymphocytes above background. 
Data represents number of IFNγ+ spots after background had been subtracted. Each 
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4.2.1.2 CMV gB binding B cells can be detected using biotinylated CMV gB 
Once it was established that CMV gB would be a good model protein to use, the assay 
to detect antigen binding B cells could be optimised. After a review of the literature, it 
was decided that incubating a biotinylated version of the CMV gB protein with PBMC 
and using streptavidin to visualise the B cells that bound the protein would be an 
appropriate method to try in the first instance. It was hypothesised that by using a 
biotinylated protein, as opposed to a directly fluorescently conjugated protein, the 
antigen binding population would be brighter and therefore more easily distinguished 
from the negative, non-antigen binding population.  
The biotinylated CMV gB protein was incubated with PBMC from a leukocyte cone at 
increasing concentrations in order to find the optimal concentration of protein that 
allowed the detection of antigen binding B cells without excessive background binding. 
Figure 4.2 illustrates dot plots from this titration experiment comparing frequencies of 
antigen binding B cells in the B cell gate versus the non-B lymphocyte gate. Minimal 
binding was observed on the non-B lymphocytes. Any non-specific binding on these 
populations was used to guide the positioning of the gate to define a positive CMV gB 
binding B cell population. Figure 4.3 shows the median with range of the frequency of 
CMV gB binding B cells in the B cell gate (Fig. 4.3 (a)) compared with the non-B 
lymphocyte gate (Fig. 4.3 (b)) from 5 leukocyte cones. An increase in non-specific 
binding of the non B lymphocyte population was detected at 0.194µg/ml which 
increased with each upwards titration. An increase in CMV gB binding B cells was also 
observed from 0.194µg/ml to 0.785µg/ml. It was therefore decided that 0.384µg/ml 
would be the concentration of CMV gB to use in future experiments as this was 
deemed an acceptable compromise in order to detect as many CMV gB binding B cells 
as possible, without causing too much non-specific binding. For ease of use in future 







Figure 4.2 Example dot plots of CMV gB binding B cells 
PBMC were incubated with increasing concentrations of biotinylated CMV gB (as 
indicated in figure) at 4°C and stained with CD19 APC-efluor 780 and streptavidin PE. 
Minimal binding was observed on non B lymphocytes. Any non-specific binding on 
these populations was used to guide the positioning of the gate to define a positive 















Figure 4.3 Detecting CMV gB binding B cells 
PBMC from 5 leukocyte cones were incubated with increasing concentrations of 
biotinylated CMV gB at 4°C and stained with CD19 APC-efluor 780 and streptavidin 
PE in order to determine the optimum concentration required to detect CMV gB binding 
B cells. A titration effect was observed where increasing frequencies of CMV gB 
binding B cells could be detected when PBMC were incubated with higher 
concentrations of CMV gB.  Minimal binding was observed on non-B lymphocytes: very 
small frequencies were observed when higher concentrations of CMV gB were used 
(0.192µg/ml-0.768µg/ml). The median frequency (with range) of CMV gB binding B 






















































4.2.1.3 Biotinylated CMV gB binds the B cell receptor  
In order to ascertain whether the binding of the CMV gB to the B cells was in an antigen 
specific manner, ie, binding to the B cell receptor, three different experiments were 
carried out. Firstly, the binding of B cells to biotinylated and non-biotinylated BSA was 
assessed. BSA was chosen as it is a readily available laboratory protein that the 
majority of humans should not be antigen exposed to, and therefore should not have 
a memory B cell response towards it. Figure 4.4 shows that in the two leukocyte cones 
that were tested (Fig. 4.4 (a) and (b)), antigen binding B cells were not detected when 
non-biotinylated CMV gB, non-biotinylated BSA or biotinylated BSA were incubated 
with the PBMC. This demonstrates that the events observed in the positive CMV gB 
gate were not due to the B cells binding non-specifically to the streptavidin, BSA, or 
the biotin respectively.  
To check that the CMV gB was binding the cells directly and not forming a complex 
between CMV specific antibodies in the serum and CD32, the FCγRIIB receptor 
expressed on B cells, the biotinylated CMV gB was incubated with 10µg/ml of a 
blocking anti-CD32 antibody prior to incubation with the biotinylated CMV gB (Fig. 4.5). 
Blocking the Fc receptor did not impact the frequency of antigen binding B cells that 
were detected.  
The role that CMV gB plays in viral entry remains unclear. Some studies report 
evidence to suggest that CMV gB binds directly to either epidermal growth factor 
receptor (EGFR) or platelet derived growth factor receptor (PDGFR) on the cell surface 
in order to facilitate cell entry (Soroceanu et al., 2008, Wang et al., 2003). Other studies 
have questioned these findings and report that although CMV gB is required for cell 
entry, it does not directly bind receptors on the cell surface (Isaacson et al., 2007, 
Vanarsdall et al., 2012, Wille et al., 2013). In order to confirm that the CMV gB used in 
this assay was binding the B cell receptor as opposed to any other receptor on the B 
cell, the B cell receptor was blocked using increasing concentrations of Fab anti-
IgG/IgM whilst incubating the PBMC with the biotinylated CMV. The data shown in 
Figure 4.6 suggests that the CMV gB is binding the BCR as there is a clear titration 








Figure 4.4 B cells do not bind streptavidin or biotin 
PBMC from two different leukocyte cones (a) and (b) were incubated with increasing 
concentrations of either biotinylated CMV gB (pink) non biotinylated CMV gB (blue), 
biotinylated BSA (green) or non-biotinylated BSA (purple) for 30 minutes on ice and 
























































































































































Figure 4.5 Blocking FCγRIIB does not reduce the frequency of CMV gB binding B cells 
detected 
PBMC from four different cones (indicated as pink, blue, green or purple) were 
incubated with 10µg/ml anti-human CD32 for 30 minutes prior to incubation with 
biotinylated CMV gB for 30 minutes on ice. PBMC were then stained with CD19 APC-
efluor 780 and streptavidin PE. Cones compared with and without αCD32 using a 




































































Figure 4.6 CMV gB binds the B cell receptor 
PBMC from two different cones (as indicated by the square and circle) were co-
incubated with 0.35µg/ml biotinylated CMV gB and increasing concentrations of anti-
human IgM/IgG Fab (H+L) to block the BCR. PBMC were incubated for 30 minutes on 













































4.2.1.4 CMV gB binding B cells are predominantly IgM+ 
Now confident that the CMV gB was binding the BCR, a panel of phenotyping 
antibodies was used to determine the phenotype of these CMV gB binding B cells in 
PBMC samples from 15 leukocyte cones. The PBMC were initially incubated with 
0.35µg/ml biotinylated CMV gB, washed, and then stained with a combination of B cell 
surface markers CD19, CD27, IgM, IgG, CD24 and CD38. The median frequency of 
CMV gB binding B cells detected was 1.83% (range 1.04%-3.37%). For phenotyping 
analysis, all gates were drawn on the entire B cell population and then applied to the 
CMV gB binding B cell population. The B cells were initially divided into transitional 
(CD24hiCD38hi) and non-transitional B cells (everything else) (Fig 4.7 (c)). All 
subsequent gating was applied to only the non-transitional population and is shown in 
Figure 4.8. 
The frequency of each CMV gB binding B cell subset was compared to the frequency 
of each B cell subset in the overall B cell population to determine whether the 
phenotype of CMV gB binding B cells is distinct from the overall B cell population. 
Figure 4.9 shows that the CMV gB binding B cells are predominantly of a non-
transitional phenotype but are overrepresented in the transitional gate compared to the 
overall B cell population (P=0.0009). Within the non-transitional gate, the CMV gB 
binding B cells were found to be predominantly IgM+ and significantly 
underrepresented in the CD27+ and IgG+ populations when compared with the overall 
B cell population (Fig 4.10 (a) and (b), P=0.0054 and 0.0002 respectively). 
Interestingly, there was a significant overrepresentation of IgMhi B cells in the CMV gB 
binding population (Fig 4.10 (c), P=0.0001). Populations of B cells that are IgMhi 
include IgM+ memory B cells, T3 B cells and Marginal zone precursor B cells (Bemark, 
2015). Therefore, to further characterise this population of CMV gB+ B cells, the co-
expression of CD27, a memory marker on B cells, and IgM was analysed. Figure 4.11 
shows that the frequency of both CD27+IgMhi B cells and CD27-IgMhi B cells were 
significantly higher in the CMV gB binding population than the overall B cell population 
(P=0.0003 and 0.0001 respectively). So although an overall underrepresentation of 
CD27+ cells in the CMV gB binding population was observed, when the co-expression 
of CD27 and IgM was analysed, the data suggests that CMV gB binding B cells are a 
mixed population consisting of both IgM+ memory B cells and possibly T3 or marginal 







Figure 4.7 Gating strategy for phenotyping CMV gB binding B cells 
(a) B cells were defined as CD19+ and CMV gB binding B cell were gated on using the 
negative control of 0.0µg/ml CMV gB and the non B lymphocytes population. (b) B 
cells were divided into two populations: transitional B cells (CD24hiCD38hi) and non-
transitional B cells (everything else). Gates were initially drawn on the whole B cell 
















Figure 4.8 Dot plots to illustrate the gating strategy for phenotyping the CMV gB binding 
B cells 
All gates were initially drawn on the whole non-transitional B cell population and then 
applied to the non-transitional CMV gB binding B cell population. 
 









Figure 4.9 Frequency of non-transitional and transitional B cells in the overall B cell 
population compared to the CMV gB binding B cell population 
(a) Non transitional B cells are underrepresented in the CMV gB binding B cell 
population (P= 0.0001). (b) Transitional B cells are overrepresented in the CMV gB 
binding population (P=0.0009). Each line on the graph represents a leukocyte cone 
(n=15). P values were obtained using a Wilcoxon matched pairs signed rank test.   
 










































Figure 4.10 Frequency of different B cell subsets in the overall B cell population 
compared to the CMV gB+ B cell population 
(a) CD27+ B cells are underrepresented in the CMV gB binding population (P=0.0054 
for CD27+ and >0.05 for CD27-). (b) IgM+ B cells are overrepresented in the CMV gB+ 
population with a corresponding underrepresentation of IgG+ cells (P=0.0003 and 
0.0002 respectively). (c) IgMhi B cells are overrepresented in the CMV gB+ population 
with a corresponding underrepresentation of IgMlo B cells (P=0.0001 and 0.0054 
respectively). Each line on the graph represents a leukocyte cone (n=15). P values 
were obtained using a Wilcoxon matched pairs signed rank test.   



















































































Figure 4.11 Frequency of IgM+ memory and naive subsets in the gB+ B cell population 
compared to the overall B cell population 
(a) CD27+IgMhi are overrepresented in the CMV gB+ B cell population whilst 
CD27+IgM- are underrepresented (P=0.0003 and <0.0001 respectively). (b) CD27-
IgMhi B cells are overrepresented (P=0.0001 for CD27-IgMhi and >0.05 for CD27-
IgM+). Each line on the graph represents a leukocyte cone (n=15). P values were 














































































As recent publications in the literature have suggested that the expression of CD45RB 
MEM55 (from here on in referred to as CD45RB) is a more specific marker of memory 
B cells than CD27, and also a defining marker of Transitional 3, or marginal zone (MZ) 
pre-cursor B cells in humans, CMV gB binding B cells were stained for CD45RB 
expression and compared to the overall B cell population to investigate whether the 
CD27-IgMhi population is enriched for T3 or MZ pre-cursor cells in the CMV gB binding 
B cell population (Bemark et al., 2012, Descatoire et al., 2014, Koethe et al., 2011, 
Bemark, 2015).  
As described in Figure 1.3 in the introduction to this thesis, T3 cells are thought to be 
late stage transitional B cells that will either differentiate into naïve follicular B cells or 
MZ/IgM+ memory B cells. The expression of CD45RB is thought to distinguish 
MZ/IgM+ memory pre cursor B cells from transitioning cells that will mature into naïve 
follicular B cells. Figure 4.12 shows the distribution of CD45RB+ B cells within the 
different B cell subsets when defined according to IgM and CD27 expression. The 
majority of CD27+ B cells express CD45RB. Approximately 50% of CD27-IgMhi B cells 






















Figure 4.12 CD45RB MEM 55 expression on CD27+ and CD27- B cell populations.   
Representative staining on a leukocyte cone is shown. CD27+ and CD27- populations 
have been divided according to high (IgMhi), low (IgM+) or negative (IgM-) expression 







Figure 4.13 shows an example of a dot plot from a leukocyte cone that was incubated 
with CMV gB prior to staining with an antibody phenotyping panel. In this individual, 
the CMV gB binding B cells are overrepresented in both the CD45RB+IgMhi and 
CD45RB-IgMhi populations compared to the overall B cell population. When this 
analysis was carried out on 8 cone samples (Fig. 4.14), it showed that the CD45RB-
IgMhi population was consistently overrepresented in the CMV gB binding population 
compared to the overall B cell population (Fig 4.14 (b), P=0.0078) and the 
CD45RB+IgMhi population was overrepresented in the CMV gB binding population in 
5/8 cone samples (Fig 4.14 (a), P>0.05). The data suggests that the MZ/IgM+ memory 
precursor subset is not overrepresented in the CMV gB binding population as there 
was no difference found in the frequency of the CD27-CD45RB+ subset between the 
CMV gB binding population and the overall B cell population (Fig 4.14 (c), P>0.05) This 
data therefore demonstrates a trend that in the majority of individuals, the CMV gB 
binding B cell population is a mixed population of IgM+ memory B cells and IgMhi naïve 
follicular pre-cursor B cells. However, in some individuals, the phenotype of the CMV 
gB binding B cells is skewed towards an IgMhi naïve follicular pre-cursor phenotype. 
In addition, this analysis confirms that CMV gB binding B cells are not represented in 
the class switched memory population (IgM-CD45RB+) as they are underrepresented 























Figure 4.13 Dot plots to illustrate the gating strategy for IgM memory and naïve B cell 
populations based on CD45RB expression.  
All gates were drawn on the non-transitional population of whole all  the CD19+ cells 
(All B cells) and then applied to the CD19+ non transitional CMV gB+ population (CMV 











Figure 4.14 Frequency of IgM+ memory and naïve populations in the CMV gB binding B 
cell population compared to the overall B cell population according to CD45RB 
expression.  
(a) CD45RB+IgMhi are overrepresented in the CMV gB+ B cell population in 5/8 
leukocyte cones tested (P>0.05), whilst class switched CD45RB+IgM- are 
underrepresented in 8/8 (P= 0.0078). (b) CD45RB-IgMhi B cells are overrepresented 
in the CMV gB+ population in 8/8 (P=0.0078), whereas a slight trend towards 
underrepresentation of the CD45RB-IgM+ B cells in the CMV gB+ population can be 
observed (P>0.05). (c) CMV gB+ B cells are not overrepresented in the T3/MZ 
precursor population CD27-CD45RB+ (P>0.05). P values were obtained using a 
Wilcoxon matched pairs signed rank test.   
 





























































































4.2.1.5 Do CMV gB binding B cells make antibodies that bind to CMV gB?  
When taken together the data presented in Figures 4.2-4.14 strongly suggests that B 
cells specific for CMV gB are binding the CMV gB protein via the B cell receptor. This 
binding can be blocked by using an anti-fab IgM/IgG antibody and the CMV gB binding 
B cells have a phenotype that is distinct from the overall phenotype of the B cell 
population. However, as the IgMhi phenotype of the antigen binding B cells was 
unexpected, it was decided that more experiments would be done to ascertain whether 
the antigen binding B cells are specific for just CMV gB or whether they would bind 
other proteins. This seemed particularly important since IgM is known for its broad 
specificity. A ‘cold inhibition’ assay was used where increasing concentrations of non-
biotinylated CMV gB was incubated with PBMCs at the same time as 0.35µg/ml of 
biotinylated CMV gB for 30 minutes before staining the cells as in Figures 4.2-4.14. To 
test whether the binding to the biotinylated CMV gB could be inhibited by a different 
protein, and therefore ascertain whether the BCR binding to CMV gB was antigen 
specific, increasing concentrations of VZV gE were also incubated with PBMCs at the 
same time as 0.35µg/ml of biotinylated CMV gB. VZV gE was chosen for this purpose 
because it is derived from a virus that elicits an antibody response and that most 
people will have encountered. Therefore, most people should have a memory B cell 
response towards it (Manikkavasagan et al., 2010).  
Figure 4.15 shows the results of this assay carried out on three different cones. The 
results indicate a complex picture: a high concentration of CMV gB was required to 
inhibit the binding of the biotinylated CMV gB to the B cells. The inhibition that was 
achieved was variable at different concentrations but the overall decrease in binding 
from an inhibiting concentration of 0 µg/ml to 14µg/ml was 37% in (a), 40% in (b) and 
50% in (c). Incubating with VZV gE did cause a decrease in B cell binding, but the 
overall picture when the binding at 0µg/ml and 14µg/ml is compared, a 4% decrease 
in binding was observed in (a), a 64% increase in binding was observed in (b) and a 
33% decrease in binding was observed in (c). Of note, the molecular weights of CMV 
gB and VZV gE are very similar so the level of inhibition is comparable between the 





Figure 4.15 Binding of biotinylated CMV gB to B cells can be partially inhibited by non-
biotinylated CMV gB 
PBMC from three leukocyte cones (a), (b) and (c), were co-incubated with 0.35µg/ml 
biotinylated CMV gB and increasing concentrations of non-biotinylated CMV gB or 
non-biotinylated VZV gE as a control. PBMC were incubated for 30 minutes on ice and 

























































































































Figure 4.15 suggests that the binding is only partially specific and it is likely that non-
specific binding of the B cell receptor to the CMV gB protein is blurring the picture. It 
therefore seemed appropriate to investigate whether the CMV gB binding B cells were 
able to produce CMV gB specific antibodies that could bind CMV gB in an ELISA, as 
this would provide further evidence to support the hypothesis that the CMV gB binding 
B cells that were being detected by flow cytometry were indeed CMV gB specific. An 
opportunity arose to collaborate with Professor Jo Spencer which enabled deep 
sequencing of the BCR from single CMV gB binding B cells that had been sorted by 
flow cytometry. PBMC from 3 leukocyte cones were incubated with CMV gB and 
stained as per the protocol detailed in section 2.5.3. PBMC were then passed through 
a FACS machine where single CMV gB binding, IgMhi B cells were collected in each 
well of a 96 well plate. Once sequenced, the BCR was cloned and expressed first in 
E.coli and then finally in a mammalian cell system where supernatants containing 
antibodies could be measured for their ability to bind the CMV gB in an ELISA. The 
staining and sorting of the CMV gB+ B cells was performed by me and downstream 
analysis was performed by Dr Verena Hehle from the Spencer laboratory. The gating 
strategy and examples of the cells pre and post sort are shown in Figure 2.4.  
Unfortunately, this series of experiments did not yield any positive results with regards 
to finding a clone that secreted antibodies that bound to an ELISA plate coated with 












 Applying the CMV gB binding assay to a renal transplant patient setting 
Once the method to detect and phenotype antigen binding B cells was optimised, it 
was used to look for HLA binding B cells in a subset of patients enrolled on the 
RituxiCAN C4 trial. 
Biotinylated and non-biotinylated versions of a Pure™ recombinant HLA A1:01 
monomer protein (from here on in referred to as HLA A1) were sourced from Pure™ 
Proteins LLC. A patient that was enrolled on to the RituxiCAN C4 trial and who had an 
HLA A1 mismatched kidney transplant with sufficient PBMC samples available was 
identified (G002). It was important that the Pure™ HLA protein could be used in the 
ELISpot assay to induce IFNγ production as well as in the flow cytometric assay to 
detect HLA binding B cells. Therefore, the non-biotinylated HLA A1 was titrated to 
determine the optimal concentration required for the ELISpot and the biotinylated pure 
HLA A1 was titrated to determine the optimal concentration for detecting HLA binding 
B cells.  
4.2.2.1 Pure HLA proteins can be used to elicit a B cell dependent IFNγ 
response 
CD8+ or CD8+ & CD19+ depleted PBMC from a patient with an A1 mismatched kidney 
transplant were stimulated with increasing concentrations of HLA A1 from 0.0-
0.5µg/ml, as per the ELISpot assay method described in section 2.3.5 of the materials 
and methods chapter. A reactive response was defined as ≥25 IFNγ spots per million 
CD4+ Lymphocytes and was observed in this patient. Figure 4.16 shows the number 
of IFNγ+ spots per million CD4+ lymphocytes before and after the background spots 
were subtracted (Fig. 4.16 (a) and (b) respectively). A titration effect could be seen 
where the spot count decreased as the concentration of HLA A1 increased. Figure 
4.16 also shows that IFNγ production was dependent on B cells. An example of an 
ELISpot well for both depletion conditions is shown in Figure 4.17.  
A leukocyte cone (Cone 23) was used as a control to investigate whether the HLA A1 
protein would stimulate IFNγ production in a non-transplant recipient. The sex and 
pregnancy history of this individual is unknown. However, as they are a registered 
blood donor, they will not have experienced a prior sensitisation event due to blood 
transfusion or transplantation. The ELISpot was set up at the same time as the patient 
and stimulated in exactly the same way. Figure 4.18 shows the number of IFNγ+ spots 
per million CD4+ lymphocytes before and after the background spots were subtracted 
(Fig 4.18 (a) and (b) respectively). This leukocyte cone did not produce IFNγ in 
response to the HLA A1 protein, regardless of whether B cells were present. In order 
162 
 
to show that this was an antigen specific response to the HLA A1, both patient (G002) 
and leukocyte cone (Cone 23) were stimulated in separate wells from the HLA A1 with 
CMV gB in the same assay. Figure 4.19 shows that a reactive response that was 
dependent on the presence of B cells was observed in Cone 23 but G002 did not react 
to the viral protein. Based on the results from these experiments and availability of 
reagents, it was decided that 0.05µg/ml, 0.1µg/ml and 0.2µg/ml would be used in each 
experiment if there was enough PBMCs, as it was hypothesised that there would be 
variability in the response to different concentrations of the Pure™ HLA proteins 


























Figure 4.16 Titrating the Pure™ HLA A1 to determine the optimal concentration to induce 
antigen specific IFNγ in the indirect ELISpot assay  
PBMC from a patient enrolled on the RituxiCAN trial who had an A1 mismatched 
transplant was used. The background IFNγ spot count shown in (a) as 0.0µg/ml HLA 
A1 was subtracted from each stimulation concentration. Spot counts per million CD4+ 
lymphocytes minus the background are shown in (b). A reactive response was defined 
as ≥25 IFNγ+ spots per million CD4+ lymphocytes. The mean of triplicate wells with 
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Figure 4.17 Example of ELISpot wells 
Un-stimulated (0.0µg/ml HLA A1) control and 0.1µg/ml HLA A1:01 conditions with CD8 
depleted PBMC and CD8 & CD19 depleted PBMC from a patient with an A1 
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Figure 4.18 Titrating Pure HLA A1 into the indirect ELISpot assay to assess reactivity 
status of a non-transplant individual 
PBMC from a Leukocyte cone were used. The background IFNγ spot count shown in 
(a) as 0.0µg/ml HLA A1 was subtracted from each stimulation concentration. (b) Spot 
counts per million CD4+ lymphocytes minus the background are shown in (b).  A 
reactive response was defined as ≥25 IFNγ+ spots per million CD4+ lymphocytes. The 
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Figure 4.19 Reactivity to viral antigen cocktail in patient G002 compared to Cone 23 
CD8+ or CD8+ & CD19+ depleted PBMC from Leukocyte Cone 23 and G002 were 
stimulated with CMV gB as a control for antigen processing and presentation for the 
HLA A1 ELISpot. Results shown are post subtraction of background IFNγ+ spots. A 





















































 HLA binding B cells can be detected in renal transplant recipients and 
leukocyte cones 
Next, the optimal concentration of HLA A1 required to detect HLA binding B cells was 
investigated. The biotinylated HLA A1 protein was titrated from 0.0µg/ml to 2.0µg/ml 
and used in the antigen binding B cell detection assay developed in section 4.2.1. HLA 
A1 binding B cells above background were detected in the same patient and time point 
used in Figure 4.16, G002. Figure 4.20 shows the flow cytometric dot plots from each 
concentration of biotinylated HLA A1 used. As with the CMV gB binding B cell 
experiments in section 4.2.1, the non-B lymphocyte gate was used as a guide to 
determine the concentration at which the non-specific binding started to increase. 
Figure 4.21 shows the frequency of HLA A1 binding B cells detected with each 
concentration of biotinylated HLA A1 used compared with the frequency of HLA binding 
non-B lymphocytes. The frequency of HLA A1 binding B cells detected when PBMC 
were incubated with all concentrations of biotinylated HLA A1 used was above the 
background events detected when 0.0µg/ml HLA A1 was used. However little 
difference was observed in the frequency detected between 0.125µg/ml and 0.5µg/ml. 
Background events in the non-B lymphocyte population were only detected once the 
concentration of biotinylated HLA A1 reached 1.0µg/ml. It was therefore decided that 
the biotinylated HLA proteins would be titrated in subsequent experiments in 0.1µg/ml 
increments from 0.1µg/ml to 0.4µg/ml. The concentration that yielded the highest 
frequency of HLA binding B cells was chosen for further analysis. If PBMC were limited, 
only 0.2µg/ml and 0.3µg/ml were used.  
As with the HLA A1 ELISpot, the same experiment was carried out using PBMC from 
a leukocyte cone to investigate whether HLA A1 B cells could be detected in an 
individual who had not received an A1 mismatched kidney transplant. Flow cytometric 
dot plots from this experiment are shown in Figure 4.22 and the frequency of HLA A1 
binding B cells and HLA A1 binding non-B lymphocytes is displayed in Figure 4.23. 
The data shows that HLA A1 binding B cells were only detected above ≥0.5µg/ml HLA 
A1 and a corresponding increase in non-specific binding to the non-B lymphocytes was 
also observed. Although the concentration of HLA A1 required to detect HLA binding 
B cells was higher in the leukocyte cone than in the patient, the results suggest that 
HLA specific B cells can be detected in non-transplant recipients. Due to this finding it 
was decided that the IFNγ ELISpot and the HLA binding B cell assay would be carried 




Figure 4.20 Dot plots to illustrate HLA A1 binding B cells in an HLA A1 mismatched 
kidney transplant patient.  
PBMC from a patient with an HLA A1 mismatched transplant were incubated with 
increasing concentrations of biotinylated HLA A1 from 0.0µg/ml – 2.0µg/ml at 4°C and 
stained with CD19 APC-efluor 780 and streptavidin PE. 















Figure 4.21 Detecting HLA A1 binding B cells in a renal transplant recipient 
PBMC from a patient with an HLA A1 mismatched transplant were incubated on ice 
with increasing concentrations of biotinylated HLA A1 from 0.0µg/ml – 2.0µg/ml and 
stained with CD19 APC-efluor 780 and streptavidin PE in order to determine what 
concentration is optimal for detecting HLA A1 binding B cells. HLA A1 binding B cells 
are detected above background at ≥0.125µg/ml. Graph highlights that non-specific 
binding begins to occur in the non-B lymphocyte population when a concentration of 









































Figure 4.22 Dot plots to illustrate HLA A1 binding B cells in a leukocyte cone  
PBMC from a leukocyte cone were incubated with increasing concentrations of 
biotinylated HLA A1 from 0.0µg/ml – 2.0µg/ml at 4°C and stained with CD19 APC-

















Figure 4.23 Detecting HLA binding B cells in a leukocyte cone  
PBMC from a leukocyte cone were incubated on ice with increasing concentrations of 
biotinylated HLA A1 from 0.0µg/ml – 2.0µg/ml and stained with CD19 APC-efluor-780 
and streptavidin PE. HLA A1 binding B cells are detected above background at 
≥0.5µg/ml. Non-specific binding occurs in the non-B lymphocyte population at 














































4.2.3.1 Background events can be reduced by using a rigorous gating strategy 
and streptavidin BV421 
Whilst conducting these experiments it became apparent that the level of background 
events detected could interfere with any phenotyping analysis as only a small 
frequency of HLA A1 binding B cells was detected above background. This problem 
was not an issue when detecting CMV gB binding B cells in section 4.2.1 as a much 
higher frequency of B cells bound the CMV gB protein. Fluorescent minus one (FMO) 
controls for each of the fluorochromes used in the B cell phenotyping panel in section 
4.2.1 were set up to discover what fluorochrome had the least amount of spectral 
overlap from the other fluorochromes in the panel. Figure 4.24 shows the frequency of 
events detected in the channel for each individual fluorochrome, when that 
fluorochrome was removed from the staining mixture. The graph indicates that after 
compensation has been applied, the PE channel has the most amount of spectral 
overlap from the other channels and that the Pacific Blue channel has the least amount 
of spectral overlap. The stain panel was therefore altered to a) change the 
fluorochrome conjugated to streptavidin from PE to BV421 (a very bright fluorochrome 
that is detected in the pacific blue channel) and b) to incorporate CD45RB PE into the 
same panel and remove IgG V450.     
In addition, the gating strategy used in section 4.2.1 was changed and a two-step 
gating strategy shown in Figure 4.25 was adopted in order to eliminate as many dead 
B cells as possible. This reduced the number of background events that were detected 
when 0.0µg/ml HLA A1 was incubated with the PBMC. As the presence of background 
events could not be completely eliminated, a cut off was used for deciding whether the 
phenotype of the HLA binding B cells could be assessed: both the number and 
frequency of events in the HLA binding B cell gate had to be at least double that 














Figure 4.24 Using FMO controls to determine spectral overlap post compensation for 
each fluorochrome used in phenotyping the B cells 
CD19+ cells were gated on and subsequent gates were drawn for each fluorochrome 
where the negative population ended. APC-efluor780 was used as the fluorochrome 
for CD19 detection so an FMO control was not used for this fluorochrome. X-axis labels 
represent the fluorochrome that was omitted from the antibody stain panel. Y-axis 
details the number of events that were detected in that channel when the fluorochrome 


































































Figure 4.25 Example of gating strategy for detecting HLA binding B cells 
Live B cells were first gated on using CD19 and a live-dead dye. The FSC-SSC profile 
was then used to remove any dead cells or debris that had not been stained with the 









4.2.3.2 HLA A1 binding B cells are predominantly IgM+ memory 
Once the assay had been optimised for detection of HLA A1 binding B cells in the 
RituxiCAN patients, patients enrolled on the trial who had an A1 mismatched transplant 
were identified and flow cytometry staining was carried out to detect and phenotype 
HLA A1 binding B cells in these patients. 11 PBMC samples from 4 patients with HLA 
A1 mismatched transplants were tested for the presence of HLA A1 binding B cells. 
HLA A1 binding B cells were detected in 4/11 samples, with a median frequency of 
0.038% (range 0.02%-0.23%).  
3/4 samples that had detectable HLA A1 binding B cells could go on to have their 
phenotype analysed because on average, the frequency of HLA A1 binding B cells 
was 3.3x that detected in the no antigen control (median 3.3x above background, range 
2.85x-5.6x). All of these samples came from the same patient (G013).  
An example of the gating strategy used is shown in Figure 4.26. This is the same 
patient sample that is shown in Figure 4.25 as the frequency of HLA A1 binding B cells 
is 5.6x that detected in the no antigen control. The dot plots in Figure 4.26 clearly show 
that the majority of HLA A1 binding B cells are non-transitional and are IgM+. In 3/3 
samples the dominant HLA A1 binding B cell population was IgM+ memory B cells 
defined as either CD27+IgMhi (median 50.0%, range 45.7%-60%) or CD45RB+IgMhi 
(median 74.3%, range 65.7%-78.6%). In all samples, this population was 
overrepresented in these two IgM+ memory B cell gates in the HLA A1 binding B cell 
gate compared to the overall B cell population. The median frequency of CD27+IgMhi 
and CD45RB+IgMhi+ B cells was 6.2% (range 5.07%-6.62%) and 11.6% (range 





Figure 4.26 Example dot plots of the phenotype of HLA A1 binding B cells 
Gates were drawn on the whole B cell population and then applied to the HLA A1 
binding population. CD19+ cells were first divided into transitional and non-transitional 
B cells according to CD24 and CD38 expression. All subsequent gates were only 
applied to the non-transitional population as indicated by the black arrows. Non-
transitional B cells were then divided into subsets based on CD27 and IgM expression, 
or CD45RB and IgM expression. 
All B cells HLA A1 B cells
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4.2.3.3 HLA A2 and HLA DR4 binding B cells are predominantly IgM+ and either 
predominantly IgM+ memory, or IgM+ naive 
Due to the promising findings using an A1 protein, Pure™ proteins HLA A*02:01 and 
HLA DR*04:02 (from here on in referred to as HLA A2 and HLA DR4 respectively), 
were obtained as a gift from Prof. Robert Higgins and Dr. Sunil Daga (Warwick 
University, UK). Patients enrolled onto the RituxiCAN C4 trial that had either HLA A2 
or HLA DR4 mismatched transplants were identified. HLA A2 and HLA DR4 binding B 
cells were detected and phenotyped using the protocol that had been optimised for 
detecting the HLA A1 binding B cells. As with the HLA A1, the Pure HLA A2 and DR4 
proteins were titrated from 0.1µg/ml-0.4µg/ml in each experiment in order to increase 
the chance of detecting HLA binding B cells. If PBMC were limited, only 0.2µg/ml and 
0.3µg/ml were used. Figure 4.27 (a) shows an example of HLA A2 binding B cells that 
were detected using 0.3µg/ml biotinylated HLA A2 in a patient with an HLA A2 
mismatched transplant. Figure 4.27 (b) shows an example of HLA DR4 binding B cells 





















Figure 4.27 Example dot plots of A2 and DR4 binding B cells  
Background events detected when PBMC were incubated with 0.0µg/ml HLA protein 
are shown alongside events detected when PBMC were incubated with either 0.3µg/ml 







0.0µg/ml HLA A2 0.3µg/ml HLA A2        





HLA A2 binding B cells were detected in 13/26 samples from 8 patients, with a median 
frequency of 0.059% (range 0.011%-0.084%). 8/13 samples, from 4 patients, had a 
frequency of HLA A2 binding B cells that were more than double that found in the no 
antigen control gate. 3 samples had no events in the no antigen control and for the 5 
samples that did, the frequency of HLA A2 binding B cells was on average 4.9x the 
background events (median 4.9x, range 2.69x-9.1x) and could be analysed for their 
phenotype. Figure 4.28 shows an example of the phenotype of the HLA A2 binding B 
cells. As with the HLA A1 binding B cells, the majority of the HLA A2 binding B cells 
were non transitional and IgM+. In 6/8 of the samples, the dominant phenotype of HLA 
A2 binding B cells was CD27+IgMhi (median 60.6%, range 45.5% – 71.4%) or 
CD45RB+IgMhi (median 65.1%, range 45.5%-76.2%). In 1/8 samples the largest 
population within the HLA A2 binding B cells was CD27-IgM+ and CD45RB-IgM+ (both 
66.7%), and in the remaining sample, the HLA binding B cells were distributed 








Figure 4.28 Example dot plots to show phenotype of HLA A2 binding B cells 
Gates were drawn on the whole B cell population and then applied to the HLA A2 
binding population. CD19+ cells were first divided into transitional and non-transitional 
B cells according to CD24 and CD38 expression. All subsequent gates were only 
applied to the non-transitional population as indicated by the black arrows. Non-
transitional B cells were then divided into subsets based on CD27 and IgM expression, 
or CD45RB and IgM expression. 
All B cells HLA A2 B cells
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The exact same phenotyping panel was used when staining the HLA A2 binding B 
cells as with the A1 binding B cells. However, at the point when the HLA DR4 binding 
cells were being stained, the phenotyping panel was changed to incorporate antibodies 
for detecting CD86, BAFFr and HLA DR (rationale for this is detailed in chapter 5). As 
a compromise, CD24, CD38 and CD27 were removed from the panel and CD10 was 
added as a way of distinguishing transitional cells from non-transitional cells. Since in 
the majority of samples a higher proportion of HLA A1 and HLA A2 binding B cells 
expressed CD45RB than CD27, CD45RB was kept in the panel as the marker used 
for distinguishing memory from naïve. HLA DR4 binding B cells were detected in 4/11 
samples from 3 patients with a median frequency of 0.12% (range 0.072%–0.28%). 
3/4 samples, from 2 patients, had a frequency of HLA DR4 binding B cells that was 
more than double that of the no antigen control (median 3.7x background, range 2.5x-
4.8x) and could be analysed for their phenotype. As with the HLA A1 and A2 binding 
B cells, the majority of HLA DR4 binding B cells were non transitional. Within the non-
transitional gate, the dominant phenotype of HLA DR4+ binding B cells was naïve, 
CD45RB-IgM+ (median 50%, range 47.4% - 57.6%), with the remaining cells being 



















Figure 4.29 Example dot plot to show phenotype of HLA DR4 binding B cells 
Gates were drawn on the whole B cell population and then applied to the HLA DR4 
binding population. CD19+ cells were first divided into transitional and non-transitional 
B cells according to CD10 expression. All subsequent gates were only applied to the 
non-transitional population as indicated by the black arrows. Non-transitional B cells 






All B cells HLA DR4 B cells
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In total, 48 PBMC samples from 15 patients were analysed for the presence of HLA 
binding B cells and IFNγ production in response to the Pure HLA proteins. This data is 
summarised in Table 4.1. HLA binding B cells were detected in 21/48 samples with a 
median frequency of 0.070% (range 0.011%-0.28%). It was possible to analyse the 
phenotype of 14 of these samples. Figure 4.30 shows the phenotype of the HLA 
binding B cells compared to the overall B cell phenotype in all of the samples tested. 
B cells that have bound to the different HLA antigens used have been assigned a 
different colour on the graphs. It is clear that the phenotype of HLA binding B cells is 
not the same in all samples, but there are some general trends that can be observed. 
For example, when compared with the overall B cell population, CD45RB+IgMhi B cells 
are overrepresented in the HLA binding B cell population in 8/14 samples (57%) (Fig 
4.30 (a), P=0.0494) and underrepresented in the CD45RB+IgM- population in 10/14 
samples (71%) (Fig 4.30 (b), P=0.0166). CD45RB-IgMhi HLA binding B cells are 
underrepresented in 9/14 samples (64%) but this difference did not reach statistical 
significance (Fig 4.30 (c)). In the CD45RB-IgM+ HLA binding population, 6/14 samples 
(43%) are overrepresented compared to the overall B cell population, 7/14 samples 
(50%) are underrepresented and 1/14 samples (7%) hasn’t changed (Fig 4.30 (d)). 
Similarly, in the CD45RB-IgM- HLA binding B cell population, 6/14 samples (42%) are 
overrepresented compared to the overall B cell population and 8/14 samples (57%) 
are underrepresented (Fig 5.15 (e)). It was possible to compare the frequency of the 
MZ/IgM+ memory pre-cursor population (CD27-CD45RB+) in the HLA A1 and HLA A2 
mismatched samples. The Frequency of this population was overrepresented in 7/11 
(64%) samples but this difference was not found to be significant (P>0.05). 
In addition to the above comparisons, the phenotype of the HLA binding B cell 
population was compared to the phenotype of the events detected in the no antigen 
background control to confirm that the data from the cells that were incubated with the 
antigen did not mirror that in the no antigen control. This data can be found in Table 








Figure 4.30 Phenotype of HLA binding B cells compared to the overall B cell population.  
(a) CD45RB+IgMhi are overrepresented in the HLA binding B cell population in 8/14 
samples (P=0.0494). (b)  Class switched CD45RB+IgM- are underrepresented in 
10/14 samples (P=0.0166). (c)-(f) No significant differences were found between the 
HLA binding B cell population and the overall B cell population in the T3 naïve follicular 
B cell precursor subset (c), IgM+naïve subset (d), CD45RB-IgM- subset (e) or T3 
MZ/IgM+ memory B cell precursor subset (f) (P>0.05). P values obtained using a 

















































































































































4.2.3.4 HLA binding B cells are not always associated with a history of 
circulating DSA.  
Table 4.1 includes details of whether each patient has ever had evidence of circulating 
DSA to the mismatched antigen being tested in the HLA binding B cell assay. As DSA 
data was not available for each time point tested in the HLA binding B cell assay, it 
was only possible to group the patients based on whether they had DSA detectable at 
some point post-transplant. Table 4.1 also contains details of the IFNγ response that 
was observed in each sample. The data shows that in 5/15 patients, HLA binding B 
cells could be detected in patients who do not have a history of detectable DSA. 5/15 
patients have both detectable HLA binding B cells and evidence of DSA and 2/15 
patients have DSA but no detectable HLA binding B cells. Finally, 3/15 patients have 
no evidence of either HLA binding B cells or DSA. In addition, G014 has evidence of 
DSA specific for HLA A1 and HLA A2 but only has B cells that bound HLA A2 and not 
HLA A1.  
2/15 patients have evidence of DSA and donor specific IFNγ production in the ELISpot. 
4/15 patients have no evidence of DSA but did produce donor specific IFNγ at one or 
more time points when tested in the ELISpot.  
7/48 samples have HLA binding B cells and evidence of donor specific reactivity in the 
IFNγ ELISpot. 5/48 samples have no detectable HLA binding B cells but evidence of 
donor specific reactivity in the IFNγ ELISpot. 
The data in Table 4.1 indicates that within the limits of the three readouts presented 
here (DSA, HLA binding B cells and ELISpot reactivity) renal transplant patients with 
CAMR are, immunologically speaking, a highly heterogenous group. No patient has 
evidence of all three readouts at the same time point tested but many have at least 

























PATIENT ID Timepoint Mismatch
Mismatch 
DSA?
% HLA+ B 





W006 05/02/2009 A1 Y 0 NR Bnon 0 0
W006 09/11/2009 A1 0 NR Bnon 0 0
W006 11/04/2011 A1 0 NR Bnon 0 0
G002 04/02/2009 A1 Y 0.23 R Bdep 121 0
G002 02/09/2009 A1 0 R Bdep 39 0
G013  14/11/2011 A1 N 0.037 R Bdep 65 0
G013 21/02/2013 A1 0.039 NR Breg 0 82
G013 09/01/2014 A1 0.02 R Bdep 110 0
G014 17/05/2012 A1 Y 0 NR Bnon 0 0
G014 12/11/2012 A1 0 NR Bnon 0 0
G014 12/12/2013 A1 0 NR Bnon 0 0
W003 11/12/2008 A2 N 0.016 R Bdep 55 11
W003 25/06/2009 A2 0.018 R Bnon 67 66
W003 21/06/2010 A2 0.011 NR Bnon 12 4
W004 25/06/2009 A2 N 0 R Bdep 94 3
W004 07/12/2009 A2 0 R Breg 45 56
W004 21/06/2010 A2 0 NR Bnon 12 0
W008 10/07/2008 A2 N 0.084 NR Bnon 0 0
W008 12/01/2009 A2 0.059 R Bdep 30 0
W008 02/07/2009 A2 0.073 NR Bnon 12 0
W008 24/09/2009 A2 0.063 NR Bnon 2 0
W008 21/06/2010 A2 0.041 NR Bnon 1 12
W008 10/01/2011 A2 0.07 R Bdep 32 12
W010 07/12/2009 A2 N 0 NR Bnon 0 0
W010 08/03/2010 A2 0 NR Bnon 0 0
W011 30/11/2009 A2 Y 0.057 NR Bnon 0 3
W011 08/11/2010 A2 0.079 NR Bnon 0 0
W011 21/11/2011 A2 0 NR Bnon 0 0
G007 09/05/2011 A2 Y 0.058 NR Bnon 3 0
G007 09/12/2011 A2 0 R Breg 100 132
G007 15/10/2012 A2 0 R Bdep 794 258
G012 14/06/2012 A2 Y 0 NR Bnon 0 0
G012 12/11/2012 A2 0 NR Bnon 0 0
G012 03/04/2013 A2 0 NR Bnon 0 0
G014 17/05/2012 A2 Y 0 NR Bnon 0 6
G014 12/11/2012 A2 0 NR Bnon 0 16
G014 12/12/2013 A2 0.07 NR Bnon 0 0
W009 16/10/2009 DR4 Y 0.16 NR Bnon 0 0
W009 07/02/2011 DR4 0.28 NR Bnon 0 0
G019 05/07/2012 DR4 N 0 NR Bnon 13 21
G019 17/01/2013 DR4 0.086 NR Bnon 0 6
G019 18/07/2013 DR4 0 NR Bnon 0 0
G011 07/10/2010 DR4 N 0 NR Bnon 0 0
G011 24/03/2011 DR4 0 NR Bnon 0 0
G011 29/06/2011 DR4 0.072 ELISpot not done
W013 08/03/2010 DR4 N 0 NR Bnon 0 0
W013 12/01/2009 DR4 0 NR Bnon 23 0
W013 14/05/2009 DR4 0 NR Bnon 0 0




Table 4.1 Summary of each sample tested for the presence of HLA binding B cells, 
presence of DSA and the response to Pure™ HLA proteins in the IFNγ ELISpot before 
and after CD19+ cell depletion.  
Samples were grouped according to whether the frequency of HLA binding B cells was 
at least double that detected in the no antigen gate. White rows represent samples 
where no HLA binding B cells were detected, blue rows represent samples where HLA 
binding B cells were detected but the frequency was less than double that detected in 
the no antigen control. Pink rows represent samples where the frequency of HLA 
binding B cells was more than double that detected in the no antigen control. Patients 
were assigned Y if they had ever had evidence of circulating DSA or N if they had not.  
Each sample was assigned a pattern of reactivity in the IFNγ ELISpot assay. R = 
reactive. NR= non-reactive. Bdep = B dependent reactivity, Breg = B regulated 
reactivity Bnon = CD19+ depletion had no effect on IFNγ production. Patterns of 



















4.2.3.5 A higher ratio of IgM+memory to IgM+naïve HLA binding B cells 
associates with IFNγ production in response to the pure HLA proteins.  
As the phenotype of HLA binding B cells is not homogeneous, it was investigated 
whether any associations could be made between the skewed phenotypes in the 
different samples and the pattern of reactivity observed in the IFNγ ELISpot in 
response to the Pure™ HLA proteins. To be able to include all events in the HLA 
binding B cell gate, non-transitional B cells were grouped according to their expression 
of either CD27 or CD45RB and called either memory (CD27+/CD45RB+) or Naïve 
(CD27-/CD45RB-). The ratio of these populations was calculated to investigate 
whether the balance of memory to naïve B cells impacts the outcome in the IFNγ 
ELISpot (Table 4.2). The following observations were made:  
1. 5/13 samples responded. All of these samples had a ratio of memory to naïve 
>1 when CD45RB is used as a memory marker. Therefore the dominant 
phenotype of their HLA binding B cells is memory. In 4/5 samples, this ratio is 
higher in the HLA binding B cells than the global B cell population.  
 
2. 8/13 samples did not respond. 4/8 of these samples have a ratio of 
memory:naïve cells of <1 and 4/8 samples have a ratio of memory:naïve of >1. 
There is therefore no distinct pattern that defines a non-reactive sample when 
this analysis is used. 
 
3. As the pattern of reactivity changes over time, the ratio of memory:naïve B cells 
in the HLA binding B cell population also changes. It was possible to observe 
in 3 patients how the change in ELISpot pattern of reactivity relates to the 
phenotype of the HLA binding B cells over time. Interestingly, at the second 
time point tested in G013, the pattern of reactivity shifts from B dependent to B 
regulated. At the same time the ratio of memory:naïve HLA binding B cells is 
reduced when memory B cells are defined using CD45RB, and becomes <1 
when CD27 as the memory marker. The ratio of memory: naïve is <1 in the 
global B cell population at all time points. It is possible that in this patient, there 
was a temporary shift in the balance between the memory and naïve HLA 
binding B cells that lead to an overall regulated response to the HLA protein at 
the second time point. In W008, the pattern of reactivity in response to the HLA 
A2 Pure protein also changes overtime, however it is less clear how the ratio 
of memory:naïve HLA A2 binding B cells relates to this. When CD45RB is used 
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as the memory marker, the ratio of memory:naïve does not distinguish the 
reactive, B dependent samples from the other samples as 2 of the non-reactive 
samples have a higher ratio than time point 12/01/2009 which was reactive. 
However, when CD27 is used as a memory marker, the ratio of memory:naïve 
is highest in both of the reactive samples compared to the other time points. 
The same thing cannot be said for the global B cell population.  Finally, in 
W009, both samples are non-reactive to the Pure HLA DR4 protein, and at both 



























Table 4.2 Summary of all samples analysed for their HLA phenotype detailing their 
pattern of reactivity I the IFNγ ELISpot and the ratio of memory:naïve B cells, in the HLA 
binding B cell population and the overall B cell population  
 
















CD45RB+:CD45RB-                          
(% of HLA+ B cells)
CD45RB+:CD45RB-
(% of all B cells)
CD27+: CD27-       
(% of HLA+ B cells)
CD27+: CD27-     
(% of all B cells)
G013  14/11/2011 A1 R Bdep 4.00 0.26 2.18 0.18
G013 21/02/2013 A1 R Breg 2.50 0.24 0.67 0.15
G013 09/01/2014 A1 R Bdep 3.67 0.29 1.00 0.18
W008 10/07/2008 A2 NR Bnon 2.00 2.82 2.00 3.82
W008 12/01/2009 A2 R Bdep 1.99 2.99 5.50 4.37
W008 02/07/2009 A2 NR Bnon 1.20 3.07 3.40 5.14
W008 24/09/2009 A2 NR Bnon 4.49 3.28 4.50 4.15
W008 10/01/2011 A2 R Bdep 20.00 3.68 9.50 5.23
W011 30/11/2009 A2 NR Bnon 0.20 0.22 1.00 0.28
G007 09/05/2011 A2 NR Bnon 2.00 2.39 2.00 1.20
G014 12/12/2013 A2 NR Bnon 0.50 0.56 0.00 0.12
W009 16/10/2009 DR4 NR Bnon 0.18 0.32
W009 07/02/2011 DR4 NR Bnon 0.73 0.43
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There are hints in the data above to suggest that the balance of memory to naïve B 
cells may impact the IFNγ response to Pure™ HLA proteins. As the dominant 
phenotype of the HLA binding B cells was often found to be either IgM+ memory or 
IgM+ naïve, the ratio of these two subsets was calculated by defining the IgM+ memory 
B cells as either CD27+IgMhi or CD45RB+IgMhi, and the IgM+ naïve cells as CD27-
IgM+ or CD45RB-IgM+ (Table 4.3). A similar pattern is observed for G013 where a 
shift from B dependent to B regulated pattern of reactivity is associated with a reduction 
in the ratio of IgM+memory:IgM+naïve. Again, the data shows that when CD45RB is 
used as a memory marker the data from W008 does not fit a clear pattern. However, 
when CD27 is used to define IgM+ memory cells, the difference in the ratio of 
IgM+memory:IgM+naïve B cells between the reactive B dependent samples and the 
non-reactive samples is much greater. The same distinction is not observed in the 
overall B cell population. This suggests that in this patient, there may be a higher 
proportion of T3 or marginal zone precursors that are detected in the CD45RB+IgMhi 
population which makes it harder to resolve differences in the ratio of memory:naïve B 
cells. When using CD27 as the memory marker, these cells are omitted from the 
analysis as they fall into the CD27-IgMhi gate.  CD27 was not used in the stain panel 
for the DR4 binding B cells, however, when using CD45RB as the memory marker, 
W009 has a ratio of IgM+memory:IgM+naïve B cells of <1 which is consistent with the 



















Table 4.3 Summary of all samples analysed for their HLA phenotype detailing their 
pattern of reactivity in the IFNγ ELISpot to pure HLA proteins and the ratio of 
IgM+memory to IgM+naïve cells in the HLA binding B cell population and the overall B 
cell population.  
 
IgM+ memory cells were defined as CD45RB/CD27+IgMhi, and IgM+ naïve B cells 















 CD45RB+IgMhi  
:CD45RB-IgM+       
(% of HLA+ B cells)
 CD45RB+IgMhi:  
CD45RB-IgM+      
(% of all B cells)
CD27+IgMhi: 
CD27-IgM+           
(% of HLA+ B cells)
CD27+IgMhi:   
CD27-IgM+           
(% of all B cells)
G013  14/11/2011 A1 R Bdep 3.72 0.15 1.91 0.08
G013 21/02/2013 A1 R Breg 2.55 0.13 0.70 0.06
G013 09/01/2014 A1 R Bdep 5.50 0.16 1.17 0.08
W008 10/07/2008 A2 NR Bnon 2.00 2.14 2.00 2.67
W008 12/01/2009 A2 R Bdep 2.36 2.22 7.00 2.97
W008 02/07/2009 A2 NR Bnon 1.25 2.33 2.00 3.51
W008 24/09/2009 A2 NR Bnon 3.49 2.75 3.00 3.06
W008 10/01/2011 A2 R Bdep 16.01 3.43 7.50 4.26
W011 30/11/2009 A2 NR Bnon 0.00 0.07 0.50 0.06
G007 09/05/2011 A2 NR Bnon 2.00 1.02 2.00 0.56
G014 12/12/2013 A2 NR Bnon 0.50 0.40 0.00 0.03
W009 16/10/2009 DR4 NR Bnon 0.08 0.21
W009 07/02/2011 DR4 NR Bnon 0.33 0.30
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4.2.3.6 Can HLA binding B cells be detected in individuals who do not have a 
mismatched kidney transplant to the HLA antigen in question? 
The cross-reactivity of antibodies to non-DSA that has been widely reported make it 
very difficult to truly control the experiments described in this chapter (Süsal, 2015, 
Lachmann et al., 2009). Nevertheless, it was decided that where sufficient PBMC were 
available, the patients with A2 or DR4 mismatched kidneys would also be analysed for 
the presence of HLA A1 specific B cells and whether they produced IFNγ in response 
to the Pure™ A1 protein. In addition, PBMC from leukocyte cones were also tested. 
A1 binding B cells could be detected in 2/9 patient samples (0.106% and 0.049%) and 
in 4/8 leukocyte cones with a median frequency of 0.14% (range 0.114%-0.303%). The 
frequency of HLA binding B cells from all samples tested is shown in Figure 4.31. The 
X axis label relates to the biotinylated HLA antigen that was used to detect the HLA 
binding B cells. Samples are grouped according to whether they are derived from a 
patient who has a kidney mismatched to that antigen, a patient who does not have a 
kidney mismatched to that antigen, or a leukocyte cone. Surprisingly, the group that 
has the highest detectable frequency of HLA binding B cells is the leukocyte cones, 
whom in theory should not be sensitised to HLA A1. However this difference was not 
found to be significant when the frequency of HLA A1 binding B cells detected in the 
patients with the A1 mismatched transplants was compared with the leukocyte cones 
using a Mann Whitney U test (P>0.05). The difference in frequency of HLA A1 binding 
B cells between the patients who had an HLA A1 mismatched transplant and those 
















Figure 4.31 Frequency of HLA binding B cells in all sample groups tested.  
Labels on X axis show the biotinylated HLA antigen that the PBMC were incubated with. Black 
circles are samples from patients who have a mismatched kidney to that antigen (n=4 for HLA 
A1, n=13 for HLA A2 and n=4 for HLA DR4).  Black triangles are patients who do not have a 
mismatched kidney to HLA A1 (n=2). Black squares are samples from leukocyte cones who 
theoretically should not be sensitised to HLA A1. Black lines on graph represent the median. 

























































4.2.3.7 Do Pure HLA proteins elicit an IFNγ response in individuals who do not 
have an allograft that contains a mismatch for that Pure™ protein? 
At the same time as staining the B cells from the leukocyte cones for HLA A1 binding 
B cells, the indirect IFNγ ELISpot assay was carried out using the same non-
biotinylated Pure™ HLA A1 protein to see if similar results were observed in leukocyte 
cones as in the patients. In addition to this, if there were enough cells available, 
patients who had an A2 or DR4 mismatched kidney transplant were also stimulated 
with the Pure™ HLA A1 protein in the IFNγ ELISpot. The phenotype of the HLA A1 
binding B cells was then correlated with the pattern of reactivity in the IFNγ ELISpot as 
in section 4.2.3.5.  
HLA A1 binding B cells were detected in 2/9 patient samples tested and phenotyping 
was only possible in one of them as the other sample did not reach the cut-off 
previously defined where the frequency of HLA binding B cells must be at least double 
that detected in the no antigen control (Table 4.4). In the sample where the phenotype 
was analysed, 66.7% of the HLA binding B cells were either CD27+IgM- or 
CD45RB+IgM- and the remaining 33.3% were either CD27+IgMhi or CD45RB+IgMhi. 
This sample therefore did not contain any naïve HLA binding B cells and consistent 
with the results in section 4.2.3.5, this sample displayed a reactive, B dependent 
response to the HLA A1 protein in the IFNγ ELISpot. Two other patient samples 
produced IFNγ in response to the HLA A1 protein: one was B dependent and the other 
















Table 4.4 Patients with A2 or DR4 mismatched kidney transplants tested for reactivity to 
HLA A1 Pure™ protein and presence of A1 binding B cells.  
 
White rows represent samples where no HLA binding B cells were detected, blue rows 
represent samples where HLA binding B cells were detected but the frequency was 
less than double that detected in the no antigen control. Pink rows represent samples 
where the frequency of HLA binding B cells was more than double that detected in the 
















CD8&     
CD19-
W004 07/12/2009 A2 0.106 R Bdep 43 0
W004 21/06/2010 A2 0 R Breg 0 35
W010 07/12/2009 A2 0 R Bdep 41 3
W011 21/11/2011 A2 0 NR Bnon 0 0
W011 30/11/2009 A2 0 NR Bnon 0 0
G012 12/11/2012 A2 0 NR Bnon 0 0
G012 14/06/2012 A2 0 NR Bnon 0 3
W013 12/01/2009 DR4 0.049 NR Bnon 0 0





HLA binding B cells were detected in 4/8 of the leukocyte cones tested (Table 4.5). 
The majority of HLA A1 binding B cells in all leukocyte cones were non-transitional and 
of a naïve CD45RB-IgM+ or CD27-IgM+ phenotype (Table 4.6). The ratio of 
memory:naïve populations and IgM+memory:IgM+naïve was <1 for all samples. The 
distribution of each subset in the HLA A1 binding cell gate was similar to that of the 
overall B cell population in all Leukocyte cones. 1/4 of these samples produced IFNγ 
in response to the Pure HLA A1 in a B regulated manner. Two other samples also 
displayed a reactive B regulated response to the HLA A1 protein but HLA binding B 
cells could not be detected in these samples. This data is consistent with that of the 
patients where if the dominant HLA binding B cell population is naïve, a non-reactive 
response or reactive B regulated response is observed in the IFNγ ELISpot. However, 
the phenotype of HLA binding B cells in many of the patient samples is distinct from 
the overall B cell population. This was not observed in the Leukocyte cones. It is 
therefore possible that the HLA binding B cells detected in the leukocyte cones may 
not be clonally expanded antigen specific B cells but just non-specific naïve B cells 






















Table 4.5 Leukocyte cones tested for reactivity to A1 Pure protein and the presence of 
A1 binding B cells 
 
White rows represent samples where no HLA binding B cells were detected, Pink rows 
represent samples where the frequency of HLA binding B cells was more than double 
















CD8&     
CD19-
Cone 23 0.156 R Breg 26 126
Cone 26 0.303 NR Bnon 0 0
Cone 27 0 R Breg 0 32
Cone 28 0 NR Bnon 0 0
Cone 29 0 R Breg 0 41
Cone 34 0.118 NR Bnon 0 0
Cone 35 0.114 NR Bnon 0 0










Table 4.6 Phenotype of HLA A1 binding B cells compared to the overall B cell population 
in leukocyte cones.  
 
(a) Leukocyte cones that were stained with CD45RB. (b) One Leukocyte cone that was 

















 CD45RB+:CD45RB-       
(% of HLA+ B cells)
 CD45RB+:CD45RB- 
(% of all B cells)
 CD45RB+IgMhi  
:CD45RB-IgM+       
(% of HLA+ B cells)
 CD45RB+IgMhi: 
CD45RB-IgM+      
(% of all B cells)
Cone 23 R Breg 0.25 0.27 0.23 0.21
Cone 34 NR Bnon 0.1 0.14 0 0.04






CD27+: CD27-        
(% of HLA+ B cells)
CD27+: CD27-          
(% of all B cells)
CD27+IgMhi:           
CD27-IgM+                 
(% of HLA+ B cells)
CD27+IgMhi:          
CD27-IgM+                    
(% of all B cells)
Cone 26 NR Bnon 0.21 0.19 0.2 0.14
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 Key points in chapter 4 
 
1. CMV gB B cells can be detected using biotinylated CMV gB protein. 
 
2. CMV gB binding B cells are predominantly IgMhi and are a mixed population 
of IgM+ memory B cells and Transitional 3 B cells that will most likely 
differentiate into naïve follicular B cells. 
 
3. HLA A1, HLA A2 and HLA DR4 binding B cells can be detected in renal 
transplant recipients using biotinylated Pure™ HLA proteins.   
 
4. The majority of HLA binding B cells have an IgM+ phenotype. Most patient 
samples have a dominant phenotype of HLA binding B cells that is either 
CD27/CD45RB+IgMhi memory or CD27/CD45RB-IgM+ naïve. 
 
5. Pure™ HLA proteins can be used to induce IFNγ production that is dependent 
on the presence of B cells in the indirect IFNγ ELISpot assay. A higher ratio of 
IgM+ memory to IgM+ naïve HLA binding B cells is associated with a B 
dependent IFNγ response to the Pure™ proteins when CD27 is used as the 
marker to define memory.  
 
6. HLA A1 binding B cells can be detected in the peripheral blood of individuals 
who have not received a kidney transplant (Leukocyte cones). The majority of 
these B cells are of a naïve, IgM+ phenotype and are not distinct from the 
overall B cell population.  
 
7. A subset of Leukocyte cones tested produced IFNγ in response to the Pure™ 
HLA A1 protein. IFNγ production showed a B regulated pattern of reactivity in 





In chapter 3, evidence of B cell dependent reactivity towards donor membrane proteins 
was found in CAMR patients recruited on to the RituxiCAN C4 trial.  No differences 
were found in the global B cell phenotype of these patient’s at enrolment compared to 
those that did not have a B cell dependent response. At later time points in the trial, 
evidence of B regulated reactivity towards the donor membrane proteins was also 
found in some samples. This lead to the hypothesis that, if no differences could be 
detected in the global phenotype of the B cells, then perhaps the differences lay within 
the antigen specific populations, in this case the donor HLA specific B cell population. 
An assay to detect antigen specific B cells that was compatible with the indirect IFNγ 
ELISpot was therefore developed to address this hypothesis. A model system using 
CMV gB was used to optimise the assay in order to preserve the valuable patient 
samples. This assay was then translated to a patient setting using Pure HLA proteins.  
 Antigen binding B cells can be detected flow cytometrically using 
biotinylated recombinant proteins 
After a review of the literature it was decided that using biotinylated CMV gB combined 
with streptavidin PE would be the best way of detecting CMV binding B cells (Doucett 
et al., 2005, Amanna and Slifka, 2006). Several experiments were carried out to 
determine that the antigen was binding the B cells via the BCR as opposed to non-
specifically binding other molecules on the surface of the B cells, or even via CMV 
specific antibodies in the human AB serum that was used. Whilst confident that these 
results demonstrated that the antigen was binding the BCR, it was not possible to show 
that this binding was completely specific for CMV gB. A cold inhibition assay that was 
designed to demonstrate that the binding was specific for CMV gB was inconclusive 
as incubation with increasing concentrations of a different non-biotinylated viral 
antigen, VZV gE, had a similar effect on the level of binding of the biotinylated CMV 
gB to the non-biotinylated CMV gB. Some studies that have flow cytometrically 
detected antigen specific B cells have shown that those B cells can also be induced to 
make antibodies that bind to the same antigen in an ELISA. This was therefore 
investigated further by single cell sorting the CMV gB binding B cells, sequencing and 
cloning their BCRs and transfecting 293T cells so they would secrete antibodies that 
could be tested in a CMV gB ELISA for their specificity. This set of experiments did not 
yield any positive results, so whether the BCRs that are binding the CMV gB are 
exclusively specific for just CMV gB remains unclear and limits the interpretations that 
can be made from the data.  
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 CMV binding B cells are predominantly IgM+ and overrepresented in the 
IgMhi populations when compared to the global B cell phenotype 
The frequency of CMV gB binding B cells detected ranged from 1.04% - 3.37% 
(median 1.83%) in the 15 leukocyte cones tested. This figure is higher than that 
reported in Potzsch et al. where a directly fluorescently labelled CMV gB was used to 
detect 0.33%-1.4% CMV gB binding B cells in the circulation of 15 HCMV seropositive 
individuals. However, this difference in results could be explained by the fact that the 
frequency of CMV gB binding B cells reported by Potzsch et al. is restricted to just the 
CD27+ IgG+ B cell population, where they showed that the frequency of CD27+IgG+ 
CMV binding B cells was higher in HCMV seropositive individuals than seronegative 
individuals.  Although not highlighted in the text of the paper, the figure that is included 
of the FACS plots shows that the frequency of CD27+IgG- B cells that bind the CMV 
gB protein is in fact almost double that of the CD27+IgG+ population (Pötzsch et al., 
2011). Importantly, the same result was also detected in HCMV seronegative patients 
in this paper, a finding that is relevant to the interpretation of the data in this thesis, as 
the HCMV status of the leukocyte cones used here is not known. The results reported 
in Potzsch et al therefore support those reported in this thesis, where the majority of 
CMV gB binding B cells were found to be IgM+.  
Interestingly, the population that was most overrepresented in the CMV gB binding B 
cell gate compared to the overall B cell population was the IgMhi B cells. The IgMhi B 
cells were further subdivided according to the expression of the memory markers CD27 
and CD45RB which revealed that both CD27+IgMhi and CD27-IgMhi B cells were 
overrepresented in the CMV gB binding B cell gate compared to the overall B cell 
population. In contrast, only CD45RB-IgMhi B cells, and not CD45RB+IgMhi B cells, 
were overrepresented in the CMV gB binding gate compared to the overall B cell 
population. Interestingly, the CD27-CD45RB+ MZ/IgM+ memory precursor B cells 
were also not enriched in the CMV gB binding population. Therefore, when considered 
together, the phenotyping data suggests that CMV gB binding B cells are enriched in 
the IgM+ memory population and the T3 naïve follicular pre cursor B cell population. 
This result was largely unexpected due to the fact that CD27+IgM+ (IgM+ memory B 
cells) are widely reported to be specific for polysaccharide antigens, such as those 
found on pneumococcal bacteria, and that they are considered by many researchers 
in the field to develop independently from the rest of the B cell population (Capolunghi 
et al., 2013, Kruetzmann et al., 2003, Carsetti et al., 2005). However, it has been 
previously reported that IgM+ memory B cells specific for tetanus toxoid, rhesus 
antigen and rotavirus like particles are enriched in human peripheral blood and that 
203 
 
switched memory B cells are underrepresented compared to the global B cell 
population, thus demonstrating that IgM+ memory B cells specific for a wide range of 
pathogens can be detected (Della Valle et al., 2014, Herrera et al., 2014, Rojas et al., 
2008). Moreover, Della-Valle et al. demonstrated that both CD27- and CD27+ IgM+ 
cells specific for rhesus antigen had somatically mutated variable regions that were 
clonally related to each other, and the CD27+IgG+ rhesus antigen specific subset 
(Della Valle et al., 2014). Very recently, Dauby et al. reported that HCMV binding B 
cells in chronically infected individuals are activated CD27+CD21hi memory B cells 
(Dauby et al., 2015). Unfortunately, they did not look at the isotype of these cells so 
the data is not directly comparable to the data in this thesis, but it would be interesting 
to investigate whether the CD27+IgM+ CMV binding B cell population found in this 
thesis also express CD21 at high levels.  
It is difficult to investigate the kinetics of the B cell response in humans as this requires 
access to secondary lymph organs and is also made more complicated by the fact that 
humans aren’t kept in controlled environments, where the primary and secondary 
antigen encounters can be controlled. Studies in animals must therefore be used to 
help understand the B cell response. In the last 5 years or so studies in mice have 
shed light on the kinetics of the germinal centre reaction and have revealed that IgM+ 
memory cells specific for protein antigens are formed within 2 days of primary antigenic 
challenge in the extrafollicular space, prior to the initiation of the germinal centre 
reaction (Weisel et al., 2016, Taylor et al., 2012, Pape et al., 2011, Dogan et al., 2009). 
In addition, IgM+ memory B cells have also been shown to be the products of early 
germinal centre reactions (Dogan et al., 2009). 
Pape et al. showed that the IgM+ memory B cells were maintained at their original 
numbers for the duration of the experiment (500 days) whereas isotype switched 
memory B cells began to decline after 50 days. In this model, the switched memory B 
cells would re-enter a germinal centre reaction to form long lived plasma cells upon 
secondary encounter with antigen if the titre of switched serum Immunoglobulin was 
high. However, when the switched immunoglobulin titre declined, IgM+ memory B cells 
entered germinal centre reactions to form a new population of plasma blasts. It appears 
that the IgM+ memory B cells in this model were therefore acting as a long-lived 
reserve for the immune response (Pape et al., 2011).  Dogan et al. showed that IgM+ 
memory cells that have emerged early on after formation of a germinal centre have the 
ability to reinitiate a germinal centre reaction to form class switched germinal centre B 
cells when boosted with antigen (Dogan et al., 2009). In contrast, Zuccarino-Catania 
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et al. showed that the fate of a memory B cell upon secondary exposure to antigen is 
independent of the isotype of the BCR that the memory B cell expresses but is instead 
dependent on its expression of co-stimulatory/inhibitory molecules CD80 and PDL-2; 
IgM+ memory B cells that did not express these molecules (double negatives) were 
able to form germinal centre B cells and differentiate into antibody secreting cells. 
However, IgM+ memory B cells that expressed both molecules (double positives) were 
not able to form a germinal centre reaction but very efficiently differentiated into isotype 
switched antibody secreting cells (Zuccarino-Catania et al., 2014).  
From these papers, it is becoming apparent that during a primary immune response, 
there are ‘multiple layers’ of memory created, from the initial encounter of antigen, to 
the eventual differentiation and production of long lived plasma cells. IgM+ memory B 
cells, it seems, play a much wider role in this layering of memory than previously 
thought. It is possible here, that the CMV gB binding IgM+ memory B cells detected 
have come from two different sources: some are the products of an early germinal 
centre reaction and were derived from naïve follicular B cells, and some are the 
products of differentiation of the MZ/IgM+ memory B cell subset. Interestingly, the T3 
subset thought to be the precursors to the naïve follicular B cells (CD27-CD45RB-
IgMhi) were enriched in the CMV gB binding population but the T3 subset that is 
reported to be the pre-cursor to MZ/IgM+ memory B cells (CD27-CD45RB+IgMhi) was 
not. One could therefore speculate on a model with multiple layers whereby the 
MZ/IgM+ memory pre cursor B cells specific for CMV gB have all differentiated into 
mature CD27+CD45RB+IgMhi cells by adulthood, a theory considered plausible as 
this subset has been reported to be enriched in children (Bemark et al., 2013, 
Descatoire et al., 2014). At the same time, there continues to be a pool of naïve 
follicular pre-cursor B cells that are able to mature into naïve follicular B cells and 
subsequently be activated by the CMV gB antigen to form new IgM+ memory B cells, 
that originate from either an extrafollicular engagement with T cells, or an early 
germinal centre reaction.  
 HLA binding B cells detected using Pure™ HLA proteins are found at a 
much lower frequency in the peripheral blood than reported using other 
methods of detection 
HLA binding B cells have previously been detected in the peripheral blood of renal 
transplant patients using two different methods to the one used in this thesis. Firstly, 
Frans Claas’ group at Leiden university described a method in which HLA A*0201, 
HLA A*2402 and HLA B*0702 tetramers carrying peptides specific for either HIV gag 
or melanoma derived antigen MART-1 were used to detect a mean frequency of 4.65% 
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HLA binding B cells in the peripheral blood of renal transplant patients that had 
evidence of sensitisation due to the presence of circulating antibodies specific for the 
same HLA antigen as the tetramer used. They also detected HLA binding B cells in 
the peripheral blood of unsensitised individuals at an average frequency of 2.33%. 
(Zachary et al., 2007a, Mulder et al., 2001, Mulder et al., 2003, Zachary et al., 2007b). 
The second paper, published by John Paul Soulilou’s group, used a method based on 
the Luminex® technology normally used to detect HLA specific antibodies in the 
circulation, where instead of incubating fluorescent dye impregnated HLA antigen 
coated polystyrene beads with serum, they incubated them with isolated B cells. Each 
HLA specific B cell population was then detected as a bead-cell rosette on the 
Luminex® machine. Using this method they detected a mean frequency of 1.29% and 
0.6% HLA A*0201 binding B cells in sensitised renal transplant recipients and healthy 
volunteers respectively (Degauque et al., 2013). The mean frequency of HLA binding 
B cells of all the samples tested in this thesis from the patients with an HLA A1, HLA 
A2 or HLA DR4 mismatched kidney was 0.07%, and in the leukocyte cones it was 
0.14%. There is therefore a large discrepancy between the frequency of HLA binding 
B cells that are detected in the circulation of both renal transplant recipients and 
healthy volunteers between the three methods used. This could be due to differences 
in both the specificity and sensitivity of each assay system, but also the individuals 
tested. For example, Zachary et al. tested their method on patients with end-stage 
renal disease and Degauque et al. used renal transplant recipients who had either 
stable graft function or antibody mediated rejection, but not chronic rejection. In terms 
of healthy control subjects, Zachary et al. used male subjects and Degauque et al. 
didn’t specify any characteristics of their healthy volunteer population. Very little is 
known about the leukocyte cones used here, apart from that they are blood donors. It 
is possible that they have a sensitisation history from previous pregnancies as their 
sex is unknown. However, they will not have received a transplant or a blood 
transfusion.   
It is likely that the tetramer method is the least specific of all of the techniques as the 
frequency of HLA binding B cells is very high considering that the B cell repertoire 
should, in theory, contain B cells with a BCR to every antigen that an individual will 
encounter. Little information is provided about the characteristics of the transplant 
patients in the study by Zachary et al. but it is possible that an individual undergoing 
an acute rejection episode may have a high frequency of HLA binding B cells, but it is 
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unlikely that an unsensitised healthy volunteer would truly have HLA binding B cells 
specific to just one HLA antigen at a frequency as high as 2.33%.  
To really understand whether the variability of the results in these three studies is due 
to the different patients/healthy volunteer cohorts studied, or the technique itself, 
requires testing of the same sample using all three techniques. As a major aim of this 
thesis was to correlate the pattern of reactivity in the IFNγ ELISpot with the phenotype 
of the HLA binding B cells, the techniques used by Zachary et al. and Degauque et al. 
would not have been suitable for this purpose, as a tetramer or a polystyrene coated 
bead could not be used as the source of B cell stimulating antigen in the IFNγ ELISpot 
assay as they are large complexes which contain many more antigens than just the 
HLA molecule. In addition, multi-parameter flow cytometric analysis of the phenotype 
of the cells would not be compatible with the Luminex® bead method.      
In an attempt to improve on the sensitivity and specificity of the tetramer based assay 
that was developed in the same department at Leiden University, Sebastian Heidt’s 
group have used Pure™ HLA monomers to develop an ELISpot assay that can be 
used to detect both class I and class II specific memory B cells (Karahan et al., 2015b, 
Heidt et al., 2012). It would therefore be possible to validate the flow cytometric antigen 
binding B cell assay described in this thesis (which used HLA monomers from Pure™ 
proteins LLC) with the ELISpot assay developed by Heidt’s group using the exact same 
source of HLA.    
Two papers using this ELISpot assay to study renal transplant recipients have recently 
been published. Lucia et al. reported that the presence of donor HLA specific memory 
B cells in the periphery of renal transplant patients often correlated with the presence 
of DSA, but in some cases they were detected in the absence of DSA. This was 
particularly true when patients were tested before transplant; the presence of donor 
specific HLA memory B cells before transplant was associated with development of 
antibody mediated rejection, even when the patient was classed as negative for DSA 
(Lúcia et al., 2015). Snanoudj et al. carried out a very similar study in three groups of 
patients with end stage renal disease who were grouped according to whether they 
had circulating DSA and/or a previous sensitisation event such as a transplant or 
pregnancy. Consistent with Lucia et al., this study found that the presence of HLA 
specific memory B cells was strongly associated with a previous sensitisation event. 
However in contrast to the findings of Lucia et al, they also found that the presence of 
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HLA specific B cells was always associated with detectable circulating DSA (Snanoudj 
et al., 2015).  
A common goal of the assays mentioned above is to highlight the weaknesses in just 
monitoring serum DSA as a means to measuring the sensitisation status of a patient 
before and after transplantation, and that developing a clinical test that gives an 
alternative readout of a patient’s humoral sensitisation to HLA antigens may aid in the 
initial matching of recipient donor pairs pre-transplant, and in the subsequent 
management of rejection post-transplant (Karahan et al., 2015a). The focus of these 
studies is still very much on the antibody producing function of a B cell and does not 
shed any light on other contributions that B cells may be making to the alloimmune 
response. The data in this thesis, therefore, is highly novel in that it is uses the same 
HLA monomers as used in the studies mentioned above, but for the purpose of 
investigating the contribution that different B cell subsets may be making to the indirect 
T cell alloimmune response. Moreover, this thesis focusses on this response in a 
chronic rejection setting, whereas the studies mentioned above are mainly focussed 
on the pre-transplant and acute rejection stages.  
 HLA binding B cells are predominantly IgM+ and are either IgM+ naïve or 
IgM+ memory B cells 
When the assay for detecting antigen binding B cells was applied to an HLA setting, it 
was found that the phenotype of HLA binding B cells detected in the patients and 
leukocyte cones was also IgM+. Although the results were more variable than the CMV 
gB binding B cells when the IgM+ cells were divided into different subsets according 
to CD45RB and IgM expression, general trends could be observed where the 
predominant phenotype of the of HLA binding B cells was either CD45RB+IgMhi 
memory population or CD45RB-IgM+ naïve. This data is supported by that of 
Degauque et al. where they reported that the HLA A1+ B cells that they detected using 
their antigen coated bead system were overrepresented in the non-class switched 
memory B cell population (CD27+IgD+) and underrepresented in the class switched B 
cell population when compared to the overall B cell population (Degauque et al., 2013).  
Based on the findings of the murine studies of the germinal centre reaction mentioned 
above, and studies in humans conducted by Ralf Kupper’s group, one could speculate 
that the HLA binding IgM+ memory B cells detected in the RituxiCAN patients are either 
products of extrafollicular engagement with T cells, or early products of a germinal 
centre reaction (Pape et al., 2011, Dogan et al., 2009, Weisel et al., 2016, Seifert et 
al., 2015, Seifert and Küppers, 2009, Budeus et al., 2015). It is well established, that 
not all antibody secreting cells are long lived (Nutt et al., 2015). For example, it has 
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recently been shown in a cohort of patients with RA, that Rituximab treatment lead to 
a reduction in the levels of RA related antibodies, but not of tetanus toxoid specific or 
rotavirus specific antibodies (Herrera et al., 2014). This suggests that the maintenance 
of antibody titres to some antigens does not come from long lived plasma cells but 
from a continual activation of naïve or memory cells to produce short lived antibody 
secreting cells. It is therefore possible that the IgM+ memory B cells detected here 
represent the population of B cells that become activated to form new germinal centres 
once the IgG DSA titre has reduced to a certain level, as previously described in the 
mouse (Pape et al., 2011). Thus this re-activation of IgM+ memory B cells represents 
a new wave of immune activation (and antibody production) that could contribute to 
the destruction of the graft.  
 The ratio of IgM+ memory to IgM+ naïve B cells in the HLA binding B cell 
population may impact the IFNγ to Pure™ HLA proteins 
The results in this chapter show that Pure™ HLA proteins can be used to stimulate an 
IFNγ response that is B cell dependent in some samples and B regulated in others. As 
with the results in chapter 3, where donor membrane proteins were used, this pattern 
of reactivity changed over time in the same patient. This provided the opportunity to 
correlate the IFNγ response with the phenotype of the HLA binding B cells. This 
analysis revealed that CD27 proved to be the best marker of memory for resolving any 
associations between the phenotype of the HLA binding B cells and the pattern of 
reactivity in response to the Pure™ HLA protein. When CD27 is used to define 
memory, the data suggests that a higher ratio of IgM+ memory cells to IgM+ naïve 
cells is associated with B dependent IFNγ production. It is possible that the balance of 
these two populations within the antigen specific B cell compartment has an effect on 
the outcome of the ELISpot, but where the balance lies is different in each patient. In 
one patient, a switch from B dependent IFNγ production to B regulated IFNγ production 
was associated with a switch from IgM+ memory B cells being the dominant phenotype 
in the HLA binding B cell population to IgM+ naïve B cells being the dominant 
population. In another patient, the IgM+ memory population was always more 
dominant than the IgM+ naïve population (the ratio of IgM+ memory:IgM+ naïve B cells 
was always at least 2), however, an increase in this ratio to 7 or above was associated 
with the IFNγ response switching from a non-reactive response to a reactive B 
dependent response at two time points. 
There are of course limitations to the interpretation of the data due to the small number 
of patients that were studied. For example, the HLA A1 binding B cells were all 
overrepresented in the IgM+ memory population compared to the global B cell 
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population, but the samples that this data was derived from all came from the same 
patient. A much larger study is required to find more concrete patterns in the phenotype 
of the HLA binding B cells and how that relates to the pattern of reactivity in the IFNγ 
ELISpot. This would require a large panel of Pure™ HLA proteins to be used, and 
many patients with a variety of mismatched transplants. This was beyond the 
resources available for this thesis, but the preliminary data presented here will prove 
useful in designing such a study. In addition, the number of events in the HLA binding 
B cell gate is small which can result in small changes in phenotype (for example 
between the CD45RB+ and CD27+ populations) appearing very large when cell 
frequencies are compared as ratios as presented here. For the purpose of this thesis, 
no minimum number of events inside the HLA binding B cell gate was set. However a 
cut off was required that the number of events must be at least double that of the 
background gate in order to analyse the phenotype of the cells. The number of cells 
that could be stained was limited as the same sample was also used in the IFNγ 
ELISpot. To strengthen the robustness of the results in future studies, it would be wise 
to stain a much larger number of PBMCs in order to detect more events in the HLA 
binding B cell gate. To be able to achieve this whilst concomitantly carrying out the 
IFNγ ELISpot, freshly isolated PBMCs could be used to eliminate the problem 















5 Results part 3 
 Introduction 
One of the major aims of this thesis was to investigate the impact that the antigen 
specific B cells have on CD4+ T cell IFNγ production in the ELISpot assay. As patient 
samples were limited, the CMV gB model system was used to explore this aim. The 
experiments in this chapter were based around linking the IgM+ memory phenotype of 
CMV gB binding B cells with the ELISpot pattern of reactivity, with the aim of 
demonstrating that IgM+ memory B cells are the subset of B cells responsible for 
inducing antigen specific CD4+ IFNγ production. These experiments also sought to 
explore the mechanism by which B cells were regulating the IFNγ production in some 
samples.  
A limitation of the ELISpot was discovered when the ELISpot was carried out on the 
same lymphocyte cone on a different day; the pattern of reactivity in response to the 
CMV gB was found to be variable. This could be due to a number of factors but most 
likely it is due to the freeze/thawing process and the number or frequency of CMV gB 
specific T and B cells that were contained within each vial of PBMCs that were frozen 
down. It was therefore decided that if the result of the ELISpot was to be correlated 
with results from a different assay, the same vial of cells must be thawed and used for 
both assays on the same day. In addition, any other experiments carried out would be 













 B cell depletion leads to both B dependent and B regulated phenotypes 
in leukocyte cones when stimulated with CMV gB in the IFNγ ELISpot 
The IFNγ ELISpot assay was carried out on CD8+ depleted PBMCs from the same 15 
leukocyte cones used in Chapter 4 with CMV gB as the stimulating antigen. These 
ELISpots were carried out at the same time as the antigen binding B cell assay 
described in Chapter 4. Both reactive, B dependent and B regulated patterns of 
reactivity were observed. 3/15 of the leukocyte cones produced IFNγ above 
background when stimulated with CMV gB (Fig. 5.1 (a)). IFNγ production in 3/3 of 
these reactive cones was dependent on the presence of B cells (Fig. 5.1 (b)). A further 
6 individuals became reactive to the protein post B cell depletion and were deemed B 

























Figure 5.1 Impact of B cell depletion on 15 leukocyte cones when stimulated with CMV 
gB in the IFNγ ELISpot  
(a) 3/15 individuals tested were deemed reactive when just CD8+ cells were depleted 
as they produced ≥25 IFNγ+ spots per million CD4+ lymphocytes. (b) When CD8+ and 
CD19+ cells were depleted, B dependency was revealed in these 3 individuals as IFNγ 
production decreased to <25 IFNγ+ spots per million CD4+ T cells in all 3 of these 
reactive individuals. (c) When CD8+ and CD19+ cells were depleted from the 12/15 
non-reactive individuals, IFNγ increased to ≥25 IFNγ+ spots per million CD4+ T cells 





































































































































 CMV gB binding B cell phenotype does not correlate with the pattern of 
reactivity in the IFNγ ELISpot  
It was hypothesised that the phenotype of the CMV gB binding B cells may correlate 
with the pattern of reactivity in response to CMV gB in the IFNγ ELISpot. The 15 
leukocyte cones tested in 5.2.1 were therefore grouped according to the three patterns 
of reactivity observed; reactive, B dependent (n=3), reactive, B regulated (n=6) and 
non-reactive (n=6). The phenotype of their CMV gB binding B cells was compared 
between the three groups (Fig 5.2). 
No significant differences were found between the three groups with respect to the 
frequency of transitional and non-transitional populations, IgM+ and IgG+ expressing 
populations or CD27 expressing populations (Fig. 5.2 (a), (b) & (c), P>0.05). No 
significant correlations were found when this analyses was extended to comparing the 
different B cell subsets according to their dual expression of IgM and CD27 (Fig. 5.2 
(d) & (e), P>0.05). Similarly no correlations were found when the phenotype of the 
global B cell population was compared between the three groups (Fig. 5.3, P>0.05). In 
addition, no differences were found between the ratios of CD27+:CD27- or 
CD27+IgMhi:CD27-IgM+ populations in either the CMV gB binding B cell population 
or the global B cell population (Fig 5.4, P>0.05). All data was analysed using a Kruskall 









Figure 5.2 Correlating the phenotype of CMV gB binding B cells with the pattern of 
reactivity in the IFNγ ELISpot.  
Leukocyte cones were grouped according to their pattern of reactivity to CMV gB in 
the IFNγ ELISpot. R (Bdep) = reactive, B dependent; R (Breg) = reactive, B regulated; 
NR = non-reactive. The frequencies of each B cell subset within the CMV gB binding 
B cell gate was compared between the three groups using a Kruskall Wallis test with 
Dunns multiple comparison test (p>0.05 for all analyses). Black line on graphs 
represents the median. 




























































































































































Figure 5.3 Correlating the phenotype of the global B cell population with the pattern of 
reactivity in the IFNγ ELISpot.  
Leukocyte cones were grouped according to their pattern of reactivity to CMV gB in 
the IFNγ ELISpot. R (Bdep) = reactive, B dependent; R (Breg) = reactive, B regulated; 
NR = non-reactive. The frequencies of each B cell subset within the CD19+ gate was 
compared between the three groups using a Kruskall Wallis test with Dunns multiple 
comparison test (p>0.05 for all analyses). Black line on graphs represents the median. 
 






























































































































































Figure 5.4 Correlating the ratio of memory to naïve or IgM+ memory to naïve B cells with 
the pattern of reactivity in IFNγ ELISpot 
Leukocyte cones were grouped according to their pattern of reactivity to CMV gB in 
the IFNγ ELISpot. R (Bdep) = reactive, B dependent; R (Breg) = reactive, B regulated; 
NR = non-reactive. The ratio of memory to naïve B cells (CD27+:CD27-) in both the 
CMV gB binding population (a) and the global B cell population (b) was compared 
between groups. The ratio of IgM+ memory and IgM+ naive B cells 
(CD27+IgMhi:CD27-IgM+) in both the CMV gB binding Population (c) and the global 
B cell population (d) was compared between groups. Groups were compared using a 
Kruskall Wallis test with Dunns multiple comparison test (p>0.05 for all analyses). 
Black line on graphs represents the median. 
   
 
 















































































































































 Using an experimental approach to dissect the role that B cells play in 
producing different patterns of reactivity in the IFNγ ELISpot.   
As the analysis carried out in section 5.2.2 did not reveal any straightforward 
correlations between the ELISpot pattern of reactivity and CMV gB binding B cell 
phenotype, a series of experiments was conducted with the aim of gaining an insight 
into why different samples display different patterns of reactivity to an antigen in the 
IFNγ ELISpot.    
5.2.3.1 Do B cells suppress IFNγ production in the CMV gB ELISpot assay by 
secreting IL-10?  
IL-10 production is one of the defining characteristics of regulatory B cells and it is 
required to suppress a T cell response (Blair et al., 2010, Flores-Borja et al., 2013, 
Iwata et al., 2011, Das et al., 2012b, Carter et al., 2012, Cherukuri et al., 2014, Bouaziz 
et al., 2010). An IL-10 blocking antibody was therefore added to the CMV gB ELISpot 
assay to assess whether blocking IL-10 would mirror the effect observed when B cells 
were depleted and a Breg response was observed. Figure 5.5 shows the results from 
5 different leukocyte cones. When B cells are present and IL-10 is blocked, IFNγ 
always increases. When B cells are depleted and IL-10 is blocked, IFNγ production 
increases further, but to varying degrees depending on the individual. The cones in 
Figure 5.5 (a) and (b) have a reactive, B regulated response to the CMV gB when IL-
10 is not blocked. There appears to be an additive effect on IFNγ production when IL-
10 is blocked and B cells are depleted because the increase in IFNγ production post 
B cell depletion is similar in the isotype control wells and the anti-IL-10 wells when B 
cells are depleted.  This suggests that in these two cones B cells may not be acting 
through IL-10 production to suppress IFNγ production, as it would be unlikely to see 
the additive effect of blocking IL-10 and depleting B cells if this was the case. 
Interestingly, this additional increase in IFNγ was also observed in the individuals 
represented in Fig. 5.5 (c) and (d), despite there being no evidence of B regulation in 
the isotype control wells. The cone in Figure 5.5 (e) has a reactive, B dependent 
response to the CMV gB protein, however when B cells are depleted in the presence 
of the IL-10 blocking antibody, the B dependency is not apparent, in fact there is a 
slight increase in IFNγ production. It appears that in this sample, the effect of blocking 
IL-10 is so powerful that it drowns out any contribution that the B cells are making to 




Figure 5.5 Blocking IL-10 in the IFNγ ELISpot 
CMV gB stimulated, CD8+ and CD8+/CD19+ depleted IFNγ ELISpots were set up in 
the presence of an anti-IL10 blocking antibody or the appropriate isotype control. Each 
graph represents one leukocyte cone ((a)-(e)). Pink bars represent the isotype control 
wells and blue bars represent the wells where IL-10 blocking antibody was added. IFNγ 


























































































































































































































































































































5.2.3.2 Intracellular cytokine staining is not sensitive enough to detect T or B 
cell derived IFNγ or IL-10 but does detect IFNγ+ NK cells. 
Figure 5.5 suggests that B cells may not be suppressing IFNγ production via an IL-10 
mediated mechanism, however, the data does not definitively show this. Intracellular 
cytokine staining was therefore carried out in PBMC that were cultured under the same 
conditions used in the ELISpot to investigate further. This also served as an opportunity 
to confirm that the IFNγ reduction seen in B cell dependent samples was not because 
B cells were producing the IFNγ. Cell cultures were set up to replicate the conditions 
used in the ELISpot wells with the modification that Brefeldin A was added 5 hours 
before the end of the 24 hour incubation. Polyclonal stimulus anti-CD3/CD28 beads 
were used as a control, as per the ELISpot protocol.  
Table 5.1 and 5.2 show the results obtained from 5 leukocyte cones tested. The results 
indicate that intracellular staining is not a sensitive enough technique to detect antigen 
specific T cell IFNγ production, as IFNγ production was only detected when the PBMC 
were stimulated polyclonally (Table 5.1). However, concomitant ELISpots were not 
carried out to confirm this. A very small proportion of NK cells were detected above 
background as IFNγ+ in 3/5 individuals when CD8 cells were depleted (median 
0.272%, range 0.154%-0.418%) and 3/5 when CD8/CD19 cells were depleted (median 
0.174% and range 0.115-0.94%) (Table 5.1). Whether the NK cells are being activated 
by the antigen, for example via TLRs, or are just non-specifically producing IFNγ from 
the freeze thawing and culturing process remains unclear, but it is an important finding 
that requires further investigation.  A similar proportion of NK cells were IFNγ+ as the 
CD4+ T cells when anti-CD3/CD28 beads were used (median 7.33%, range 4.43%-
10.46% for CD4+T cells and median 5.8%, range 2.966%-14.328% for NK cells). B 
cells did not make IFNγ in the presence of either stimulus.   
IL-10+ cells were not detected in the B, T or NK cell populations when stimulated with 
CMV gB. IL-10+ T cells were detected in 5/5 individuals when polyclonally stimulated 
with anti-CD3/CD28 beads (median 1.622, range 0.53%-5.271% for CD8 depleted, 
median 1.644%, range 0.715%-6.58% for CD8+&CD19+ depleted). When a Wilcoxon 
pairs signed rank test was used to compare this population pre and post B cell 
depletion, no difference was found (P>0.05). A very small proportion of IL-10+ NK cells 
was detected in 2/5 individuals when stimulated with anti-CD3/CD28 beads, although 




Table 5.1 IFNγ production in response to CMV gB measured by intracellular staining.  
 
Figures represent the percentage of IFNγ+ events detected after different stimulation 
conditions. CD8 depleted PBMC are in pink, CD8/CD19 depleted PBMC are in blue. An isotype 
control was used to gate on IFNγ+ cells within B cells (CD19+), CD4 T cells (CD3+CD4+) and 
NK cells (CD3-CD56+) and the frequency of isotype control+ events was subtracted from the 





Table 5.2 IL-10 production in response to CMV gB measured by intracellular staining.  
 
Figures represent the percentage of IL-10+ events detected after different stimulation 
conditions. CD8 depleted PBMC are in pink, CD8/CD19 depleted PBMC are in blue. 
An isotype control was used to gate on IL-10+ cells within B cells (CD19+), CD4 T cells 
(CD3+CD4+) and NK cells (CD3-CD56+) and the frequency of isotype control+ events 




Cone ID Media CMV gB CD3/CD28 Media CMV gB CD3/CD28 Media CMV gB CD3/CD28
Cone 27 0 0 0.128 0 0 8.53 0.006 0.272 1.98
Cone 28 0 0 0.026 0 0 4.43 0.161 0.418 6.793
Cone 32 0 0 0 0 0 7.33 0 0.154 4.11
Cone 34 0.012 0 0 0 0 4.52 0 0 5.8
Cone 35 0 0 0.07 0 0 10.46 0.94 0.54 12.449
Cone 27 NA 0.041 0 8.63 0 0.115 2.966
Cone 28 0 0.084 7.9 0.152 0.174 14.328
Cone 32 0 0 8.71 0.298 0 5.82
Cone 34 0 0 4.84 0 0 6.674
Cone 35 0 0 12.11 0.474 0.94 12.037
B cells CD4+ T cells NK cells
Cone ID Media CMV gB CD3/CD28 Media CMV gB CD3/CD28 Media CMV gB CD3/CD28
Cone 27 0 0 0.027 0 0 2.259 0.014 0 0
Cone 28 0 0 0.147 0 0 1.662 0 0 0.023
Cone 32 0 0 0.148 0 0 0.889 0 0 0
Cone 34 0 0 0.136 0 0 0.53 0 0 0
Cone 35 0 0 0.352 0 0 5.271 0 0 0.061
Cone 27 NA 0.042 0 2.484 0.048 0 0
Cone 28 0 0 1.644 0 0 0
Cone 32 0 0 0.715 0 0 0.038
Cone 34 0 0 1.203 0 0 0.092
Cone 35 0 0 6.58 0 0 0
B cells CD4+ T cells NK cells
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5.2.3.3 Enriching for different B cell populations impacts reactivity to the CMV 
gB antigen 
As the intracellular staining was not deemed suitable for using in an antigen specific 
system, a different approach was taken. This involved modifying the ELISpot in a 
series of depletion and add back experiments of different B cell subsets in order to 
dissect out the role that each B cell subset plays in the ELISpot assay. It seemed 
logical to start with attempting to deplete the CMV gB binding B cells as this would be 
the best way of directly showing that the antigen binding B cell population is impacting 
IFNγ production in the ELISpot.            
Several attempts were made using FACS sorting as a way of depleting populations 
from PBMC as this is the best way to obtain pure populations of different subsets of 
cells. However, it was deemed that this technique was incompatible with the ELISpot 
as it rendered the cells un-responsive and incapable of producing IFNγ. 
In an attempt to overcome this problem and to conserve the T cells, PBMC were 
passed through the sorter and the relevant B cell population was sorted and collected 
before being added back to CD8+ & CD19+ depleted PBMC that had not been passed 
through the sorter. However, this approach did not improve IFNγ production.  
With a lack of success using FACS sorting, a compromise was made by using 
magnetic beads to isolate or deplete different B cell populations. This is a more gentle 
approach but the populations obtained are less pure. Initially, the CMV gB binding B 
cells were isolated from the whole B cell population using anti-PE magnetic beads 
which would bind to the B cell-gB-Streptavidin PE complex. This only resulted in a 50% 
pure population (see Figure 2.6 for dot plot). It was therefore decided that this approach 
would not yield robust enough results, as a much purer population of the CMV gB 
binding B cells would be necessary to categorically demonstrate that they are the B 
cells that are influencing IFNγ production. As an alternative, it was decided that the 
hypothesis that different B cell subsets impact IFNγ production in different ways would 
be tested. This was done by using anti-CD27 magnetic beads to separate the B cells 
into CD27+ (memory) and CD27- (naïve) populations. Separating the B cells into 
subsets according to the co-expression of IgM and CD27 would have been more ideal 
given the results described in Chapter 4, however this approach was deemed 
unsuitable as it would have involved using antibodies that bound the IgM BCR and 
therefore potentially would have interfered with the subsequent binding and 
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internalisation of the CMV gB protein in the ELISpot assay, or possibly have 
polyclonally activated the B cells. 
B cells were initially isolated by negative selection and then incubated with anti-CD27 
labelled magnetic beads and passed through a magnetic column. The CD27- B cells 
were collected in the flow through and the CD27+ cells were removed from the column. 
Each fraction was counted and added back to CD8+&CD19+ depleted PBMC and used 
in the ELISpot assay. The number of CD27- and CD27+ B cell fractions were added 
back to the PBMC according to the frequency of these subsets in the whole PBMC 
population, which was obtained from previous phenotyping of these cones. This 
resulted in populations of PBMC that were enriched for either CD27+ or CD27- B cells 
as shown in Figure 5.6. Isolated CD19+ cells were also added back to CD8+&CD19+ 
depleted PBMC to illustrate that the same result in the ELISpot assay is obtained when 













CD8 depleted CD27+ enriched CD27- enriched
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Figure 5.7 (a) and (b) shows two individuals that were non-reactive when CD19+ cells 
were either present or depleted. When the CD27+ enriched PBMC were added to the 
ELISpot, IFNγ production increased, a result that was not observed with the CD27- 
enriched PBMC. Of note, in (b) IFNγ increased to just shy of the cut off to be deemed 
a reactive response at 24 IFNγ spots per million CD4+ T cells. Additionally, Figure 5.7 
(c) shows an individual who had a non-reactive, B regulated response that produced 
IFNγ when CD27+ enriched PBMC were added to the ELISpot, but not when the CD27- 
enriched PBMC were used. These results therefore suggest that CD27+ B cells 
support T cell IFNγ production and that CD27- B cells do not. The data from Figure 5.7 
(c) also suggests that the CD27- B cell population may be suppressing T cell IFNγ 
production in this individual. 
To investigate whether it is transitional B cells within the CD27- population that are 
responsible for suppressing the IFNγ production, CD10+ cells were depleted from 
isolated B cells. Both Dynabead® and MACS bead systems were used for this process 
but neither produced a level of CD10+ depletion that was satisfactory and so the 
ELISpot data that was produced from these experiments is not robust enough to 


















Figure 5.7 CD27+ B cells support IFNγ production in response to CMV gB.  
(a-c) Each graph represents a different leukocyte cone.  Adding isolated B cells back 
to the ELISpot reproduces the same result observed in just CD8 depleted B cells. 
Adding CD27+ B cell enriched PBMC supports IFNγ production: a substantial increase 
was observed in (c) and a moderate increase in IFNγ production was observed in (a) 





























































































































































































































































































 HLA DR and CD86 are expressed more brightly on CMV gB binding B cells 
compared to the overall B cell population 
As the data presented in section 5.2.3.3 suggests that memory B cells support T cell 
IFNγ production, it was hypothesised that memory B cells may express molecules 
associated with antigen presentation at a higher level than naive B cells. Therefore, 
the surface level expression of HLA DR and CD86 on the CMV gB binding B cells and 
the whole B cell population was measured using flow cytometry (Fig. 5.8). The B cell 
phenotyping panel used in results chapter 4 was modified to include HLA DR and 
CD86, so CD24 and CD38 were omitted and replaced with CD10 to define transitional 
B cells. CD27 was removed and CD45RB was used to define memory B cells. In the 
majority of individuals, close to 100% of their B cells express HLA DR. This was 
observed in both the overall B cell population (median 99.7%, range 97.8-99.9%) and 
the CMV gB binding B cell population (median 99.5%, range 97.7-99.9%). When the 
frequency of HLA DR+ B cells within each subset was analysed, this revealed that 
there were no differences between the whole B cell population and the CMV gB binding 
B cell population, with the exception of the CD45RB+IgM- subset which had a lower 
proportion of B cells that were HLA DR+ in the CMV gB binding population (Fig. 5.9 
(a), median 90.1% and range 73.7-100%, P=0.0049). The MFI (mean fluorescence 
intensity) of HLA DR expression is different on each B cell subset with CD45RB-IgMhi 
and CD45RB-IgM+ B cells expressing it most brightly (Fig. 5.9 (b)). Interestingly, HLA 
DR expression was brighter on the CMV gB binding B cell population than the overall 
B cell population in all B cell subsets apart from the CD45RB-IgM- subset (Fig. 5.10). 
This difference was most striking with the transitional population and memory 















Figure 5.8 Representative dot plots of HLA DR (a) and CD86 (b) expression on B cells 
and CMV gB binding B cells.   
B cells were initially divided into Transitional (CD10+) and non-transitional (CD10-). 
Non-transitional B cells were then divided further into subsets based on CD45RB and 
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Figure 5.9 Expression of HLA DR on B cells and CMV gB binding B cells.  
(a) HLA DR was gated on according to the isotype control and applied to each B cell 
subset within the CD19+ gate and the CMV gB binding B cell gate. (b) MFI of the HLA 
DR+ population within each B cell subset. Black lines represent the median of the 12 











































































































































Figure 5.10 Comparison of HLA DR expression on B cell subsets within the whole B cell 
population and the CMV gB binding population 
The mean fluorescence intensity of HLA DR expression on the different B cell subsets 
was compared between the overall B cell population and the CMV gB+ binding B cell 
population. HLA DR was expressed more brightly on the CMV gB binding population 
on all subsets apart from the CD45RB-IgM- subset. P = 0.0010 for (a) (b) and (c), P= 
0.0244 for (d), P=0.0244 for (e). P values obtained using a Wilcoxon matched pairs 





























































































































































































































A median of 2.4% (range 1.15-4.52) of B cells and 5.53% (range 2.7-11.2) of CMV gB+ 
B cells express CD86. Different B cell subsets contain different frequencies of CD86+ 
B cells (Fig 5.11 (a)). Switched memory B cells (CD45RB+IgM-) B cells contain the 
highest frequency of CD86+ B cells (median 6.59%, range 2.91-14.4%) and Naïve 
(CD45RB-IgM+) the least (median 1.04%, range 0.483-1.91%). The CMV gB binding 
B cell population contains a higher frequency of CD86+ B cells than the overall B cell 
population in all subsets apart from CD45RB-IgM- B cells (Fig. 5.12). This difference 
was most striking in the Transitional, IgM+ memory (CD45RB+IgMhi+) and naïve 
subsets (Fig. 5.12 (a), (b) and (d), P=0.0010 for all).  
Figure 5.11 (b) shows that the MFI of CD86 expression was highest on the transitional 
B cells (median 27.1, range 15.5-53.6) and lowest on the CD45RB-IgMhi B cell subset 
(median 15.2, range 22.4-8.99). As with HLA DR expression, CD86 expression was 
brighter on the CMV gB binding B cell population compared to the overall B cell 
population in all B cell subsets apart from the CD45RB-IgM- subset (Fig. 5.13). This 
difference was most striking in the transitional and CD45RB-IgMhi populations (Fig. 






















Figure 5.11 Expression of CD86 on B cells and CMV gB binding B cells.  
(a) CD86 was gated on according to the isotype control and applied to each B cell 
subset within the CD19+ gate and the CMV gB binding B cell gate. (b) MFI of the 
CD86+ population within each B cell subset. Black lines represent the median of the 











































































































































Figure 5.12 Comparison of CD86+ B cell subsets within the whole B cell population and 
the CMV gB binding population.  
The frequency of CD86 expressing cells in the different B cell subsets was compared 
between the overall B cell population and the CMV gB+ binding B cell population. The 
CMV gB binding population had more CD86+ cells than the overall B cell population in 
all subsets apart from the CD45RB-IgM- population. P= 0.0010 for (a), (b) and (d), P= 
0.0020 for (c), P=0.0068 for (e). P values obtained using a Wilcoxon matched pairs 











































































































































































Figure 5.13 Comparison of CD86 expression on B cell subsets within the whole B cell 
population and the CMV gB binding population 
The mean fluorescence intensity of CD86 expression on the different B cell subsets 
was compared between the overall B cell population and the CMV gB+ binding B cell 
population. CD86 was expressed more brightly on the CMV gB binding population on 
the CD45RB+IgM- (a), CD45RB-IgM+ (b) and CD45RB-IgMhi (c) populations. 
P=0.0020 for (a) and (b), P=0.0010 for (c). P values obtained using a Wilcoxon 


















































































































































































































 BAFFr is not differentially expressed on different B cell subsets.  
Therapeutic agents that target B cells are not limited to Rituximab. For example, 
Belimumab, a monoclonal antibody specific for BAFF receptor (BAFFr), is currently 
being used in a clinical trial to prevent kidney transplant rejection (Clinicaltrials.gov.uk 
identifier NCT01536379). Atacicept, a fusion protein that binds B cell survival factors 
BAFF and APRIL, has been used in a number of clinical trials to treat RA, SLE and MS 
with varying degrees of success (van Vollenhoven et al., 2011), Clinicaltrials.gov.uk 
identifier NCT01972568 & (Hartung and Kieseier, 2010), Clinicaltrials.gov.uk identifier 
NCT00642902).  
Selectively depleting pathogenic B cell subsets and conserving those that are 
protective could potentially be a more beneficial treatment for chronic rejection than 
pan B cell depletion as is the case with Rituximab. Surface expression of BAFFr and 
TACI on different B cell subsets was therefore measured to investigate whether there 
is any potential to preferentially target specific B cell subsets with the use of either 
Belimumab or Atacicept.  
PBMC were stained with the same antibody panel used in section 5.2.4 with BAFFr 
and TACI replacing HLA DR and CD86. Unfortunately, positive TACI staining could 
not be achieved despite titrating the antibody, staining different individuals, following 
recommendations by the manufacturer and using two different vials of TACI antibody 
conjugated to two different fluorochromes (Fig. 5.14 (a)). 
The antibody for BAFFr however stained very clearly (Fig. 5.14 (b)). Figure 5.15 shows 
that the majority of individuals have BAFFr expressed on the vast majority of their B 
cells (median 99.4%, range 96.3-100%) with the exception of one individual who did 
not have BAFFr expressed on their B cells. A slightly lower frequency of transitional B 
cells expressed BAFFr (median 93.2, range 70.1-98.3). No difference in BAFFr 
expression was detected between the CMV gB binding B cell population and the 
overall B cell population (Fig. 5.15 (a) & (b)).  
When the MFI was analysed, BAFFr was found to be most brightly expressed on Naïve 
B cells (CD45RB-IgM+, median 1205 and range 769-1915) and least on transitional B 
cells (Fig. 5.15 (b), median 771, range 394-1484, P=0.0010). Note, the individual who 
did not express BAFFr on their B cells was removed from the analysis used to derive 











Figure 5.14 Representative dot plots of TACI and BAFFr expression on B cells and CMV 
gB binding B cells.  
(a) Positive TACI events were not detected with any volume of antibody used. (b) For 
BAFFr staining analysis, B cells were initially divided into Transitional (CD10+) and 
non-transitional (CD10-). Non-transitional B cells were then divided further into subsets 
based on CD45RB and IgM expression. Each subset of non-transitional B cells is 
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Figure 5.15 Expression of BAFFr on B cells and CMV gB binding B cells 
(a) BAFFr was gated on according to the isotype control and applied to each B cell 
subset within the CD19+ gate and the CMV gB binding B cell gate. (b) The MFI 
represents the BAFFr+ population of each of the subsets. Black lines represent the 



































































































































 Key points in Chapter 5 
 
1. The phenotype of CMV gB binding B cells does not correlate with the pattern 
of reactivity observed when PBMC from leukocyte cones are stimulated with 
CMV gB in the IFNγ ELISpot.  
 
2. When B cells are depleted and IL-10 is blocked in the IFNγ ELISpot, IFNγ 
production is greater than when B cells are present and IL-10 is blocked.  
 
3. Enriching for CD27+ B cells in the IFNγ ELISpot leads to increased IFNγ 
production whereas enriching for CD27- B cells does not.  
 
4. Class switched memory B cells, IgM+ memory B cells and Transitional B cells 
contain greater frequencies of CD86 expressing B cells than naïve B cells. 
CMV gB binding B cells contain a higher proportion of CD86 expressing B cells 
in all subsets than the overall B cell population (apart from CD45RB-IgM-),  and 
both HLA DR and CD86 are more brightly expressed on CMV gB binding B 
cells compared to the overall B cell population.   
 
5. BAFFr is not differentially expressed on B cell subsets or between the CMV gB 












The major aim of the final results chapter of this thesis was to investigate further the 
results obtained in chapters 3 and 4. Gathering in vitro mechanistic data to build an 
argument is always challenging. Here, various strategies were tried to investigate the 
impact that different B cell subsets have on the outcome of the IFNγ ELISpot assay. 
Due to limited patient material, frozen aliquots of PBMCs from a cohort of leukocyte 
cones were used in combination with CMV gB to conduct these experiments. It became 
apparent that a major limitation of this approach was that the pattern of reactivity 
observed in the IFNγ ELISpot would differ in the same sample when thawed on 
different days. To make use of the data collected, whilst not compromising the integrity 
of it, it was decided that the data would only be interpreted on an individual experiment 
basis. All assays conducted on the vial of cells that was thawed could be correlated 
with each other, but assays conducted on different days could not. For example, where 
the CMV gB binding B cell phenotyping data was correlated with the pattern of 
reactivity, these assays were set up on the same day from the same starting 
suspension of PBMCs.  
Blocking IL-10 in the ELISpot assay revealed that IL-10 is suppressing the production 
of IFNγ from many cells. When B cells were depleted in addition to blocking IL-10, IFNγ 
always increased, regardless of whether the initial pattern of reactivity was B regulated 
or not. These results suggest that B cells may be partially suppressing IFNγ production 
in an IL-10 independent manner as their depletion heightened any effects that were 
observed when just the IL-10 blocking antibody was used. However, the involvement 
of B cell derived IL-10 could not be ruled out, so intracellular staining was used to try 
and detect B cell specific IL-10 when PBMC were stimulated in the same way as in the 
ELISpot assay. Unfortunately, it was very difficult to detect B cell derived IL-10 or T 
cell derived IFNγ. Intracellular staining is not as sensitive technique as the ELISpot, 
which is often regarded as the most sensitive technique for detecting antigen specific 
responses, and this result may just be evidence of that. It does not prove that B cells 
or T cells were not secreting IL-10 or IFNγ in response to the CMV gB protein as 
concomitant ELISpots were not carried out at the same time. However, an important 
finding of these experiments that requires further investigation is that a small 
percentage of NK cells produced IFNγ in response to the CMV gB. It is important to 
determine whether this level of IFNγ production is just background or if it would reach 
above the threshold used in the IFNγ ELISpot to determine whether a sample 
responded to the antigen or not (ie. ≥ 25 IFNγ+ spots per million CD4+ T cells). In 
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future, it may be wise to add in the depletion of CD56+ cells to produce more robust 
results. Using freshly isolated PBMC or introducing a resting phase post thaw would 
help reduce the level of background IFNγ produced and therefore make it easier to 
resolve an antigen specific CD4+ T cell response. 
As no correlations could be found with this type of analysis, an experimental approach 
was taken to investigate whether different subsets of B cells could support or suppress 
T cell IFNγ production. Progress with these experiments was hampered by inadequate 
depletion of various subsets and the downstream effects that these depletions had. To 
support the hypothesis that the effects in the ELISpot are mediated by antigen specific 
B cells, the ideal experiment would be to compare the pattern of reactivity in the IFNγ 
ELISpot when just CMV gB binding B cells were added compared to the non-CMV gB 
binding B cell population. Whilst FACS sorting is the best way to obtain a pure 
population, the stress-effects of this technique on the cells appeared to be incompatible 
with the ELISpot assay, as no IFNγ was produced even when all PBMCs used in the 
assay, apart from the B cells, were not passed through the sorter. As an alternative, 
the Miltenyi MACS beads system was used to isolate the CMV gB binding B cell 
population, but the purity of the population obtained was approximately 50%. This was 
not deemed sufficient for the purpose of the experiment as this would not definitively 
show that it was the CMV gB binding B cells mediating the effects observed in the 
ELISpot assay. It was therefore decided that a less specific approach would be taken 
and an enrichment of different B cell subsets would be used in the ELISpot assay. 
Again, compromises were made with this approach as IgM could not be used as a 
marker to separate the different B cell populations, because this would involve directly 
binding the B cell receptor and therefore potentially influencing the results of the 
ELISpot assay. Instead, B cells were separated based on their expression of CD27. 
When the CD27+ B cell population was enriched in the ELISpot assay, IFNγ production 
was greater than when all B cells were present. However, when B cells were enriched 
for CD27- B cells, IFNγ production was not detected. From the three leukocyte cones 
tested in this assay, it was concluded that memory (CD27+) B cells support IFNγ 
production whereas naïve (CD27-) B cells do not. In addition, there was evidence to 
suggest in one individual that the CD27- B cell population was suppressing IFNγ 
production. With these results in mind, it was hypothesised that the memory B cell 
populations would express greater levels of molecules involved in antigen presentation 
and T cell activation. Therefore HLA DR and CD86 expression was measured on the 
different B cell subsets. Whilst the proportions of HLA DR+ B cells did not differ 
239 
 
between the different B cell populations, the level of expression was found to be least 
bright on the memory B cell populations. Class switched memory and IgM+ memory B 
cell subsets contained a greater frequency of CD86 expressing B cells than naïve B 
cells which has also been reported elsewhere (Nova-Lamperti et al., 2016). Greater 
expression of CD86+ within the memory B cell subset suggests that they will have 
greater antigen presenting capabilities than Naive B cells and supports the data from 
the ELISpots which suggest that the CD27+ B cell population supports CD4+ T cell 
IFNγ production. Interestingly, the CMV gB binding population was distinct from the 
overall B cell population in that it contained a higher frequency of B cells that expressed 
CD86, indicating that CMV gB binding B cells are in an activated state. 
The transitional B cell population contained a higher frequency of CD86+ cells than the 
naïve CD45RB-IgM+ subset. The exact reason for this remains unclear but it has 
previously been published that CD86 expression on transitional B cells is required for 
effective suppression of T cell activation and proliferation (Blair et al., 2010, Khoder et 
al., 2014). Conversely, a recent study has shown that transitional B cells inhibit T cell 
activation due to the autocrine action of IL-10 which causes downregulation of CD86 
on their surface. This data would suggest that B cells do not require CD86 expression 
to mediate their suppressive effects on T cells and in fact down-regulating CD86 on 
their surface may be the mechanisms by which they reduce T cell activation. 
Interestingly this study applied the relevance of this finding to a renal transplant setting 
and found that tolerant patients produced more IL-10 and had lower CD86 expression 
upon ligation of CD40 than patients with chronic rejection (Nova-Lamperti et al., 2016).   
In addition to CD86 and HLA DR, the surface expression of BAFFr and TACI, two 
receptors for B cell survival cytokines, was compared between the overall B cell 
population and the CMV gB binding population. This was to investigate whether there 
was any therapeutic potential for targeting specific B cell subsets with monoclonal 
antibody therapies aimed at these receptors (Belimumab and Atacicept). BAFFr 
expression was found to be uniformly expressed on all B cell subsets. TACI was 
chosen to include in the stain panel over BCMA because BCMA is expressed at lower 
levels in peripheral blood B cells than TACI and TACI has previously been shown to 
be more highly expressed on memory B cell subsets, so it was of interest to see 
whether it was highly expressed on IgM+ memory B cells specifically (Salazar-
Camarena et al., 2015, Darce et al., 2007). However, it was not possible to detect any 
TACI positive B cells using the two different antibodies purchased. Different 
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6 Final discussion and future directions 
 Summary 
CAMR is a major cause of graft loss in a renal transplant setting (Lamb et al., 2011). 
Currently, there is an unmet need in renal transplantation for effective treatments of 
CAMR, largely due to the fact that the mechanisms driving CAMR remain unclear. It is 
widely believed that donor specific antibodies mediate the damage observed upon 
biopsy because several studies have reported a correlation between the presence of 
donor specific antibody in the circulation and worse graft outcome (Lachmann et al., 
2009, Campos et al., 2006, Worthington et al., 2003, Pelletier et al., 2002, Lee et al., 
2002).  Despite this strong correlation, there are many patients who maintain good 
graft function in the presence of circulating DSA, and others who have pathology 
consistent with CAMR, but no circulating DSA (Bartel et al., 2008, Hayde et al., 2014, 
Banasik et al., 2013, Campos et al., 2006, Lee et al., 2002). Moreover, there is 
insufficient mechanistic evidence in humans to definitively prove that DSA are the 
cause of CAMR.  
The aim of this thesis was to build on the evidence published by Shiu et al. that 
suggested B cells can either support or regulate T cell activation via the indirect 
pathway of allorecognition, thereby driving the chronic rejection of renal transplants. 
This aim was initially addressed by using the indirect IFNγ ELISpot assay described in 
Shiu et al. to study a cohort of patients with CAMR who had been recruited onto the 
RituxiCAN C4 trial. As the patients had to meet eligibility criteria to be enrolled onto 
the trial, a more uniform population of patients was studied here than in Shiu et al. The 
IFNγ ELISpot data reported in this thesis supports the major findings of Shiu et al., that 
IFNγ production in response to donor derived antigens is influenced by different 
lymphocyte subsets in different patients, and sometimes within the same patient at 
different time points. IFNγ production in the RituxiCAN C4 patients was largely 
dependent on the presence of B cells. However, an IFNγ response was observed in 
some samples only when either B cells or CD25+ cells were depleted. These three 
patterns of reactivity were defined as B dependent (Bdep), B regulated (Breg), or T 
regulated (Treg). When the patterns of reactivity at enrolment were correlated with 
clinical outcome at the end of phase I of the trial, the majority of patients who displayed 
evidence of donor specific reactivity, whether that was with a Bdep, Breg or Treg 
pattern of reactivity, did not pass phase I (ie. their graft function did not stabilise). A 
small percentage of patients with evidence of donor specific reactivity at enrolment 
went on to pass phase I. Overall, these results suggest that cellular immune activity is 
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associated with a poorer clinical outcome, however an in depth analysis of all clinical 
data would have to be carried out to confirm this. Such analysis was beyond the scope 
of this thesis. As there were no correlations found between the pattern of reactivity in 
the IFNγ ELISpot and the global B cell phenotype, the relationship between IFNγ 
production and the antigen specific B cell population was investigated.   
Biotinylated CMV gB was used as a model protein to facilitate the optimisation of the 
assay to flow cytometrically detect antigen binding B cells, before using biotinylated 
Pure™ HLA proteins to detect HLA binding B cells in patients who had kidney 
transplants mismatched to those antigens. Surprisingly, the dominant phenotype of 
antigen binding B cells in both the CMV gB and HLA systems was IgM+. CMV gB 
binding B cells were enriched in the IgM+ memory B cell population and the T3 CD27-
IgMhi population in a cohort of leukocyte cones. HLA binding B cells were 
predominantly enriched in either the IgM+ memory or IgM+ naïve B cell populations. A 
higher ratio of IgM+ memory B cells to IgM+ naïve B cells was associated with a 
reactive, B dependent response to the mismatched HLA antigen in the IFNγ ELISpot, 
but a larger number of samples and patients need to be studied to confirm this finding. 
Finally, using the CMV gB+ antigen system to dissect out the contribution that different 
B cell subsets make to CD4+ T cell IFNγ production, B cells were separated based on 
their expression of the memory marker CD27. In three leukocyte cones tested, it 
appeared that IFNγ production was supported when CD27+ B cells were enriched, but 
not when CD27- B cells were enriched. In one leukocyte cone, the data suggested that 
the CD27- B cells may be suppressing the IFNγ response.  
 Future directions 
The data in this thesis presents many avenues down which to explore unanswered 
questions. At present, a major limitation of the ELISpot assay is that the output is 
limited to one cytokine and it is impossible to know for certain which cell type is 
secreting the cytokine. A Fluorospot assay, which has the potential to give a readout 
of three cytokines, could be a way of partially overcoming this limitation (Janetzki et 
al., 2014). In a Fluorospot assay, fluorescently labelled detection antibodies are used 
to distinguish between the three different cytokines being produced. When the correct 
filters are applied, it is possible to visualise cells that are making more than one 
cytokine. This could be particularly useful to gain insights into the contribution that the 
B cells are making to the donor specific responses. For example, it would be possible 
to visualise in the B regulated samples, whether there is a decrease in IL-10 producing 
spots when B cells are depleted. This analysis could be extended to assessing the 
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change in dual or triple cytokine producing spots when just certain subsets of B cells 
are added to the cultures. For example, it may be possible to measure IFNγ secreting 
cells whilst simultaneously assessing the dual expression of IL10 and TNF-alpha in 
different B cell subsets (CD27+ versus CD27-). This data could be related to that 
reported in Cherukuri et al. where they found that the ability of a B cell to suppress a 
T cell response was based on the ratio of IL10:TNFα that it produces. Transitional B 
cells were found to be the subset that are best able to suppress and have a higher 
ratio of IL10:TNFα than naïve and memory B cells. This ratio was lower in patients who 
were rejecting their graft compared to those who had stable graft function (Cherukuri 
et al., 2014). 
It has been assumed that B cells in the reactive B dependent samples are processing 
and presenting antigen to the CD4+ T cells. This assumption could be tested by using 
a transwell system in which the CD19+ cells are separated from the CD4+ T cells by 
a membrane and are therefore prevented from contacting each other. It could also be 
used to test the hypothesis that the B cells in the reactive B regulated samples require 
cell-cell contact to effectively suppress a T cell response, as this is controversially 
discussed in the literature (Blair et al., 2010, Khoder et al., 2014, Nova-Lamperti et al., 
2016). As with the fluorospot assay, different B cell subsets could be added to the 
transwell system to investigate what effect the lack of cell-cell contact has on the ability 
of the CD27+ B cells to support CD4+ T cell IFNγ production. Or likewise what effect 
this has on the ability of the CD27- or transitional population to suppress. 
Recent advances in the technology used to study cells at the single cell level could be 
taken advantage of in order to study the antigen specific B cell and T cell populations. 
With sufficient starting cell numbers it would be possible to single cell sort the HLA 
binding B cells from patients with CAMR and sequence their BCR to determine whether 
there is any evidence of specific clonal expansion. The B cell repertoire in this 
population could be compared to those detected in the no antigen ‘background’ gate 
and also compared between patients and non-sensitised healthy volunteers to see if a 
specific skewing of BCRs can be identified in the patients. This analysis could also be 
used to clonally relate the different IgMhi B cell subsets to establish whether the HLA 
or CMV gB binding B cells are a mixed pool of cells that originate from both MZ/IgM+ 
memory B and naïve follicular-germinal centre pathways of B cell differentiation. 
To complement and strengthen the results obtained from the ELISpot, a flow 
cytometric T cell activation assay could be used to analyse donor specific CD4+ T 
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cells. It is possible to flow cytometrically detect and sort antigen specific CD4+ T cells, 
identified by their co-expression of CD154 and CD69, early on after in vitro stimulation 
with antigen (Estorninho et al., 2013, Chattopadhyay et al., 2005, Chattopadhyay et 
al., 2006). It would be interesting to investigate whether this assay could be applied to 
a transplant setting where HLA specific T cells are activated using Pure™ HLA 
proteins. By using microfluidic quantitative PCR methods for studying single cells, 
there is the potential to analyse the TCR repertoire and gene expression of single 
sorted indirect donor specific CD4+ T cells, thus providing information about the T cell 
response in renal transplant recipients with CAMR, which may prove useful in 
translating effective treatments into the clinic (Sanchez-Freire et al., 2012, Eugster et 
al., 2013). In addition, the antigen specific response could be studied in this assay in 
the presence or absence of B cells, and thus be used as a way of validating the results 
observed in the IFNγ ELISpot. It may also be possible to study the gene expression of 
the B cells to establish whether B dependent and B regulated patterns of reactivity can 
be distinguished from each other at the molecular level. 
 Conclusion 
To conclude, the data in this thesis supports that found in Shiu et al and strengthens 
the argument for the involvement of a cell-mediated component in chronic rejection. 
Interest in the contribution that B cells make to chronic rejection is gaining momentum, 
however the major theme that runs through much of the research conducted around 
this topic remains focussed on a humoral component. There is some evidence from 
animal models that B cells contribute to chronic rejection in an antibody independent 
manner, and in humans, the outcome of the OuTSMART clinical trial should shed light 
on whether treatments targeting cellular rejection are an effective way of preventing 
the development of chronic rejection in individuals who are HLA antibody positive 







Figure 7.1 Table for no antigen control from section 4.2.3.3
CD45RB+ IgMhi CD45RB+ IgM- CD45RB-IgMhi CD45RB-IgM+ CD45RB-IgM-
11.1 22.2 0 44.4 22.2
74.3 5.71 0 20 0
80 0 0 20 0
65.7 5.71 2.86 22.9 2.86
0 0 0 50 50
78.6 0 7.14 7.14 7.14
0 0 0 0 0
66.7 7.69 33.3 0 0
0 28.6 28.6 0 42.9
48.7 17.9 10.3 10.3 7.69
50 0 0 50 0
45.5 13.6 22.7 13.6 9.09
100 0 0 0 0
63.6 18.2 0 18.2 0
66.7 33.3 0 0 0
76.2 19 4.76 0 0
0 0 0 0 0
0 16.7 33.3 16.7 33.3
100 0 0 0 0
66.7 0 0 33.3 0
0 0 0 0 0
33.3 0 0 66.7 0
36.8 21.1 5.26 31.6 5.26
5.88 9.41 14.1 57.6 12.9
0 60 0 20 20
15.8 26.3 0 47.4 10.5
25 50 0 0 25
16.7 16.7 16.7 50 0
Expressed as % of Non transitional HLA+ B cells
PATIENT ID Timepoint Mismatch
Antigen 
(µg/ml) Transitional Non Transitional CD27+ IgMhi CD27+ IgM- CD27-IgMhi CD27-IgM+ CD27- IgM-
G013  14/11/2011 A1 0 18.2 81.8 11.1 0 0 66.7 22.2
G013  14/11/2011 A1 0.2 5.41 94.6 60 8.57 11.4 20 0
G013 21/02/2013 A1 0 28.6 71.4 40 20 20 20 0
G013 21/02/2013 A1 0.2 0 100 45.7 0 14.3 37.1 2.86
G013 09/01/2014 A1 0 0 100 0 0 0 50 50
G013 09/01/2014 A1 0.2 0 100 50 0 28.6 14.3 7.14
W008 10/07/2008 A2 0 0 0 0 0 0 0 0
W008 10/07/2008 A2 0.3 0 100 66.7 0 0 33.3 0
W008 12/01/2009 A2 0 0 100 14.3 71.4 14.3 0 0
W008 12/01/2009 A2 0.3 0 100 53.8 30.8 5.13 2.56 7.69
W008 02/07/2009 A2 0 0 100 50 0 0 50 0
W008 02/07/2009 A2 0.3 0 100 45.5 31.8 18.2 4.55 0
W008 24/09/2009 A2 0 0 100 50 0 50 0 0
W008 24/09/2009 A2 0.3 0 100 54.5 27.3 9.09 9.09 0
W008 10/01/2011 A2 0 0 100 66.7 33.3 0 0 0
W008 10/01/2011 A2 0.3 0 100 71.4 19 9.52 0 0
W011 30/11/2009 A2 0 0 0 0 0 0 0 0
W011 30/11/2009 A2 0.2 0 100 16.7 33.3 16.7 16.7 16.7
G007 09/05/2011 A2 0 0 100 0 0 100 0 0
G007 09/05/2011 A2 0.2 25 75 66.7 0 0 33.3 0
G014 12/12/2013 A1/A2 0 0 0 0 0 0 0 0
G014 12/12/2013 A1/A2 0.2 0 100 0 0 33.3 66.7 0
W009 16/10/2009 DR4 0 0 100
W009 16/10/2009 DR4 0.4 6.59 93.4
W009 07/02/2011 DR4 0 0 100
W009 07/02/2011 DR4 0.3 20.8 79.2
G011 29/06/2011 DR4 0 0 100
G011 29/06/2011 DR4 0.4 0 100
Expressed as % of HLA + B 
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